{ "instance": { "gnft-20221231.htm": { "axisCustom": 6, "axisStandard": 30, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 44, "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full": 1832 }, "contextCount": 870, "dts": { "calculationLink": { "local": [ "gnft-20221231_cal.xml" ] }, "definitionLink": { "local": [ "gnft-20221231_def.xml" ] }, "inline": { "local": [ "gnft-20221231.htm" ] }, "labelLink": { "local": [ "gnft-20221231_lab.xml" ] }, "presentationLink": { "local": [ "gnft-20221231_pre.xml" ] }, "schema": { "local": [ "gnft-20221231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.ifrs.org/taxonomy/2022-03-24/full_ifrs/full_ifrs-cor_2022-03-24.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 1186, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 4, "total": 4 }, "keyCustom": 199, "keyStandard": 330, "memberCustom": 171, "memberStandard": 46, "nsprefix": "gnft", "nsuri": "http://www.genfit.com/20221231", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://www.genfit.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i170daf4fe2b84ac183f676b30f17c618_D20210101-20211231", "decimals": "-5", "first": true, "lang": "en-US", "name": "gnft:ImpactOnSubcontractingCosts", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Major Events in the Period and Events After the Period", "menuCat": "Notes", "order": "10", "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "shortName": "Major Events in the Period and Events After the Period", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i7363b17ee08f4555baa88389c7cc9467_D20220101-20220929", "decimals": null, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R100": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ResearchAndDevelopmentExpense", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000107 - Disclosure - Operating Expense - Summary of Operating Expenses and Other Operating Income (Details)", "menuCat": "Details", "order": "100", "role": "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails", "shortName": "Operating Expense - Summary of Operating Expenses and Other Operating Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "gnft:ReorganizationAndRestructuringExpenses", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R101": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:AverageNumberOfEmployees", "reportCount": 1, "unitRef": "employee", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000108 - Disclosure - Operating Expense - Additional Information (Details)", "menuCat": "Details", "order": "101", "role": "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "shortName": "Operating Expense - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000109 - Disclosure - Operating Expense - Summary of Employee Expenses and Number of Employees (Details)", "menuCat": "Details", "order": "102", "role": "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails", "shortName": "Operating Expense - Summary of Employee Expenses and Number of Employees (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfInformationAboutEmployeesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:WagesAndSalaries", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000110 - Disclosure - Share-Based Compensation - Additional Information (Details)", "menuCat": "Details", "order": "103", "role": "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "shortName": "Share-Based Compensation - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R104": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:SharebasedCompensationAnnualExpense", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000111 - Disclosure - Share-Based Compensation - Summary of Share-based Compensation Under Each Plan According to Change in Estimate (Details)", "menuCat": "Details", "order": "104", "role": "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "shortName": "Share-Based Compensation - Summary of Share-based Compensation Under Each Plan According to Change in Estimate (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i34e83e0ca64b43a69ec201f99ef11cd0_D20220101-20221231", "decimals": "4", "lang": "en-US", "name": "gnft:PercentageOfExercisableInstrumentsRelatingToCompanysRDProgramPortfolio", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000112 - Disclosure - Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Share Warrants (Details)", "menuCat": "Details", "order": "105", "role": "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "shortName": "Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Share Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i2cf5eb65616d47959988c3d51710d6f2_D20170101-20171231", "decimals": "2", "lang": "en-US", "name": "ifrs-full:ExercisePriceShareOptionsGranted2019", "reportCount": 1, "unique": true, "unitRef": "eurPerShare", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000113 - Disclosure - Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Free Shares (Details)", "menuCat": "Details", "order": "106", "role": "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "shortName": "Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Free Shares (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i563b95f907974819abed580c59f8eae6_I20221231", "decimals": "0", "lang": "en-US", "name": "gnft:NumberOfOtherEquityInstrumentsSubscribedInShareBasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R107": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000114 - Disclosure - Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Stock Options (Details)", "menuCat": "Details", "order": "107", "role": "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "shortName": "Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Stock Options (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i8399ef9405e34805add537435b6df9d1_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "gnft:DescriptionOfExercisePeriodForShareBasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R108": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i94b84583b8b54e8cb98f76f69239c258_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "gnft:NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToPBCAndELATIVE", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000115 - Disclosure - Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Details)", "menuCat": "Details", "order": "108", "role": "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "shortName": "Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i94b84583b8b54e8cb98f76f69239c258_I20211231", "decimals": "0", "first": true, "lang": "en-US", "name": "gnft:NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToPBCAndELATIVE", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R109": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iea20d5769c9d47d4af617fe19869841f_D20210101-20211231", "decimals": "4", "first": true, "lang": "en-US", "name": "gnft:PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate20October2024", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000116 - Disclosure - Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Parenthetical) (Details)", "menuCat": "Details", "order": "109", "role": "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "shortName": "Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Performance Conditions (Parenthetical) (Details)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iea20d5769c9d47d4af617fe19869841f_D20210101-20211231", "decimals": "4", "first": true, "lang": "en-US", "name": "gnft:PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate20October2024", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Basis of Presentation", "menuCat": "Notes", "order": "11", "role": "http://www.genfit.com/role/BasisofPresentation", "shortName": "Basis of Presentation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R110": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000117 - Disclosure - Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Redeemable Warrants (Details)", "menuCat": "Details", "order": "110", "role": "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "shortName": "Share-Based Compensation - Summary of Key Terms and Conditions of Share-Based Compensation Based on Redeemable Warrants (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id2c8e09043f4498c9f2ff107b829047d_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "ifrs-full:NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R111": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000118 - Disclosure - Financial Income and Expenses - Summary of Financial Income and Expenses (Details)", "menuCat": "Details", "order": "111", "role": "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails", "shortName": "Financial Income and Expenses - Summary of Financial Income and Expenses (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i43c584ebe41e4da99f1e7d95d8b09a59_D20200101-20201231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:RevenueFromInterest", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R112": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:FinanceIncomeFromRenegotiationOfDebt", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000119 - Disclosure - Financial Income and Expenses - Additional Information (Details)", "menuCat": "Details", "order": "112", "role": "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "shortName": "Financial Income and Expenses - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R113": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:DeferredTaxLiabilities", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000120 - Disclosure - Income Tax - Breakdown of Deferred Taxes by Nature (Details)", "menuCat": "Details", "order": "113", "role": "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "shortName": "Income Tax - Breakdown of Deferred Taxes by Nature (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i3453a79e70d2465c9a70a6e90018e724_I20211231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R114": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000121 - Disclosure - Income Tax - Schedule of Effective Tax Rate (Details)", "menuCat": "Details", "order": "114", "role": "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails", "shortName": "Income Tax - Schedule of Effective Tax Rate (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R115": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentTaxLiabilitiesCurrent", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000122 - Disclosure - Income Tax - Narrative (Details)", "menuCat": "Details", "order": "115", "role": "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "shortName": "Income Tax - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R116": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000123 - Disclosure - Earnings (Loss) Per Share - Summary of Earnings (Loss) Per Share (Details)", "menuCat": "Details", "order": "116", "role": "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "shortName": "Earnings (Loss) Per Share - Summary of Earnings (Loss) Per Share (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:EarningsPerShareExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "0", "lang": "en-US", "name": "ifrs-full:WeightedAverageShares", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R117": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i811f2c492188460db6a11116be26a746_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "gnft:NumberOfCoFoundersHoldShareCapitalOfRelatedParty", "reportCount": 1, "unique": true, "unitRef": "co-founder", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000124 - Disclosure - Related Parties - Additional Information (Details)", "menuCat": "Details", "order": "117", "role": "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "shortName": "Related Parties - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i811f2c492188460db6a11116be26a746_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "gnft:NumberOfCoFoundersHoldShareCapitalOfRelatedParty", "reportCount": 1, "unique": true, "unitRef": "co-founder", "xsiNil": "false" } }, "R118": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock", "gnft:CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:KeyManagementPersonnelCompensationAttendanceFees", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000125 - Disclosure - Compensation of Corporate Officers - Summary of Compensation Paid to Officers (Details)", "menuCat": "Details", "order": "118", "role": "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails", "shortName": "Compensation of Corporate Officers - Summary of Compensation Paid to Officers (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock", "gnft:CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:KeyManagementPersonnelCompensationAttendanceFees", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R119": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:RentalPaymentObligationUnderLeaseAgreement", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000128 - Disclosure - Commitments - Additional Information (Details)", "menuCat": "Details", "order": "119", "role": "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails", "shortName": "Commitments - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:RentalPaymentObligationUnderLeaseAgreement", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "12", "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPolicies", "shortName": "Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": null }, "R120": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:AccruedPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000129 - Disclosure - Cash flow statement (Details)", "menuCat": "Details", "order": "120", "role": "http://www.genfit.com/role/CashflowstatementDetails", "shortName": "Cash flow statement (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:AccruedPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Operating segments", "menuCat": "Notes", "order": "13", "role": "http://www.genfit.com/role/Operatingsegments", "shortName": "Operating segments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Financial Risks Management", "menuCat": "Notes", "order": "14", "role": "http://www.genfit.com/role/FinancialRisksManagement", "shortName": "Financial Risks Management", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinancialRiskManagementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Cash and Cash Equivalents", "menuCat": "Notes", "order": "15", "role": "http://www.genfit.com/role/CashandCashEquivalents", "shortName": "Cash and Cash Equivalents", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashAndCashEquivalentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Intangible Assets", "menuCat": "Notes", "order": "16", "role": "http://www.genfit.com/role/IntangibleAssets", "shortName": "Intangible Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Property, Plant and Equipment", "menuCat": "Notes", "order": "17", "role": "http://www.genfit.com/role/PropertyPlantandEquipment", "shortName": "Property, Plant and Equipment", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Trade and Other Receivables", "menuCat": "Notes", "order": "18", "role": "http://www.genfit.com/role/TradeandOtherReceivables", "shortName": "Trade and Other Receivables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfOtherFinancialAssetsExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Other Financial Assets", "menuCat": "Notes", "order": "19", "role": "http://www.genfit.com/role/OtherFinancialAssets", "shortName": "Other Financial Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ix:continuation", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfOtherFinancialAssetsExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "false", "longName": "0000002 - Document - Audit Information", "menuCat": "Cover", "order": "2", "role": "http://www.genfit.com/role/AuditInformation", "shortName": "Audit Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "dei:AuditorName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Other Assets", "menuCat": "Notes", "order": "20", "role": "http://www.genfit.com/role/OtherAssets", "shortName": "Other Assets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Loans and Borrowings", "menuCat": "Notes", "order": "21", "role": "http://www.genfit.com/role/LoansandBorrowings", "shortName": "Loans and Borrowings", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfBorrowingsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Fair Value of Financial Instruments", "menuCat": "Notes", "order": "22", "role": "http://www.genfit.com/role/FairValueofFinancialInstruments", "shortName": "Fair Value of Financial Instruments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueMeasurementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Trade and Other Payables", "menuCat": "Notes", "order": "23", "role": "http://www.genfit.com/role/TradeandOtherPayables", "shortName": "Trade and Other Payables", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTradeAndOtherPayablesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Deferred Income and Revenue", "menuCat": "Notes", "order": "24", "role": "http://www.genfit.com/role/DeferredIncomeandRevenue", "shortName": "Deferred Income and Revenue", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDeferredIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Provisions", "menuCat": "Notes", "order": "25", "role": "http://www.genfit.com/role/Provisions", "shortName": "Provisions", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfProvisionsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfBenefitPaymentsUndereCompanysFrenchRetirementEntityTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Employee Benefits", "menuCat": "Notes", "order": "26", "role": "http://www.genfit.com/role/EmployeeBenefits", "shortName": "Employee Benefits", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "ifrs-full:DisclosureOfEmployeeBenefitsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Equity", "menuCat": "Notes", "order": "27", "role": "http://www.genfit.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Operating Income", "menuCat": "Notes", "order": "28", "role": "http://www.genfit.com/role/OperatingIncome", "shortName": "Operating Income", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherOperatingIncomeExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Operating Expense", "menuCat": "Notes", "order": "29", "role": "http://www.genfit.com/role/OperatingExpense", "shortName": "Operating Expense", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfExpensesByNatureExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - Consolidated Statements of Financial Position", "menuCat": "Statements", "order": "3", "role": "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "shortName": "Consolidated Statements of Financial Position", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:Inventories", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Share-Based Compensation", "menuCat": "Notes", "order": "30", "role": "http://www.genfit.com/role/ShareBasedCompensation", "shortName": "Share-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Financial Income and Expenses", "menuCat": "Notes", "order": "31", "role": "http://www.genfit.com/role/FinancialIncomeandExpenses", "shortName": "Financial Income and Expenses", "subGroupType": "", "uniqueAnchor": null }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Income Tax", "menuCat": "Notes", "order": "32", "role": "http://www.genfit.com/role/IncomeTax", "shortName": "Income Tax", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfIncomeTaxExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Earnings (Loss) Per Share", "menuCat": "Notes", "order": "33", "role": "http://www.genfit.com/role/EarningsLossPerShare", "shortName": "Earnings (Loss) Per Share", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "ifrs-full:DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Litigation and Contingent Liabilities", "menuCat": "Notes", "order": "34", "role": "http://www.genfit.com/role/LitigationandContingentLiabilities", "shortName": "Litigation and Contingent Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfRelatedPartyExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Related Parties", "menuCat": "Notes", "order": "35", "role": "http://www.genfit.com/role/RelatedParties", "shortName": "Related Parties", "subGroupType": "", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "gnft:CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000038 - Disclosure - Compensation of Corporate Officers", "menuCat": "Notes", "order": "36", "role": "http://www.genfit.com/role/CompensationofCorporateOfficers", "shortName": "Compensation of Corporate Officers", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "gnft:CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCommitmentsExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000039 - Disclosure - Commitments", "menuCat": "Notes", "order": "37", "role": "http://www.genfit.com/role/Commitments", "shortName": "Commitments", "subGroupType": "", "uniqueAnchor": null }, "R38": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000040 - Disclosure - Cash flow statement", "menuCat": "Notes", "order": "38", "role": "http://www.genfit.com/role/Cashflowstatement", "shortName": "Cash flow statement", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfCashFlowStatementExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000041 - Disclosure - Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "39", "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies", "shortName": "Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:RevenueFromRenderingOfServices", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:ProfitLossFromOperatingActivities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000043 - Disclosure - Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "40", "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesTables", "shortName": "Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000044 - Disclosure - Operating segments (Tables)", "menuCat": "Tables", "order": "41", "role": "http://www.genfit.com/role/OperatingsegmentsTables", "shortName": "Operating segments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000045 - Disclosure - Financial Risks Management (Tables)", "menuCat": "Tables", "order": "42", "role": "http://www.genfit.com/role/FinancialRisksManagementTables", "shortName": "Financial Risks Management (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000046 - Disclosure - Cash and Cash Equivalents (Tables)", "menuCat": "Tables", "order": "43", "role": "http://www.genfit.com/role/CashandCashEquivalentsTables", "shortName": "Cash and Cash Equivalents (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000047 - Disclosure - Intangible Assets (Tables)", "menuCat": "Tables", "order": "44", "role": "http://www.genfit.com/role/IntangibleAssetsTables", "shortName": "Intangible Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000048 - Disclosure - Property, Plant and Equipment (Tables)", "menuCat": "Tables", "order": "45", "role": "http://www.genfit.com/role/PropertyPlantandEquipmentTables", "shortName": "Property, Plant and Equipment (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000049 - Disclosure - Trade and Other Receivables (Tables)", "menuCat": "Tables", "order": "46", "role": "http://www.genfit.com/role/TradeandOtherReceivablesTables", "shortName": "Trade and Other Receivables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000050 - Disclosure - Other Financial Assets (Tables)", "menuCat": "Tables", "order": "47", "role": "http://www.genfit.com/role/OtherFinancialAssetsTables", "shortName": "Other Financial Assets (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R48": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id1d840cf102040c88a339b53f30cfffb_D20171016-20171016", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutBondsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000051 - Disclosure - Loans and Borrowings (Tables)", "menuCat": "Tables", "order": "48", "role": "http://www.genfit.com/role/LoansandBorrowingsTables", "shortName": "Loans and Borrowings (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id1d840cf102040c88a339b53f30cfffb_D20171016-20171016", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutBondsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000052 - Disclosure - Fair Value of Financial Instruments (Tables)", "menuCat": "Tables", "order": "49", "role": "http://www.genfit.com/role/FairValueofFinancialInstrumentsTables", "shortName": "Fair Value of Financial Instruments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - Consolidated Statements of Other Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss", "shortName": "Consolidated Statements of Other Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000053 - Disclosure - Trade and Other Payables (Tables)", "menuCat": "Tables", "order": "50", "role": "http://www.genfit.com/role/TradeandOtherPayablesTables", "shortName": "Trade and Other Payables (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R51": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfChangeInProvisionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000054 - Disclosure - Other provisions, contingent liabilities and contingent assets (Tables)", "menuCat": "Tables", "order": "51", "role": "http://www.genfit.com/role/OtherprovisionscontingentliabilitiesandcontingentassetsTables", "shortName": "Other provisions, contingent liabilities and contingent assets (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfChangeInProvisionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfBenefitPaymentsUndereCompanysFrenchRetirementEntityTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000055 - Disclosure - Employee Benefits (Tables)", "menuCat": "Tables", "order": "52", "role": "http://www.genfit.com/role/EmployeeBenefitsTables", "shortName": "Employee Benefits (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R53": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfOtherIncomeExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000057 - Disclosure - Operating Income (Tables)", "menuCat": "Tables", "order": "53", "role": "http://www.genfit.com/role/OperatingIncomeTables", "shortName": "Operating Income (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfOtherIncomeExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000058 - Disclosure - Operating Expense (Tables)", "menuCat": "Tables", "order": "54", "role": "http://www.genfit.com/role/OperatingExpenseTables", "shortName": "Operating Expense (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfShareBasedCompensationExpenseExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000059 - Disclosure - Share-Based Compensation (Tables)", "menuCat": "Tables", "order": "55", "role": "http://www.genfit.com/role/ShareBasedCompensationTables", "shortName": "Share-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfShareBasedCompensationExpenseExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R56": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000060 - Disclosure - Financial Income and Expenses (Tables)", "menuCat": "Tables", "order": "56", "role": "http://www.genfit.com/role/FinancialIncomeandExpensesTables", "shortName": "Financial Income and Expenses (Tables)", "subGroupType": "tables", "uniqueAnchor": null }, "R57": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000061 - Disclosure - Income Tax (Tables)", "menuCat": "Tables", "order": "57", "role": "http://www.genfit.com/role/IncomeTaxTables", "shortName": "Income Tax (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000062 - Disclosure - Earnings (Loss) Per Share (Tables)", "menuCat": "Tables", "order": "58", "role": "http://www.genfit.com/role/EarningsLossPerShareTables", "shortName": "Earnings (Loss) Per Share (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:EarningsPerShareExplanatory", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000064 - Disclosure - Compensation of Corporate Officers (Tables)", "menuCat": "Tables", "order": "59", "role": "http://www.genfit.com/role/CompensationofCorporateOfficersTables", "shortName": "Compensation of Corporate Officers (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ifrs-full:DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProfitLoss", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "6", "role": "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:AdjustmentsForDepreciationAndAmortisationExpense", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:ReorganizationAndReductionInForce", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000066 - Disclosure - Major Events in the Period and Events After the Period - Termination of RESOLVE-IT and the development program of elafibranor in NASH (Details)", "menuCat": "Details", "order": "60", "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "shortName": "Major Events in the Period and Events After the Period - Termination of RESOLVE-IT and the development program of elafibranor in NASH (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i7baafa2251a94105b893197f4e34abfe_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:LossesOnDisposalsOfPropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentTaxLiabilitiesCurrent", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000067 - Disclosure - Major Events in the Period and Events After the Period - Acquisition of the Clinical-stage Biopharmaceutical Company Versantis (Details)", "menuCat": "Details", "order": "61", "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "shortName": "Major Events in the Period and Events After the Period - Acquisition of the Clinical-stage Biopharmaceutical Company Versantis (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "5", "lang": "en-US", "name": "gnft:ExchangeRateCHFEuroUsedForVersantisAcquisitionConversion", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ExpenseOfRestructuringActivities", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000068 - Disclosure - Major Events in the Period and Events After the Period - Additional Information (Details)", "menuCat": "Details", "order": "62", "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "shortName": "Major Events in the Period and Events After the Period - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i15fa952611f94f7d9ffd94c5c912a0d4_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "gnft:ReorganizationAndReductionInForce", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfSharesIssued", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000069 - Disclosure - Major Events in the Period and Events After the Period - Signature of a Licensing and Partnership Agreement with Ipsen (Details)", "menuCat": "Details", "order": "63", "role": "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "shortName": "Major Events in the Period and Events After the Period - Signature of a Licensing and Partnership Agreement with Ipsen (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R64": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ProvisionsForEmployeeBenefits", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000070 - Disclosure - Basis of Presentation (Details)", "menuCat": "Details", "order": "64", "role": "http://www.genfit.com/role/BasisofPresentationDetails", "shortName": "Basis of Presentation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "ifrs-full:ClosingForeignExchangeRate", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000071 - Disclosure - Summary of Significant Accounting Policies - Summary of Applicable Exchange Rates Used to Translate Financial Statements (Details)", "menuCat": "Details", "order": "65", "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails", "shortName": "Summary of Significant Accounting Policies - Summary of Applicable Exchange Rates Used to Translate Financial Statements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "5", "lang": "en-US", "name": "gnft:AverageForeignExchangeRateUSDEuro", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "gnft:NumberOfSegment", "reportCount": 1, "unitRef": "bond", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000072 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)", "menuCat": "Details", "order": "66", "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "gnft:ResearchTaxCreditCarryforwardPeriod", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i3ef3ce69d6e041c99ef1d9fc53fc6c57_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000073 - Disclosure - Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Details)", "menuCat": "Details", "order": "67", "role": "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails", "shortName": "Summary of Significant Accounting Policies - Summary of Estimated Useful Lives (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i3ef3ce69d6e041c99ef1d9fc53fc6c57_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R68": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000075 - Disclosure - Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of US Dollar against Euro (Details)", "menuCat": "Details", "order": "68", "role": "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "shortName": "Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of US Dollar against Euro (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i170daf4fe2b84ac183f676b30f17c618_D20210101-20211231", "decimals": "0", "lang": "en-US", "name": "ifrs-full:AverageForeignExchangeRate", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheCHFAgainstTheEuroExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i8299a5ffb5d64aad8cb52032a8dcf26e_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000076 - Disclosure - Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of CHF against Euro (Details)", "menuCat": "Details", "order": "69", "role": "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "shortName": "Financial Risks Management - Sensitivity of Group's Cash and Cash Equivalents and Expenses to Variation 10% of CHF against Euro (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheCHFAgainstTheEuroExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i8299a5ffb5d64aad8cb52032a8dcf26e_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "ibe91bd3d11ca42cda07fe7e3e62930df_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Consolidated Statements of Changes in Equity", "menuCat": "Statements", "order": "7", "role": "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "shortName": "Consolidated Statements of Changes in Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "ibe91bd3d11ca42cda07fe7e3e62930df_I20191231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:NumberOfSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000077 - Disclosure - Financial Risks Management - Summary of Cash, Cash Equivalents and Financial Assets (Details)", "menuCat": "Details", "order": "70", "role": "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails", "shortName": "Financial Risks Management - Summary of Cash, Cash Equivalents and Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id2f95c3b36c2457788a7a74167f304c9_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:CashAndCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "1", "first": true, "lang": "en-US", "name": "gnft:FluctuationInCurrencyUSDToEUR", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000078 - Disclosure - Financial Risks Management - Additional Information (Details)", "menuCat": "Details", "order": "71", "role": "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "shortName": "Financial Risks Management - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "1", "first": true, "lang": "en-US", "name": "gnft:FluctuationInCurrencyUSDToEUR", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000079 - Disclosure - Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details)", "menuCat": "Details", "order": "72", "role": "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails", "shortName": "Cash and Cash Equivalents - Summary of Cash and Cash Equivalents (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:ShorttermDepositsClassifiedAsCashEquivalents", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000080 - Disclosure - Intangible Assets - Schedule of Variations in Intangible Assets (Details)", "menuCat": "Details", "order": "73", "role": "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "shortName": "Intangible Assets - Schedule of Variations in Intangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i5db8d1341ef14506be88716c50465b5e_I20201231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:IntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000081 - Disclosure - Property, Plant and Equipment - Summary of Variations in Tangible Assets (Details)", "menuCat": "Details", "order": "74", "role": "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "shortName": "Property, Plant and Equipment - Summary of Variations in Tangible Assets (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:PropertyPlantAndEquipment", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000082 - Disclosure - Property, Plant and Equipment - Additional Information (Details)", "menuCat": "Details", "order": "75", "role": "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "shortName": "Property, Plant and Equipment - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i799e727fac144aadb96ee62461cc4988_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:RightofuseAssets", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:TradeReceivables", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000083 - Disclosure - Trade and Other Receivables - Summary of Trade and Other Receivables (Details)", "menuCat": "Details", "order": "76", "role": "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails", "shortName": "Trade and Other Receivables - Summary of Trade and Other Receivables (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "ifrs-full:DisclosureOfTradeAndOtherReceivablesExplanatory", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:TradeReceivables", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:ResearchTaxCredit", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000084 - Disclosure - Trade and Other Receivables - Additional Information (Details)", "menuCat": "Details", "order": "77", "role": "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails", "shortName": "Trade and Other Receivables - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000085 - Disclosure - Other Financial Assets - Summary of Other Financial Assets (Details)", "menuCat": "Details", "order": "78", "role": "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails", "shortName": "Other Financial Assets - Summary of Other Financial Assets (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:InvestmentAccountedForUsingEquityMethod", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:OtherFinancialAssets", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000086 - Disclosure - Other Financial Assets - Additional Information (Details)", "menuCat": "Details", "order": "79", "role": "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "shortName": "Other Financial Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "INF", "lang": "en-US", "name": "gnft:NumberOfSharesRecordedAsDeductionFromEquity", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "ifrs-full:DisclosureOfFinanceIncomeExpenseExplanatory", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Statement of financial position, current/non-current", "menuCat": "Statements", "order": "8", "role": "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent", "shortName": "Statement of financial position, current/non-current", "subGroupType": "", "uniqueAnchor": null }, "R80": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:OtherCurrentNonfinancialAssets", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000087 - Disclosure - Other Assets - Additional Information (Details)", "menuCat": "Details", "order": "80", "role": "http://www.genfit.com/role/OtherAssetsAdditionalInformationDetails", "shortName": "Other Assets - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R81": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "1", "first": true, "lang": "en-US", "name": "gnft:ValuationAssumptionVolatilityFirstLevel", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000088 - Disclosure - Loans and Borrowings - Additional Information (Details)", "menuCat": "Details", "order": "81", "role": "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "shortName": "Loans and Borrowings - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "1", "first": true, "lang": "en-US", "name": "gnft:ValuationAssumptionVolatilityFirstLevel", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "ib960b515e88c4cc09d0f0c925738a539_D20210125-20210125", "decimals": "INF", "first": true, "lang": "en-US", "name": "gnft:BuybackOfDebtInstrumentsNumberOfInstruments", "reportCount": 1, "unitRef": "oceane", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000089 - Disclosure - Loans and Borrowings - Summary of Bonds (Details)", "menuCat": "Details", "order": "82", "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "shortName": "Loans and Borrowings - Summary of Bonds (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000090 - Disclosure - Loans and Borrowings - Summary of Convertible Bonds (Details)", "menuCat": "Details", "order": "83", "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "shortName": "Loans and Borrowings - Summary of Convertible Bonds (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:OtherBorrowings", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000091 - Disclosure - Loans and Borrowings - Summary of Other Loans and Borrowings (Details)", "menuCat": "Details", "order": "84", "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "shortName": "Loans and Borrowings - Summary of Other Loans and Borrowings (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutRefundableAndConditionalAdvancesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:RefundableAndConditionalAdvancesNetBookValue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000092 - Disclosure - Loans and Borrowings - Summary of Refundable and Conditional Advances (Details)", "menuCat": "Details", "order": "85", "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails", "shortName": "Loans and Borrowings - Summary of Refundable and Conditional Advances (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R86": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfLoansAndAdvancesToBanksExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "ib5986c0eac0d491084094f19bc66b78e_D20220101-20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "gnft:FacilitySize", "reportCount": 1, "unitRef": "facilitysize", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000093 - Disclosure - Loans and Borrowings - Summary of Bank Loans (Details)", "menuCat": "Details", "order": "86", "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "shortName": "Loans and Borrowings - Summary of Bank Loans (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfLoansAndAdvancesToBanksExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i3109e145a45d468493b37db1b3e89980_D20220101-20221231", "decimals": null, "lang": "en-US", "name": "ifrs-full:BorrowingsMaturity", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ifrs-full:MaturityAnalysisForNonderivativeFinancialLiabilities", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:RefundableAndConditionalAdvances", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000094 - Disclosure - Loans and Borrowings - Summary of Maturities of Financial Liabilities (Details)", "menuCat": "Details", "order": "87", "role": "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "shortName": "Loans and Borrowings - Summary of Maturities of Financial Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R88": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:FinancialAssets", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000095 - Disclosure - Fair Value of Financial Instruments - Summary of Financial Assets And Liabilities Carrying Values By Category And Fair Values (Details)", "menuCat": "Details", "order": "88", "role": "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "shortName": "Fair Value of Financial Instruments - Summary of Financial Assets And Liabilities Carrying Values By Category And Fair Values (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i1c76c02a5d774848a267e27156723484_I20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:FinancialAssetsAtFairValue", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:TradeAndOtherPayablesToTradeSuppliers", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000096 - Disclosure - Trade and Other Payables - Schedule of Trade and Other Payables (Details)", "menuCat": "Details", "order": "89", "role": "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails", "shortName": "Trade and Other Payables - Schedule of Trade and Other Payables (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfCompanyInformationExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - The Company", "menuCat": "Notes", "order": "9", "role": "http://www.genfit.com/role/TheCompany", "shortName": "The Company", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:DisclosureOfCompanyInformationExplanatoryTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000097 - Disclosure - Trade and Other Payables - Additional Information (Details)", "menuCat": "Details", "order": "90", "role": "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "shortName": "Trade and Other Payables - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:TradeAndOtherCurrentPayablesToTradeSuppliers", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000098 - Disclosure - Deferred Income and Revenue (Details)", "menuCat": "Details", "order": "91", "role": "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "shortName": "Deferred Income and Revenue (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "if89a8db13fba4fbe803b8710a8be15f5_I20211231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:DeferredIncomeIncludingContractLiabilities", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfChangeInProvisionTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:ProvisionForLitigation", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000099 - Disclosure - Provisions - Additional Information (Details)", "menuCat": "Details", "order": "92", "role": "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails", "shortName": "Provisions - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "gnft:DisclosureOfChangeInProvisionTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "gnft:ProvisionForLitigation", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000100 - Disclosure - Employee Benefits - Additional Information (Details)", "menuCat": "Details", "order": "93", "role": "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "shortName": "Employee Benefits - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:PostemploymentBenefitExpenseDefinedContributionPlans", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfDefinedBenefitPlansExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:PopulationDescription", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000101 - Disclosure - Employee Benefits - Summary of Assumptions Used for Employees for the Measurement of Retirement Indemnity to Employees (Details)", "menuCat": "Details", "order": "94", "role": "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails", "shortName": "Employee Benefits - Summary of Assumptions Used for Employees for the Measurement of Retirement Indemnity to Employees (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i601a6b121aba46d69e3040cd271b5f02_I20211231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:LiabilityAssetOfDefinedBenefitPlans", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000102 - Disclosure - Employee Benefits - Summary of Changes in Present Value of Defined Benefit Obligation (Details)", "menuCat": "Details", "order": "95", "role": "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails", "shortName": "Employee Benefits - Summary of Changes in Present Value of Defined Benefit Obligation (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R96": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ifrs-full:DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iba86660c70294f91af10518c2de6745a_I20221231", "decimals": "4", "first": true, "lang": "en-US", "name": "ifrs-full:PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000103 - Disclosure - Employee Benefits - Summary of Sensitivity of the Retirement and Post-Employment Benefits to a Variation of the Discount Rate (Details)", "menuCat": "Details", "order": "96", "role": "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails", "shortName": "Employee Benefits - Summary of Sensitivity of the Retirement and Post-Employment Benefits to a Variation of the Discount Rate (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R97": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000104 - Disclosure - Equity - Additional Information (Details)", "menuCat": "Details", "order": "97", "role": "http://www.genfit.com/role/EquityAdditionalInformationDetails", "shortName": "Equity - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": null, "first": true, "lang": "en-US", "name": "gnft:ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R98": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:Revenue", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000105 - Disclosure - Operating Income - Additional Information (Details)", "menuCat": "Details", "order": "98", "role": "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "shortName": "Operating Income - Additional Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "gnft:ExpenseRelatingToResolutionOfDispute", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfOtherIncomeExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "id21f457e9ac74f1b978f0e4dcbdda7ee_D20220101-20221231", "decimals": "-3", "first": true, "lang": "en-US", "name": "ifrs-full:OtherIncome", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000106 - Disclosure - Operating Income - Schedule of Other Income (Details)", "menuCat": "Details", "order": "99", "role": "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails", "shortName": "Operating Income - Schedule of Other Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "gnft:DisclosureOfOtherIncomeExplanatoryTextBlock", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "iea53de0642af4783a89c6186243e3bc1_D20220101-20221231", "decimals": "-3", "lang": "en-US", "name": "ifrs-full:OtherIncome", "reportCount": 1, "unique": true, "unitRef": "eur", "xsiNil": "false" } }, "R9999": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "gnft-20221231.htm", "contextRef": "i3a74f3ac513b497992927804ed578d0a_D20220101-20221231", "decimals": "-5", "first": true, "lang": "en-US", "name": "ifrs-full:OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "reportCount": 1, "unitRef": "eur", "xsiNil": "false" }, "groupType": "", "isDefault": "false", "longName": "Uncategorized Items - gnft-20221231.htm", "menuCat": "Cover", "order": "121", "role": "http://xbrl.sec.gov/role/uncategorizedFacts", "shortName": "Uncategorized Items - gnft-20221231.htm", "subGroupType": "", "uniqueAnchor": null } }, "segmentCount": 227, "tag": { "country_CH": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "SWITZERLAND", "terseLabel": "SWITZERLAND" } } }, "localname": "CH", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "country_FR": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "FRANCE", "terseLabel": "FRANCE" } } }, "localname": "FR", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "currency_AllCurrenciesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "All Currencies [Domain]", "terseLabel": "All Currencies [Domain]" } } }, "localname": "AllCurrenciesDomain", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "domainItemType" }, "currency_CHF": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Switzerland, Francs", "terseLabel": "Switzerland, Francs" } } }, "localname": "CHF", "nsuri": "http://xbrl.sec.gov/currency/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "domainItemType" }, "dei_AddressTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.", "label": "Address Type [Domain]", "terseLabel": "Address Type" } } }, "localname": "AddressTypeDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "verboseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID", "terseLabel": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/AuditInformation" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "label": "Auditor Location", "terseLabel": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "label": "Auditor Name", "terseLabel": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/AuditInformation" ], "xbrltype": "internationalNameItemType" }, "dei_BusinessContactMember": { "auth_ref": [ "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Business contact for the entity", "label": "Business Contact [Member]", "terseLabel": "Business Contact" } } }, "localname": "BusinessContactMember", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "domainItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelFaxNumber": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Fax Number of contact personnel.", "label": "Contact Personnel Fax Number", "terseLabel": "Contact Personnel Fax Number" } } }, "localname": "ContactPersonnelFaxNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_ContactPersonnelName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of contact personnel", "label": "Contact Personnel Name", "terseLabel": "Contact Personnel Name" } } }, "localname": "ContactPersonnelName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region", "terseLabel": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard", "terseLabel": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report", "terseLabel": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r315" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement", "terseLabel": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r320" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report", "terseLabel": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r322" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressesAddressTypeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.", "label": "Entity Addresses, Address Type [Axis]", "terseLabel": "Entity Addresses, Address Type" } } }, "localname": "EntityAddressesAddressTypeAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "stringItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r325" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r323" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityNumberOfEmployees": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of persons employed by the Entity", "label": "Entity Number of Employees", "terseLabel": "Entity number of employees" } } }, "localname": "EntityNumberOfEmployees", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r317" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers", "terseLabel": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r324" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer", "terseLabel": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "yesNoItemType" }, "dei_IcfrAuditorAttestationFlag": { "auth_ref": [ "r319", "r320", "r321" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag", "terseLabel": "ICFR Auditor Attestation Flag" } } }, "localname": "IcfrAuditorAttestationFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r316" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r318" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.genfit.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "gnft_A16October2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "16October2025", "label": "16October2025 [Member]", "terseLabel": "16October2025 [Member]" } } }, "localname": "A16October2025Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_A2023Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2023", "label": "2023 [Member]", "terseLabel": "2023" } } }, "localname": "A2023Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_A2024Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2024", "label": "2024 [Member]", "terseLabel": "2024" } } }, "localname": "A2024Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_A2025Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2025", "label": "2025 [Member]", "terseLabel": "2025" } } }, "localname": "A2025Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_A2026Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2026", "label": "2026 [Member]", "terseLabel": "2026" } } }, "localname": "A2026Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_A2027Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2027", "label": "2027 [Member]", "terseLabel": "2027" } } }, "localname": "A2027Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD20161Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2016-1.", "label": "A G A D20161 [Member]", "terseLabel": "A G A D20161 [Member]" } } }, "localname": "AGAD20161Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD20162Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2016-2.", "label": "A G A D20162 [Member]", "terseLabel": "A G A D20162 [Member]" } } }, "localname": "AGAD20162Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD20171Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2017-1.", "label": "A G A D20171 [Member]", "terseLabel": "A G A D20171 [Member]" } } }, "localname": "AGAD20171Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD20172Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2017-2.", "label": "A G A D20172 [Member]", "terseLabel": "A G A D20172 [Member]" } } }, "localname": "AGAD20172Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2018.", "label": "A G A D2018 [Member]", "terseLabel": "A G A D2018 [Member]" } } }, "localname": "AGAD2018Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2019.", "label": "A G A D2019 [Member]", "terseLabel": "A G A D2019 [Member]" } } }, "localname": "AGAD2019Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2021", "label": "AGA D 2021 [Member]", "terseLabel": "AGA D 2021 [Member]" } } }, "localname": "AGAD2021Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAD2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D 2022", "label": "AGA D 2022 [Member]", "terseLabel": "AGA D 2022" } } }, "localname": "AGAD2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGADAndS20161And20162Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D and S 2016-1 and 2016-2.", "label": "A G A D And S20161 And20162 [Member]", "terseLabel": "AGA D and S 2016-1 and 2016-2" } } }, "localname": "AGADAndS20161And20162Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_AGADAndS20171And20172Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D and S 2017-1 and 2017-2.", "label": "A G A D And S20171 And20172 [Member]", "terseLabel": "AGA D and S 2017-1 and 2017-2" } } }, "localname": "AGADAndS20171And20172Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_AGADAndSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA D and S.", "label": "A G A D And S [Member]", "terseLabel": "AGA D and S" } } }, "localname": "AGADAndSMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_AGADMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGAD.", "label": "A G A D [Member]", "terseLabel": "AGA D" } } }, "localname": "AGADMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A G A", "label": "A G A [Member]", "terseLabel": "A G A" } } }, "localname": "AGAMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS20161Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA S 2016-1.", "label": "A G A S20161 [Member]", "terseLabel": "A G A S20161 [Member]" } } }, "localname": "AGAS20161Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS20162Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA S 2016-2.", "label": "A G A S20162 [Member]", "terseLabel": "A G A S20162 [Member]" } } }, "localname": "AGAS20162Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS20171Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA S 2017-1.", "label": "A G A S20171 [Member]", "terseLabel": "A G A S20171 [Member]" } } }, "localname": "AGAS20171Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS20172Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA S 2017-2.", "label": "A G A S20172 [Member]", "terseLabel": "A G A S20172 [Member]" } } }, "localname": "AGAS20172Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA S 2018.", "label": "A G A S2018 [Member]", "terseLabel": "A G A S2018 [Member]" } } }, "localname": "AGAS2018Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AG AS 2019 .", "label": "A G A S2019 [Member]", "terseLabel": "A G A S2019 [Member]" } } }, "localname": "AGAS2019Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA S 2021", "label": "AGA S 2021 [Member]", "terseLabel": "AGA S 2021 [Member]" } } }, "localname": "AGAS2021Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGAS2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGA S 2022", "label": "AGA S 2022 [Member]", "terseLabel": "AGA S 2022" } } }, "localname": "AGAS2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_AGASMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "AGAS.", "label": "A G A S [Member]", "terseLabel": "A G A S [Member]", "verboseLabel": "AGA S" } } }, "localname": "AGASMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_AccountReversalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Account Reversal", "label": "Account Reversal [Member]", "terseLabel": "Account Reversal" } } }, "localname": "AccountReversalMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_AccruedExpensesClinicalTrials": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Expenses, Clinical Trials", "label": "Accrued Expenses, Clinical Trials", "terseLabel": "Accrued expenses related to clinical trials" } } }, "localname": "AccruedExpensesClinicalTrials", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AccruedExpensesClinicalTrialsBasedOnExchangeRateNet": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Expenses, Clinical Trials Based On Exchange Rate, Net", "label": "Accrued Expenses, Clinical Trials Based On Exchange Rate, Net", "terseLabel": "Accrued expenses related to clinical trials based on the exchange rate, net" } } }, "localname": "AccruedExpensesClinicalTrialsBasedOnExchangeRateNet", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AccruedExpensesClinicalTrialsRequiringConversionToEuros": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Expenses, Clinical Trials Requiring Conversion To Euros", "label": "Accrued Expenses, Clinical Trials Requiring Conversion To Euros", "terseLabel": "Accrued expenses related to clinical trials requiring conversion to euros" } } }, "localname": "AccruedExpensesClinicalTrialsRequiringConversionToEuros", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AccruedInterestsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Accrued interests.", "label": "Accrued Interests [Member]", "terseLabel": "Accrued Interests [Member]" } } }, "localname": "AccruedInterestsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "domainItemType" }, "gnft_AccruedPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued property, plant and equipment", "label": "Accrued property, plant and equipment", "terseLabel": "Accrued property, plant and equipment" } } }, "localname": "AccruedPropertyPlantAndEquipment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashflowstatementDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AcquisitionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Acquisition costs", "label": "Acquisition costs", "terseLabel": "Acquisition costs" } } }, "localname": "AcquisitionCosts", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AcquisitionOfVersantisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Acquisition of Versantis", "label": "Acquisition of Versantis [Member]", "terseLabel": "Acquisition of Versantis" } } }, "localname": "AcquisitionOfVersantisMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_AdditionalMilestonePayments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additional milestone payments", "label": "Additional milestone payments", "terseLabel": "Additional milestone payments" } } }, "localname": "AdditionalMilestonePayments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AdditionalPaymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional payments.", "label": "Additional Payments [Member]", "terseLabel": "Additional Payments" } } }, "localname": "AdditionalPaymentsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_AdditionalShareBasedInstrumentsIssued": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additional share based instruments issued.", "label": "Additional Share Based Instruments Issued", "terseLabel": "Additional share based instruments issued (in shares)" } } }, "localname": "AdditionalShareBasedInstrumentsIssued", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_AdditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Additions", "label": "Additions [Member]", "terseLabel": "Additions" } } }, "localname": "AdditionsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_AdditionsOtherThanThroughBusinessCombinationsAndAccumulatedDepreciationAndImpairmentPropertyPlantAndEquipment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions other than through business combinations and accumulated depreciation and impairment property plant and equipment.", "label": "Additions Other Than Through Business Combinations And Accumulated Depreciation And Impairment Property Plant And Equipment", "terseLabel": "Increase" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsAndAccumulatedDepreciationAndImpairmentPropertyPlantAndEquipment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AdditionsOtherThanThroughBusinessCombinationsAndAmortisationIntangibleAssetsOtherThanGoodwill": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Additions other than through business combinations and amortisation, intangible assets other than goodwill,", "label": "Additions Other Than Through Business Combinations And Amortisation Intangible Assets Other Than Goodwill", "terseLabel": "Increase" } } }, "localname": "AdditionsOtherThanThroughBusinessCombinationsAndAmortisationIntangibleAssetsOtherThanGoodwill", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AdjustmentsForImpairmentAndProvisionForLitigation": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments for impairment and provision for litigation.", "label": "Adjustments For Impairment And Provision For Litigation", "terseLabel": "+ Impairment and provision for litigation" } } }, "localname": "AdjustmentsForImpairmentAndProvisionForLitigation", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gnft_AdjustmentsForProfitSharingGrantedToEmployees": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "order": 3.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Adjustments For Profit Sharing Granted To Employees", "label": "Adjustments For Profit Sharing Granted To Employees", "negatedTerseLabel": "Profit sharing granted to employees", "terseLabel": "Profit sharing granted to employees" } } }, "localname": "AdjustmentsForProfitSharingGrantedToEmployees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AdministrationAndManagementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Administration and management.", "label": "Administration And Management [Member]", "terseLabel": "Administration And Management [Member]" } } }, "localname": "AdministrationAndManagementMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_AdministrativeCostDestructionOfDrugTabletsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Administrative Cost, Destruction Of Drug Tablets", "label": "Administrative Cost, Destruction Of Drug Tablets [Member]", "terseLabel": "Administrative Cost, Destruction Of Drug Tablets" } } }, "localname": "AdministrativeCostDestructionOfDrugTabletsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_AmortizedCostOfFinancialDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of financial debt.", "label": "Amortized Cost Of Financial Debt", "negatedLabel": "Amortized cost of financial debt" } } }, "localname": "AmortizedCostOfFinancialDebt", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AmountsForgoRelatedPartyTransactions": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amounts forgo related party transactions.", "label": "Amounts Forgo Related Party Transactions", "terseLabel": "Amounts forgo, related party transactions" } } }, "localname": "AmountsForgoRelatedPartyTransactions", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AnneHeleneMONSELLATOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Anne-Helene MONSELLATO.", "label": "Anne Helene M O N S E L L A T O [Member]", "terseLabel": "Anne Helene M O N S E L L A T O [Member]" } } }, "localname": "AnneHeleneMONSELLATOMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_ApprenticesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Apprentices.", "label": "Apprentices [Member]", "terseLabel": "Apprentices [Member]" } } }, "localname": "ApprenticesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_AttendanceAndOtherRemunerationPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Attendance and other remuneration payable.", "label": "Attendance And Other Remuneration Payable", "terseLabel": "Amounts due" } } }, "localname": "AttendanceAndOtherRemunerationPayable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AttendanceAndOtherRemunerationPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Attendance and other remuneration payment.", "label": "Attendance And Other Remuneration Payment", "terseLabel": "Amounts paid" } } }, "localname": "AttendanceAndOtherRemunerationPayment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AttendanceFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Attendance fees.", "label": "Attendance Fees [Member]", "terseLabel": "Attendance Fees" } } }, "localname": "AttendanceFeesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_AuditInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Audit Information [Abstract]", "label": "Audit Information [Abstract]" } } }, "localname": "AuditInformationAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_AverageForeignExchangeRateCHFEuro": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "AverageForeignExchangeRateCHFEuro", "label": "AverageForeignExchangeRateCHFEuro", "terseLabel": "AverageForeignExchangeRateCHFEuro" } } }, "localname": "AverageForeignExchangeRateCHFEuro", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_AverageForeignExchangeRateUSDEuro": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "AverageForeignExchangeRateUSDEuro", "label": "AverageForeignExchangeRateUSDEuro", "terseLabel": "AverageForeignExchangeRateUSDEuro" } } }, "localname": "AverageForeignExchangeRateUSDEuro", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BIOTECHAVENIRMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BIOTECH AVENIR.", "label": "B I O T E C H A V E N I R [Member]", "terseLabel": "B I O T E C H A V E N I R [Member]" } } }, "localname": "BIOTECHAVENIRMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_BNPFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BNP 4.", "label": "B N P Four [Member]", "terseLabel": "B N P Four [Member]" } } }, "localname": "BNPFourMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_BNPPGEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BNP PGE", "label": "BNP PGE [Member]", "terseLabel": "BNP PGE [Member]" } } }, "localname": "BNPPGEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_BNPThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BNP 3.", "label": "B N P Three [Member]", "terseLabel": "B N P Three [Member]" } } }, "localname": "BNPThreeMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_BNPTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BNP 2.", "label": "B N P Two [Member]", "terseLabel": "B N P Two [Member]" } } }, "localname": "BNPTwoMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_BPIFRANCEITDIABMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BPI FRANCE - IT-DIAB.", "label": "B P I F R A N C E I T D I A B [Member]", "terseLabel": "BPI FRANCE - IT-DIAB" } } }, "localname": "BPIFRANCEITDIABMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "domainItemType" }, "gnft_BPIPGEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BPI PGE", "label": "BPI PGE [Member]", "terseLabel": "BPI PGE [Member]" } } }, "localname": "BPIPGEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_BPIPretTauxBonifieMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BPI Pret Taux Bonifie", "label": "BPI Pret Taux Bonifie [Member]", "terseLabel": "BPI Pret Taux Bonifie [Member]" } } }, "localname": "BPIPretTauxBonifieMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_BSA2014AMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA 2014-A.", "label": "B S A2014 A [Member]", "terseLabel": "BSA 2014-A" } } }, "localname": "BSA2014AMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "domainItemType" }, "gnft_BSA2014BMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA 2014-B.", "label": "B S A2014 B [Member]", "terseLabel": "BSA 2014-B" } } }, "localname": "BSA2014BMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "domainItemType" }, "gnft_BSA2015AMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA 2015-A.", "label": "B S A2015 A [Member]", "terseLabel": "BSA 2015-A", "verboseLabel": "B S A2015 A [Member]" } } }, "localname": "BSA2015AMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "domainItemType" }, "gnft_BSA2015BMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA 2015-B.", "label": "B S A2015 B [Member]", "terseLabel": "BSA 2015-B" } } }, "localname": "BSA2015BMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "domainItemType" }, "gnft_BSA2017AMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA 2017-A.", "label": "B S A2017 A [Member]", "terseLabel": "B S A2017 A [Member]" } } }, "localname": "BSA2017AMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_BSA2017BMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA 2017-B.", "label": "B S A2017 B [Member]", "terseLabel": "B S A2017 B [Member]" } } }, "localname": "BSA2017BMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_BSA2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSA 2019.", "label": "B S A2019 [Member]", "terseLabel": "B S A2019 [Member]" } } }, "localname": "BSA2019Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_BSAAR2014ABEtCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSAAR 2014-A - B et C.", "label": "B S A A R2014 A B Et C [Member]", "terseLabel": "B S A A R2014 A B Et C [Member]" } } }, "localname": "BSAAR2014ABEtCMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "xbrltype": "domainItemType" }, "gnft_BSAAR2016AEtBMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "BSAAR 2016 A et B.", "label": "B S A A R2016 A Et B [Member]", "terseLabel": "BSAAR 2016-A and B" } } }, "localname": "BSAAR2016AEtBMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "xbrltype": "domainItemType" }, "gnft_BSAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "B S A", "label": "B S A [Member]", "terseLabel": "B S A" } } }, "localname": "BSAMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "gnft_BankLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bank loans.", "label": "Bank Loans [Member]", "terseLabel": "Bank Loans [Member]" } } }, "localname": "BankLoansMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "domainItemType" }, "gnft_BeneficiariesInShareBasedPaymentArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Beneficiaries in share based payment arrangements.", "label": "Beneficiaries In Share Based Payment Arrangements", "terseLabel": "Beneficiaries" } } }, "localname": "BeneficiariesInShareBasedPaymentArrangements", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "stringItemType" }, "gnft_BiotechAvenirSASMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Biotech Avenir SAS.", "label": "Biotech Avenir S A S [Member]", "terseLabel": "Biotech Avenir SAS" } } }, "localname": "BiotechAvenirSASMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_BondsAfterOCEANEsBuybackMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonds After OCEANEs Buyback", "label": "Bonds After OCEANEs Buyback [Member]", "terseLabel": "Bonds after OCEANEs buyback" } } }, "localname": "BondsAfterOCEANEsBuybackMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "domainItemType" }, "gnft_BondsAtOriginMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonds At Origin", "label": "Bonds At Origin [Member]", "terseLabel": "Bonds at origin" } } }, "localname": "BondsAtOriginMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "domainItemType" }, "gnft_BondsConvertibleOrExchangeableIntoExistingOrNewSharesOCEANEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonds Convertible Or Exchangeable Into Existing Or New Shares O C E A N E", "label": "Bonds Convertible Or Exchangeable Into Existing Or New Shares O C E A N E [Member]", "terseLabel": "Bonds Convertible Or Exchangeable Into Existing Or New Shares O C E A N E" } } }, "localname": "BondsConvertibleOrExchangeableIntoExistingOrNewSharesOCEANEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANE2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonds Convertible Or Exchangeable Into New Or Existing Shares O C E A N E 2022", "label": "Bonds Convertible Or Exchangeable Into New Or Existing Shares O C E A N E 2022 [Member]", "terseLabel": "O C E A N E 2022" } } }, "localname": "BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANE2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Bonds convertible or exchangeable into new or existing shares (OCEANE).", "label": "Bonds Convertible Or Exchangeable Into New Or Existing Shares O C E A N E [Member]", "terseLabel": "OCEANE" } } }, "localname": "BondsConvertibleOrExchangeableIntoNewOrExistingSharesOCEANEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_BonusGeneratedByThePartialBuybackFollowingTheRenegotiation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Bonus generated by the partial buyback following the renegotiation", "label": "Bonus generated by the partial buyback following the renegotiation", "terseLabel": "Bonus generated by the partial buyback following the renegotiation" } } }, "localname": "BonusGeneratedByThePartialBuybackFollowingTheRenegotiation", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashflowstatementDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BorrowingsAmountDerecognizedAmendedObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowings, Amount Derecognized, Amended Obligation", "label": "Borrowings, Amount Derecognized, Amended Obligation", "terseLabel": "Amount derecognized" } } }, "localname": "BorrowingsAmountDerecognizedAmendedObligation", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BorrowingsDeadlineAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings Deadline", "label": "Borrowings Deadline [Axis]", "terseLabel": "Borrowings Deadline [Axis]" } } }, "localname": "BorrowingsDeadlineAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_BorrowingsDeadlineDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings Deadline [Domain]", "label": "Borrowings Deadline [Domain]", "terseLabel": "Borrowings Deadline [Domain]" } } }, "localname": "BorrowingsDeadlineDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_BorrowingsInterestRatePayableSemiAnnually": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings, Interest rate, Payable Semi-annually", "label": "Borrowings, Interest rate, Payable Semi-annually", "terseLabel": "Annual nominal interest rate, payable semi-annually (in percent)" } } }, "localname": "BorrowingsInterestRatePayableSemiAnnually", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "gnft_BorrowingsInterestRateStateGuaranteePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings, Interest Rate, State Guarantee Percentage", "label": "Borrowings, Interest Rate, State Guarantee Percentage", "terseLabel": "Interest Rate, including state guarantee (in percent)" } } }, "localname": "BorrowingsInterestRateStateGuaranteePercentage", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_BorrowingsOptionalRepaymentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings, Optional Repayment Term", "label": "Borrowings, Optional Repayment Term", "terseLabel": "Borrowings, Optional Repayment Term" } } }, "localname": "BorrowingsOptionalRepaymentTerm", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_BorrowingsRecognizedForAmendedObligation": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowings, Recognized For Amended Obligation", "label": "Borrowings, Recognized For Amended Obligation", "terseLabel": "Borrowings, recognized for amended obligation" } } }, "localname": "BorrowingsRecognizedForAmendedObligation", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BorrowingsRecognizedUsingEffectiveInterestRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowings, Recognized Using Effective Interest Rate", "label": "Borrowings, Recognized Using Effective Interest Rate", "terseLabel": "Borrowings, recognized using effective interest rate" } } }, "localname": "BorrowingsRecognizedUsingEffectiveInterestRate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BorrowingsRecognizedUsingEffectiveInterestRateLessThanAYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Borrowings, Recognized Using Effective Interest Rate, Less Than A Year", "label": "Borrowings, Recognized Using Effective Interest Rate, Less Than A Year", "terseLabel": "Borrowings, recognized using effective interest rate, less than a year" } } }, "localname": "BorrowingsRecognizedUsingEffectiveInterestRateLessThanAYear", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BorrowingsTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Borrowings, Term", "label": "Borrowings, Term", "terseLabel": "Borrowings, Term" } } }, "localname": "BorrowingsTerm", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_BuildingOnNonFreeholdLandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Building on non-freehold land.", "label": "Building On Non Freehold Land [Member]", "terseLabel": "Building on Non-Freehold Land" } } }, "localname": "BuildingOnNonFreeholdLandMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "gnft_BuildingsOnNonFreeholdLandMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buildings on non-freehold land.", "label": "Buildings On Non Freehold Land [Member]", "terseLabel": "Buildings On Non Freehold Land [Member]" } } }, "localname": "BuildingsOnNonFreeholdLandMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_BuybackBonus": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Buyback bonus.", "label": "Buyback Bonus", "terseLabel": "Buyback bonus" } } }, "localname": "BuybackBonus", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BuybackOfDebtInstrument": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buyback of debt instrument.", "label": "Buyback Of Debt Instrument", "terseLabel": "Buyback instrument" } } }, "localname": "BuybackOfDebtInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_BuybackOfDebtInstrumentAccruedInterestPerInstrument": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buyback of debt instrument accrued interest per instrument.", "label": "Buyback Of Debt Instrument, Accrued Interest Per Instrument", "terseLabel": "Accrued interest portion of buyback amount (in EUR per share)" } } }, "localname": "BuybackOfDebtInstrumentAccruedInterestPerInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "gnft_BuybackOfDebtInstrumentAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Buyback of debt instrument amount.", "label": "Buyback Of Debt Instrument Amount", "terseLabel": "Buyback amount" } } }, "localname": "BuybackOfDebtInstrumentAmount", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BuybackOfDebtInstrumentNominalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Buyback of debt instrument nominal amount.", "label": "Buyback Of Debt Instrument Nominal Amount", "terseLabel": "Buyback (nominal amount)" } } }, "localname": "BuybackOfDebtInstrumentNominalAmount", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_BuybackOfDebtInstrumentPerInstrument": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buyback of debt instrument, per instrument.", "label": "Buyback Of Debt Instrument Per Instrument", "terseLabel": "Buyback price per bond" } } }, "localname": "BuybackOfDebtInstrumentPerInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "gnft_BuybackOfDebtInstrumentPercentageOfOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buyback of debt instrument percentage of outstanding.", "label": "Buyback Of Debt Instrument Percentage Of Outstanding", "terseLabel": "Buyback amount (percent)" } } }, "localname": "BuybackOfDebtInstrumentPercentageOfOutstanding", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_BuybackOfDebtInstrumentsNumberOfInstruments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buyback Of Debt Instruments, Number Of Instruments", "label": "Buyback Of Debt Instruments, Number Of Instruments", "terseLabel": "Number of debt instruments issued" } } }, "localname": "BuybackOfDebtInstrumentsNumberOfInstruments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_BuybackOfDebtInstrumentsShareholderVotingPercentageToExtendMaturityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Buyback Of Debt Instruments, Shareholder Voting Percentage To Extend Maturity Term", "label": "Buyback Of Debt Instruments, Shareholder Voting Percentage To Extend Maturity Term", "terseLabel": "Buyback of debt instruments, shareholder voting percentage to extend maturity term" } } }, "localname": "BuybackOfDebtInstrumentsShareholderVotingPercentageToExtendMaturityTerm", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_CAPTECHSanteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CAPTECH Sant\u00e9", "label": "CAPTECH Sant\u00e9 [Member]", "terseLabel": "CAPTECH Sant\u00e9" } } }, "localname": "CAPTECHSanteMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_CDNFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CDN 5.", "label": "C D N Five [Member]", "terseLabel": "C D N Five [Member]" } } }, "localname": "CDNFiveMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_CDNFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CDN 4.", "label": "C D N Four [Member]", "terseLabel": "C D N Four [Member]" } } }, "localname": "CDNFourMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_CDNPGEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CDN PGE", "label": "CDN PGE [Member]", "terseLabel": "CDN PGE [Member]" } } }, "localname": "CDNPGEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_CDNThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CDN 3.", "label": "C D N Three [Member]", "terseLabel": "C D N Three [Member]" } } }, "localname": "CDNThreeMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_CEOCorporateContractNonCompeteIndemnityCompensationEligibilityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO corporate contract non-compete indemnity compensation eligibility period.", "label": "C E O Corporate Contract Non Compete Indemnity Compensation Eligibility Period", "terseLabel": "CEO Corporate Contract Non-Compete Indemnity Compensation Eligibility Period" } } }, "localname": "CEOCorporateContractNonCompeteIndemnityCompensationEligibilityPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO corporate contract non-compete indemnity compensation upon termination description.", "label": "C E O Corporate Contract Non Compete Indemnity Compensation Upon Termination Description", "terseLabel": "CEO corporate contract non-compete indemnity compensation upon termination description" } } }, "localname": "CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO corporate contract non-compete indemnity compensation upon termination description1.", "label": "C E O Corporate Contract Non Compete Indemnity Compensation Upon Termination Description1", "terseLabel": "CEO corporate contract non-compete indemnity compensation upon termination description" } } }, "localname": "CEOCorporateContractNonCompeteIndemnityCompensationUponTerminationDescription1", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_CEODecisionDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO decision date.", "label": "C E O Decision Date", "terseLabel": "Date of the CEO decision" } } }, "localname": "CEODecisionDate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "dateItemType" }, "gnft_CEOGrossNegligenceSeverancePayDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO gross negligence severance pay description.", "label": "C E O Gross Negligence Severance Pay Description", "terseLabel": "CEO gross negligence severance pay description" } } }, "localname": "CEOGrossNegligenceSeverancePayDescription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_CEOGrossNegligenceSeverancePayDescription1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO gross negligence severance pay description1.", "label": "C E O Gross Negligence Severance Pay Description1", "terseLabel": "CEO gross negligence severance pay description" } } }, "localname": "CEOGrossNegligenceSeverancePayDescription1", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_CEOGrossNegligenceSeverancePayEligibilityPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CEO gross negligence severance pay eligibility period.", "label": "C E O Gross Negligence Severance Pay Eligibility Period", "terseLabel": "CEO gross negligence severance pay eligibility period" } } }, "localname": "CEOGrossNegligenceSeverancePayEligibilityPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_CICFiveMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CIC 5.", "label": "C I C Five [Member]", "terseLabel": "C I C Five [Member]" } } }, "localname": "CICFiveMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_CICFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CIC 4.", "label": "C I C Four [Member]", "terseLabel": "C I C Four [Member]" } } }, "localname": "CICFourMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_CICPGEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CIC PGE", "label": "CIC PGE [Member]", "terseLabel": "CIC PGE [Member]" } } }, "localname": "CICPGEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_CIRTaxCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "CIR tax credit.", "label": "C I R Tax Credit [Member]", "terseLabel": "C I R Tax Credit [Member]" } } }, "localname": "CIRTaxCreditMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_CashAndCashEquivalentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalent.", "label": "Cash And Cash Equivalent [Line Items]", "terseLabel": "Cash and cash equivalent [line items]" } } }, "localname": "CashAndCashEquivalentLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "gnft_CashAndCashEquivalentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash And Cash Equivalents [Member]", "terseLabel": "Cash And Cash Equivalents [Member]" } } }, "localname": "CashAndCashEquivalentsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "gnft_CashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash and cash equivalents.", "label": "Cash And Cash Equivalents [Table]", "terseLabel": "Cash And Cash Equivalents [Table]" } } }, "localname": "CashAndCashEquivalentsTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "gnft_CashCashEquivalentsAndFinancialAssets": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash, cash equivalents and financial assets.", "label": "Cash Cash Equivalents And Financial Assets", "terseLabel": "Total", "verboseLabel": "Cash and cash equivalents and other financial assets" } } }, "localname": "CashCashEquivalentsAndFinancialAssets", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_CashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cash Flow Information [Abstract]", "label": "Cash Flow Information [Abstract]" } } }, "localname": "CashFlowInformationAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_CatherineLARUEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Catherine LARUE.", "label": "Catherine L A R U E [Member]", "terseLabel": "Catherine L A R U E [Member]" } } }, "localname": "CatherineLARUEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_ChairmanAndChiefExecutiveOfficerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chairman and Chief Executive Officer.", "label": "Chairman And Chief Executive Officer [Member]", "terseLabel": "Chairman and Chief Executive Officer" } } }, "localname": "ChairmanAndChiefExecutiveOfficerMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "domainItemType" }, "gnft_ChangesInWorkingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Changes in working capital abstract.", "label": "Changes In Working Capital [Abstract]", "terseLabel": "Changes In Working Capital [Abstract]" } } }, "localname": "ChangesInWorkingCapitalAbstract", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "gnft_ChiefExecutiveOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Chief Executive Officer.", "label": "Chief Executive Officers [Member]", "terseLabel": "Chief Executive Officer" } } }, "localname": "ChiefExecutiveOfficersMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "domainItemType" }, "gnft_ClassesOfDisclosureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classes of Disclosure", "label": "Classes of Disclosure [Axis]", "terseLabel": "Classes of Disclosure [Axis]" } } }, "localname": "ClassesOfDisclosureAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_ClassesOfDisclosureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Classes of Disclosure [Domain]", "label": "Classes of Disclosure [Domain]", "terseLabel": "Classes of Disclosure [Domain]" } } }, "localname": "ClassesOfDisclosureDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_ClinicalTrialRecruitmentPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Clinical Trial Recruitment Period", "label": "Clinical Trial Recruitment Period", "terseLabel": "Clinical Trial Recruitment Period" } } }, "localname": "ClinicalTrialRecruitmentPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_ClosingForeignExchangeRateCHFEuro": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "ClosingForeignExchangeRateCHFEuro", "label": "ClosingForeignExchangeRateCHFEuro", "terseLabel": "ClosingForeignExchangeRateCHFEuro" } } }, "localname": "ClosingForeignExchangeRateCHFEuro", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ClosingForeignExchangeRateUSDEuro": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "ClosingForeignExchangeRateUSDEuro", "label": "ClosingForeignExchangeRateUSDEuro", "terseLabel": "ClosingForeignExchangeRateUSDEuro" } } }, "localname": "ClosingForeignExchangeRateUSDEuro", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_CollaborationAndLicenseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaboration and License Agreement", "label": "Collaboration and License Agreement [Member]", "terseLabel": "Collaboration and License Agreement" } } }, "localname": "CollaborationAndLicenseAgreementMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "domainItemType" }, "gnft_CompanyInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Company information.", "label": "Company Information [Abstract]", "terseLabel": "Company Information [Abstract]" } } }, "localname": "CompanyInformationAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_CompensationOfCorporateOfficersTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to compensation of corporate officers.", "label": "Compensation Of Corporate Officers [Table]", "terseLabel": "Compensation Of Corporate Officers [Table]" } } }, "localname": "CompensationOfCorporateOfficersTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "stringItemType" }, "gnft_CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of notes and other explanatory information related to compensation paid to members of Company's Board of Directors.", "label": "Compensation Paid To Board of Directors Explanatory [Table Text Block]", "terseLabel": "Summary of Compensation Paid to Officers" } } }, "localname": "CompensationPaidToBoardOfDirectorsExplanatoryTableTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersTables" ], "xbrltype": "textBlockItemType" }, "gnft_ConditionalAdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional advances.", "label": "Conditional Advances [Member]", "terseLabel": "Conditional Advances [Member]" } } }, "localname": "ConditionalAdvancesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_ConditionalMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conditional.", "label": "Conditional [Member]", "terseLabel": "Conditional" } } }, "localname": "ConditionalMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_ContractCostsRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Contract costs recognized.", "label": "Contract Costs Recognized", "terseLabel": "Contract costs recognized" } } }, "localname": "ContractCostsRecognized", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ContractedResearchAndDevelopmentActivitiesConductedByThirdPartiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracted research and development activities conducted by third parties.", "label": "Contracted Research And Development Activities Conducted By Third Parties [Member]", "terseLabel": "Contracted research & development activities conducted by third parties" } } }, "localname": "ContractedResearchAndDevelopmentActivitiesConductedByThirdPartiesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_ConversionExchangePremium": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Exchange Premium", "label": "Conversion Exchange Premium", "terseLabel": "Conversion Exchange Premium" } } }, "localname": "ConversionExchangePremium", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ConversionOfConvertibleInstrumentsAsAPercentageOfShareCapital": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion Of Convertible Instruments As A Percentage Of Share Capital", "label": "Conversion Of Convertible Instruments As A Percentage Of Share Capital", "terseLabel": "Percentage of new shares issued (in percent)" } } }, "localname": "ConversionOfConvertibleInstrumentsAsAPercentageOfShareCapital", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Conversion ratio", "label": "Conversion ratio", "terseLabel": "Conversion ratio" } } }, "localname": "ConversionRatio", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "gnft_ConvertibleLoansMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Convertible loans.", "label": "Convertible Loans [Member]", "terseLabel": "Convertible Loans [Member]" } } }, "localname": "ConvertibleLoansMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "gnft_CreditNotesFromSuppliers": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Credit notes from suppliers.", "label": "Credit Notes From Suppliers", "terseLabel": "Credit notes from suppliers" } } }, "localname": "CreditNotesFromSuppliers", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_CreditNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Credit notes", "label": "Credit notes [Member]", "terseLabel": "Credit notes" } } }, "localname": "CreditNotesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "gnft_CurrentGrantsReceivables": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 5.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current grants receivables.", "label": "Current Grants Receivables", "terseLabel": "Current Grants Receivables" } } }, "localname": "CurrentGrantsReceivables", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_CurrentLiquidityContractNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current Liquidity Contract Net", "label": "Current Liquidity Contract Net", "terseLabel": "Current Liquidity Contract Net" } } }, "localname": "CurrentLiquidityContractNet", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_CurrentResearchTaxCredit": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 2.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current research tax credit.", "label": "Current Research Tax Credit", "terseLabel": "Current Research Tax Credit" } } }, "localname": "CurrentResearchTaxCredit", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_CurrentSocialSecurityCostsReceivables": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 3.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Current social security costs receivables.", "label": "Current Social Security Costs Receivables", "terseLabel": "Current Social Security Costs Receivables" } } }, "localname": "CurrentSocialSecurityCostsReceivables", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_DateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date", "label": "Date [Domain]", "terseLabel": "Date [Domain]" } } }, "localname": "DateDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_DateOfDecisionAndDelegationOfBoardOfDirectorsToCEO": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Date of decision and delegation of Board of Directors to CEO.", "label": "Date Of Decision And Delegation Of Board Of Directors To C E O", "terseLabel": "Date of the decision and delegation of the Board of Directors to the CEO" } } }, "localname": "DateOfDecisionAndDelegationOfBoardOfDirectorsToCEO", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "dateItemType" }, "gnft_DateOfExecutiveBoardMeeting": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The date of the executive board meeting.", "label": "Date Of Executive Board Meeting", "terseLabel": "Date of the Executive Board Meeting" } } }, "localname": "DateOfExecutiveBoardMeeting", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "xbrltype": "dateItemType" }, "gnft_DebtInstrumentExtensionOfMaturityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument extension of maturity.", "label": "Debt Instrument Extension Of Maturity Term", "terseLabel": "Extension of maturity" } } }, "localname": "DebtInstrumentExtensionOfMaturityTerm", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_DebtInstrumentIncreaseInConversionRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument increase in conversion ratio.", "label": "Debt Instrument Increase In Conversion Ratio", "terseLabel": "Conversion ratio (Shares per bond)" } } }, "localname": "DebtInstrumentIncreaseInConversionRatio", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "gnft_DebtInstrumentLoanDefermentOnInterestPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Loan Deferment on Interest, Period", "label": "Debt Instrument, Loan Deferment on Interest, Period", "terseLabel": "Loan deferment on interest, period (in years)" } } }, "localname": "DebtInstrumentLoanDefermentOnInterestPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_DebtInstrumentRepaymentOptionsMaximumPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Repayment Options, Maximum Period", "label": "Debt Instrument, Repayment Options, Maximum Period", "terseLabel": "Repayment options, up to (in years)" } } }, "localname": "DebtInstrumentRepaymentOptionsMaximumPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Term", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument, initial term (in years)" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_DebtInstrumentsConversionOptionPerInstrument": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instruments, conversion option per instrument.", "label": "Debt Instruments Conversion Option Per Instrument", "terseLabel": "Conversion option of a new amended OCEANE" } } }, "localname": "DebtInstrumentsConversionOptionPerInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "gnft_DebtInstrumentsDebtComponentPerInstrument": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instruments, debt component per instrument.", "label": "Debt Instruments Debt Component Per Instrument", "terseLabel": "Debt component of a new amended OCEANE (in EUR per bond)" } } }, "localname": "DebtInstrumentsDebtComponentPerInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "gnft_DebtInstrumentsFairValuePerInstrument": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instruments, fair value per instrument.", "label": "Debt Instruments Fair Value Per Instrument", "terseLabel": "Fair value of a new amended OCEANE" } } }, "localname": "DebtInstrumentsFairValuePerInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "gnft_DebtNominalUnitValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt nominal unit value.", "label": "Debt Nominal Unit Value", "terseLabel": "Nominal value per unit (in EUR per bond)" } } }, "localname": "DebtNominalUnitValue", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "gnft_DebtUnitFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Unit Fair Value", "label": "Debt Unit Fair Value", "terseLabel": "Buyback (EUR per bond)" } } }, "localname": "DebtUnitFairValue", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "gnft_DecreaseInBorrowingsThroughConversionOfConvertibleInstruments": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reduction in financial debt.", "label": "Decrease In Borrowings Through Conversion Of Convertible Instruments", "terseLabel": "Reduction in financial debt" } } }, "localname": "DecreaseInBorrowingsThroughConversionOfConvertibleInstruments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_DecreaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decrease", "label": "Decrease [Member]", "terseLabel": "Decrease" } } }, "localname": "DecreaseMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_DecreaseUnusedInProvisionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decrease (unused) in Provisions", "label": "Decrease (unused) in Provisions [Member]", "terseLabel": "Decrease (unused) in Provisions [Member]" } } }, "localname": "DecreaseUnusedInProvisionsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_DecreaseUsedInProvisionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Decrease (used) in Provisions", "label": "Decrease (used) in Provisions [Member]", "terseLabel": "Decrease (used) in Provisions [Member]" } } }, "localname": "DecreaseUsedInProvisionsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_DeferredIncomeAndRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deferred Income and Revenue [Abstract]", "label": "Deferred Income and Revenue [Abstract]" } } }, "localname": "DeferredIncomeAndRevenueAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DeferredUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Deferred upfront payment.", "label": "Deferred Upfront Payment", "terseLabel": "Deferred upfront payment" } } }, "localname": "DeferredUpfrontPayment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_DenominatedInCHFMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominated In C H F", "label": "Denominated In C H F [Member]", "terseLabel": "Denominated In C H F" } } }, "localname": "DenominatedInCHFMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_DenominatedInEURMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Denominated in EUR.", "label": "Denominated In E U R [Member]", "terseLabel": "Denominated in EUR" } } }, "localname": "DenominatedInEURMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_DenominatedInUSDMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "denominated in USD.", "label": "Denominated In U S D [Member]", "terseLabel": "Denominated in USD" } } }, "localname": "DenominatedInUSDMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_DepositsAndGuarantees": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 6.0, "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Deposits and guarantees.", "label": "Deposits And Guarantees", "terseLabel": "Deposits And Guarantees" } } }, "localname": "DepositsAndGuarantees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_DepositsAndGuaranteesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Deposits and guarantees.", "label": "Deposits And Guarantees [Member]", "terseLabel": "Deposits And Guarantees [Member]" } } }, "localname": "DepositsAndGuaranteesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "gnft_DepreciationAndAmortizationAndImpairmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Depreciation, and amortization, and impairment.", "label": "Depreciation And Amortization And Impairment [Member]", "terseLabel": "Depreciation, amortization & impairment charges" } } }, "localname": "DepreciationAndAmortizationAndImpairmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_DescriptionOfAccountingPolicyForConsolidationExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for consolidation.", "label": "Description Of Accounting Policy For Consolidation Explanatory [Text Block]", "terseLabel": "Consolidation" } } }, "localname": "DescriptionOfAccountingPolicyForConsolidationExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gnft_DescriptionOfAccountingPolicyForOtherIncomeExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The description of the entity's accounting policy for other income.", "label": "Description Of Accounting Policy For Other Income Explanatory [Text Block]", "terseLabel": "Other income" } } }, "localname": "DescriptionOfAccountingPolicyForOtherIncomeExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "gnft_DescriptionOfExercisePeriodForShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of exercise period for share based payment arrangement.", "label": "Description Of Exercise Period For Share Based Payment Arrangement", "terseLabel": "Exercice period" } } }, "localname": "DescriptionOfExercisePeriodForShareBasedPaymentArrangement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "gnft_DescriptionOfExpectedLifeShareWarrantsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of expected life share warrants granted.", "label": "Description Of Expected Life Share Warrants Granted", "terseLabel": "Expected life" } } }, "localname": "DescriptionOfExpectedLifeShareWarrantsGranted", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "durationItemType" }, "gnft_DescriptionOfNatureOfConditions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of nature of conditions.", "label": "Description Of Nature Of Conditions", "terseLabel": "Nature of conditions" } } }, "localname": "DescriptionOfNatureOfConditions", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "xbrltype": "stringItemType" }, "gnft_DevelopmentAndCommercialMilestonesPaymentsRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Development and commercial milestones payments recognized.", "label": "Development And Commercial Milestones Payments Recognized", "terseLabel": "Development and commercial milestones payments recognized" } } }, "localname": "DevelopmentAndCommercialMilestonesPaymentsRecognized", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_DiscloseInNotesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclose in notes", "label": "Disclose in notes [Member]", "terseLabel": "Disclose in notes" } } }, "localname": "DiscloseInNotesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_DisclosureOfBasisOfPresentationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of basis of presentation.", "label": "Disclosure Of Basis Of Presentation [Abstract]", "terseLabel": "Disclosure Of Basis Of Presentation [Abstract]" } } }, "localname": "DisclosureOfBasisOfPresentationAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfBenefitPaymentsUndereCompanysFrenchRetirementEntityTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of benefit payments undere company's french retirement entity", "label": "Disclosure of benefit payments undere company's french retirement entity [Text Block]", "terseLabel": "Disclosure of benefit payments undere company's french retirement entity" } } }, "localname": "DisclosureOfBenefitPaymentsUndereCompanysFrenchRetirementEntityTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of cash and cash equivalents and short-term deposits classified as cash and cash equivalents.", "label": "Disclosure Of Cash And Cash Equivalents And Short Term Deposits Classified As Cash And Cash Equivalents Explanatory [Text Block]", "terseLabel": "Summary of Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsAndShortTermDepositsClassifiedAsCashAndCashEquivalentsExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash, cash equivalents and financial assets.", "label": "Disclosure Of Cash Cash Equivalents And Financial Assets Explanatory [Text Block]", "terseLabel": "Summary of Cash, Cash Equivalents and Financial Assets" } } }, "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfCashCashEquivalentsAndFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash, cash equivalents and financial assets.", "label": "Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]", "terseLabel": "Disclosure Of Cash Cash Equivalents And Financial Assets [Line Items]" } } }, "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfCashCashEquivalentsAndFinancialAssetsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of cash, cash equivalents and financial assets.", "label": "Disclosure Of Cash Cash Equivalents And Financial Assets [Table]", "terseLabel": "Disclosure Of Cash Cash Equivalents And Financial Assets [Table]" } } }, "localname": "DisclosureOfCashCashEquivalentsAndFinancialAssetsTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfChangeInProvisionTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of change in provision", "label": "Disclosure of change in provision [Text Block]", "terseLabel": "Disclosure of change in provision" } } }, "localname": "DisclosureOfChangeInProvisionTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherprovisionscontingentliabilitiesandcontingentassetsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfCommitmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of commitments.", "label": "Disclosure Of Commitments [Abstract]", "terseLabel": "Disclosure Of Commitments [Abstract]" } } }, "localname": "DisclosureOfCommitmentsAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfCompanyInformationExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of company information.", "label": "Disclosure Of Company Information Explanatory [Text Block]", "terseLabel": "The Company" } } }, "localname": "DisclosureOfCompanyInformationExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TheCompany" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfCompensationOfCorporateOfficersAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of compensation of corporate officers.", "label": "Disclosure Of Compensation Of Corporate Officers [Abstract]", "terseLabel": "Disclosure Of Compensation Of Corporate Officers [Abstract]" } } }, "localname": "DisclosureOfCompensationOfCorporateOfficersAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of compensation of corporate officers.", "label": "Disclosure Of Compensation Of Corporate Officers Explanatory [Text Block]", "terseLabel": "Compensation of Corporate Officers" } } }, "localname": "DisclosureOfCompensationOfCorporateOfficersExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficers" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfCompensationOfCorporateOfficersLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of compensation of corporate officers.", "label": "Disclosure Of Compensation Of Corporate Officers [Line Items]", "terseLabel": "Disclosure Of Compensation Of Corporate Officers [Line Items]" } } }, "localname": "DisclosureOfCompensationOfCorporateOfficersLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfCompensationOfCorporateOfficersTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to compensation of corporate officers.", "label": "Disclosure Of Compensation Of Corporate Officers [Table]", "terseLabel": "Disclosure Of Compensation Of Corporate Officers [Table]" } } }, "localname": "DisclosureOfCompensationOfCorporateOfficersTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfConvertibleLoansTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Convertible Loans", "label": "Disclosure Of Convertible Loans [Table Text Block]", "terseLabel": "Summary of Convertible Loans" } } }, "localname": "DisclosureOfConvertibleLoansTableTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfDetailedInformationAboutBondsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Detailed Information About Bonds", "label": "Disclosure Of Detailed Information About Bonds [Table Text Block]", "terseLabel": "Summary of Bonds" } } }, "localname": "DisclosureOfDetailedInformationAboutBondsTableTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about financial income and expenses.", "label": "Disclosure Of Detailed Information About Financial Income And Expenses Explanatory [Text Block]", "terseLabel": "Summary of Financial Income and Expenses" } } }, "localname": "DisclosureOfDetailedInformationAboutFinancialIncomeAndExpensesExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesTables", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about other financial assets.", "label": "Disclosure Of Detailed Information About Other Financial Assets Explanatory [Text Block]", "terseLabel": "Summary of Other Financial Assets" } } }, "localname": "DisclosureOfDetailedInformationAboutOtherFinancialAssetsExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssets", "http://www.genfit.com/role/OtherFinancialAssetsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfDetailedInformationAboutRefundableAndConditionalAdvancesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about Refundable and conditional advances.", "label": "Disclosure Of Detailed Information About Refundable And Conditional Advances Explanatory [Text Block]", "terseLabel": "Summary of Refundable and Conditional Advances" } } }, "localname": "DisclosureOfDetailedInformationAboutRefundableAndConditionalAdvancesExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfDetailedInformationAboutShareCapitalTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of Detailed Information About Share Capital", "label": "Disclosure of Detailed Information About Share Capital [Text Block]", "terseLabel": "Disclosure of Detailed Information About Share Capital" } } }, "localname": "DisclosureOfDetailedInformationAboutShareCapitalTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of detailed information about trade and other payables.", "label": "Disclosure Of Detailed Information About Trade And Other Payables Explanatory [Text Block]", "terseLabel": "Schedule of Trade and Other Payables" } } }, "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherPayablesExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The disclosure of detailed information about trade and other receivables.", "label": "Disclosure Of Detailed Information About Trade And Other Receivables Explanatory [Text Block]", "terseLabel": "Summary of Trade and Other Receivables" } } }, "localname": "DisclosureOfDetailedInformationAboutTradeAndOtherReceivablesExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfFinancialIncomeAndExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial income and expenses.", "label": "Disclosure Of Financial Income And Expenses [Line Items]", "terseLabel": "Disclosure Of Financial Income And Expenses [Line Items]" } } }, "localname": "DisclosureOfFinancialIncomeAndExpensesLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfFinancialIncomeAndExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of financial income and expenses.", "label": "Disclosure Of Financial Income And Expenses [Table]", "terseLabel": "Disclosure Of Financial Income And Expenses [Table]" } } }, "localname": "DisclosureOfFinancialIncomeAndExpensesTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of major events in the period and events after the period.", "label": "Disclosure Of Major Events In The Period And Events After The Period [Abstract]", "terseLabel": "Disclosure Of Major Events In The Period And Events After The Period [Abstract]" } } }, "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Major Events In The Period And Events After The Period.", "label": "Disclosure Of Major Events In The Period And Events After The Period Explanatory [Text Block]", "terseLabel": "Major Events in the Period and Events After the Period" } } }, "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of major events in the period and events after the period.", "label": "Disclosure Of Major Events In The Period And Events After The Period [Line Items]", "terseLabel": "Disclosure Of Major Events In The Period And Events After The Period [Line Items]" } } }, "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of major events in the period and events after the period.", "label": "Disclosure Of Major Events In The Period And Events After The Period [Table]", "terseLabel": "Disclosure Of Major Events In The Period And Events After The Period [Table]" } } }, "localname": "DisclosureOfMajorEventsInThePeriodAndEventsAfterThePeriodTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of net assets and liabilities of Business Combination [Line Items]", "label": "Disclosure of net assets and liabilities of Business Combination [Line Items]", "terseLabel": "Disclosure of net assets and liabilities of Business Combination [Line Items]" } } }, "localname": "DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of net assets and liabilities of Business Combination [Table]", "label": "Disclosure of net assets and liabilities of Business Combination [Table]", "terseLabel": "Disclosure of net assets and liabilities of Business Combination [Table]" } } }, "localname": "DisclosureOfNetAssetsAndLiabilitiesOfBusinessCombinationTable", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of non-curent assets by geographical area", "label": "Disclosure of non-curent assets by geographical area [Table Text Block]", "terseLabel": "Disclosure of non-curent assets by geographical area" } } }, "localname": "DisclosureOfNonCurentAssetsByGeographicalAreaTableTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingsegmentsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfOperatingExpenseLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with operating expenses.", "label": "Disclosure Of Operating Expense [Line Items]", "terseLabel": "Disclosure Of Operating Expense [Line Items]" } } }, "localname": "DisclosureOfOperatingExpenseLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfOperatingExpenseTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule disclosing information related to operating expenses.", "label": "Disclosure Of Operating Expense [Table]", "terseLabel": "Disclosure Of Operating Expense [Table]" } } }, "localname": "DisclosureOfOperatingExpenseTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of operating expenses and other operating income (expenses).", "label": "Disclosure Of Operating Expenses And Other Operating Income Expenses Explanatory [Text Block]", "terseLabel": "Summary of Operating Expenses and Other Operating Income" } } }, "localname": "DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with operating expenses and other operating income (expenses).", "label": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]", "terseLabel": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Line Items]" } } }, "localname": "DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of operating expenses and other operating income (expenses).", "label": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Table]", "terseLabel": "Disclosure Of Operating Expenses And Other Operating Income Expenses [Table]" } } }, "localname": "DisclosureOfOperatingExpensesAndOtherOperatingIncomeExpensesTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfOtherFinancialAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other financial assets.", "label": "Disclosure Of Other Financial Assets [Abstract]", "terseLabel": "Disclosure Of Other Financial Assets [Abstract]" } } }, "localname": "DisclosureOfOtherFinancialAssetsAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfOtherFinancialAssetsExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other financial assets.", "label": "Disclosure Of Other Financial Assets Explanatory [Text Block]", "terseLabel": "Other Financial Assets" } } }, "localname": "DisclosureOfOtherFinancialAssetsExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssets" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfOtherIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other income.", "label": "Disclosure Of Other Income [Abstract]", "terseLabel": "Disclosure Of Other Income [Abstract]" } } }, "localname": "DisclosureOfOtherIncomeAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfOtherIncomeExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other income.", "label": "Disclosure Of Other Income Explanatory [Text Block]", "terseLabel": "Schedule of Other Income" } } }, "localname": "DisclosureOfOtherIncomeExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfOtherIncomeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other income.", "label": "Disclosure Of Other Income [Line Items]", "terseLabel": "Disclosure Of Other Income [Line Items]" } } }, "localname": "DisclosureOfOtherIncomeLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfOtherIncomeTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of other income.", "label": "Disclosure Of Other Income [Table]", "terseLabel": "Disclosure Of Other Income [Table]" } } }, "localname": "DisclosureOfOtherIncomeTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate", "label": "Disclosure Of Reconciliation Of Accounting Profit Multiplied By Applicable Tax Rates And Average Effective Tax Rate [Table Text Block]", "terseLabel": "Schedule of effective tax rate" } } }, "localname": "DisclosureOfReconciliationOfAccountingProfitMultipliedByApplicableTaxRatesAndAverageEffectiveTaxRateTableTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfRevenueBreakdownByGeographicalAreaTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of revenue breakdown by geographical area", "label": "Disclosure of revenue breakdown by geographical area [Table Text Block]", "terseLabel": "Disclosure of revenue breakdown by geographical area" } } }, "localname": "DisclosureOfRevenueBreakdownByGeographicalAreaTableTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingsegmentsTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfShareBasedCompensationExpenseExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of share based compensation expense.", "label": "Disclosure Of Share Based Compensation Expense Explanatory [Text Block]", "terseLabel": "Summary of Share-based Compensation Under Each Plan According to Change in Estimate" } } }, "localname": "DisclosureOfShareBasedCompensationExpenseExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "gnft_DisclosureOfTradeAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of trade and other payables abstract.", "label": "Disclosure Of Trade And Other Payables [Abstract]", "terseLabel": "Disclosure Of Trade And Other Payables [Abstract]" } } }, "localname": "DisclosureOfTradeAndOtherPayablesAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_DisclosureOfTradeAndOtherReceivablesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of trade and other receivables [Line Items]", "label": "Disclosure of trade and other receivables [Line Items]", "terseLabel": "Disclosure of trade and other receivables [Line Items]" } } }, "localname": "DisclosureOfTradeAndOtherReceivablesLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfTradeAndOtherReceivablesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of trade and other receivables [Table]", "label": "Disclosure of trade and other receivables [Table]", "terseLabel": "Disclosure of trade and other receivables [Table]" } } }, "localname": "DisclosureOfTradeAndOtherReceivablesTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "gnft_DisclosureOfUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of useful lives of property, plant and equipment.", "label": "Disclosure Of Useful Lives Of Property Plant And Equipment Explanatory [Text Block]", "terseLabel": "Summary of Estimated Useful Lives" } } }, "localname": "DisclosureOfUsefulLivesOfPropertyPlantAndEquipmentExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "gnft_DiscontinuanceOfStudyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discontinuance Of Study", "label": "Discontinuance Of Study [Member]", "terseLabel": "Discontinuance of Study" } } }, "localname": "DiscontinuanceOfStudyMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_DiscountedRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Discounted rate.", "label": "Discounted Rate", "terseLabel": "Discounted rate" } } }, "localname": "DiscountedRate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_EffectiveInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Interest Rate", "label": "Effective Interest Rate", "terseLabel": "Effective Interest Rate" } } }, "localname": "EffectiveInterestRate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "gnft_EffectiveInterestRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Interest Rate", "label": "Effective Interest Rate [Member]", "terseLabel": "Effective Interest Rate" } } }, "localname": "EffectiveInterestRateMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_EffectsOfDiscounting": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Effects of discounting.", "label": "Effects Of Discounting", "terseLabel": "Refundable and conditional advances, Effects of discounting" } } }, "localname": "EffectsOfDiscounting", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_EmployeeBenefitExpensesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee benefit expenses.", "label": "Employee Benefit Expenses [Member]", "terseLabel": "Employee expenses" } } }, "localname": "EmployeeBenefitExpensesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_EmployeesAndOfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees and officers.", "label": "Employees And Officers [Member]", "terseLabel": "Employees and Officers" } } }, "localname": "EmployeesAndOfficersMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_EmployeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employees.", "label": "Employees [Member]", "verboseLabel": "Employees" } } }, "localname": "EmployeesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_EndowmentFundBalance": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Endowment fund balance.", "label": "Endowment Fund Balance", "terseLabel": "Endowment fund balance" } } }, "localname": "EndowmentFundBalance", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_EquityComponentBondIssueOCEANE": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity component Bond issue OCEANE", "label": "Equity component Bond issue OCEANE", "terseLabel": "Equity component Bond issue OCEANE" } } }, "localname": "EquityComponentBondIssueOCEANE", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "gnft_EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesBeforeDeferredTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity Component Of Bonds Convertible Or Exchangeable Into New Or Existing Shares Before Deferred Taxes", "label": "Equity Component Of Bonds Convertible Or Exchangeable Into New Or Existing Shares Before Deferred Taxes", "terseLabel": "Increase in equity before deferred taxes" } } }, "localname": "EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesBeforeDeferredTaxes", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesNetOfDeferredTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity component of bonds convertible or exchangeable into new or existing shares net of deferred taxes.", "label": "Equity Component Of Bonds Convertible Or Exchangeable Into New Or Existing Shares Net Of Deferred Taxes", "terseLabel": "Equity component of OCEANE net of deferred taxes" } } }, "localname": "EquityComponentOfBondsConvertibleOrExchangeableIntoNewOrExistingSharesNetOfDeferredTaxes", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "gnft_EquityInstrumentsEquityComponentPerInstrument": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Instruments Equity Component Per Instrument", "label": "Equity Instruments Equity Component Per Instrument", "terseLabel": "Equity instrument of new amended OCEANE (in EUR per bond)" } } }, "localname": "EquityInstrumentsEquityComponentPerInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "gnft_EricBACLETMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Eric BACLET.", "label": "Eric B A C L E T [Member]", "terseLabel": "Eric B A C L E T [Member]" } } }, "localname": "EricBACLETMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_EstimatedFairValueOfShareAccordingToIFRS2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated fair value of share according to IFRS 2.", "label": "Estimated Fair Value Of Share According To I F R S2", "terseLabel": "Estimated fair value - according to IFRS 2 (in EUR per share)" } } }, "localname": "EstimatedFairValueOfShareAccordingToIFRS2", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "gnft_EstimatedFairValueOfShareWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated fair value of share warrant.", "label": "Estimated Fair Value Of Share Warrant", "terseLabel": "Estimated fair value - valued by expert opinion" } } }, "localname": "EstimatedFairValueOfShareWarrant", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "xbrltype": "perShareItemType" }, "gnft_EstimatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Estimated", "label": "Estimated [Member]", "terseLabel": "Estimated" } } }, "localname": "EstimatedMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "domainItemType" }, "gnft_EvaluationDateForPerformanceConditions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Evaluation date for performance conditions.", "label": "Evaluation Date For Performance Conditions", "terseLabel": "Evaluation date for performance conditions" } } }, "localname": "EvaluationDateForPerformanceConditions", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "xbrltype": "stringItemType" }, "gnft_ExchangeRateCHFEuroUsedForVersantisAcquisitionConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exchange Rate CHF Euro used for Versantis acquisition conversion", "label": "Exchange Rate CHF Euro used for Versantis acquisition conversion", "terseLabel": "Exchange Rate CHF Euro used for Versantis acquisition conversion" } } }, "localname": "ExchangeRateCHFEuroUsedForVersantisAcquisitionConversion", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ExchangeRateUSDEuroUsedForVersantisAcquisitionConversion": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Exchange Rate USD Euro used for Versantis acquisition conversion", "label": "Exchange Rate USD Euro used for Versantis acquisition conversion", "terseLabel": "Exchange Rate USD Euro used for Versantis acquisition conversion" } } }, "localname": "ExchangeRateUSDEuroUsedForVersantisAcquisitionConversion", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ExistingHeadquartersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing headquarters.", "label": "Existing Headquarters [Member]", "terseLabel": "Existing Headquarters" } } }, "localname": "ExistingHeadquartersMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_ExistingTurnoverRateAssumption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Existing turnover rate assumption.", "label": "Existing Turnover Rate Assumption", "terseLabel": "Existing turnover rate" } } }, "localname": "ExistingTurnoverRateAssumption", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ExpenseByNatureAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expenses, by nature.", "label": "Expense By Nature [Axis]", "terseLabel": "Expense By Nature" } } }, "localname": "ExpenseByNatureAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "stringItemType" }, "gnft_ExpenseByNatureDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expense By Nature [Domain]", "label": "Expense By Nature [Domain]", "terseLabel": "Expense By Nature [Domain]" } } }, "localname": "ExpenseByNatureDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_ExpenseRelatingToResolutionOfDispute": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Expense Relating To Resolution Of Dispute", "label": "Expense Relating To Resolution Of Dispute", "terseLabel": "Expense relating to resolution of dispute" } } }, "localname": "ExpenseRelatingToResolutionOfDispute", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_FacilitySize": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Facility size.", "label": "Facility Size", "terseLabel": "Facility size" } } }, "localname": "FacilitySize", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "decimalItemType" }, "gnft_FairValueOfShareOptionsShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fair value of share options share based payment arrangement.", "label": "Fair Value Of Share Options Share Based Payment Arrangement", "terseLabel": "Fair value" } } }, "localname": "FairValueOfShareOptionsShareBasedPaymentArrangement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "xbrltype": "perShareItemType" }, "gnft_FemaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Female.", "label": "Female [Member]", "terseLabel": "Female [Member]" } } }, "localname": "FemaleMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_FinanceIncomeConvertibleDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance Income, Convertible Debt", "label": "Finance Income, Convertible Debt", "terseLabel": "Of which Financial income incurred by renegotiating the convertible bond debt OCEANE", "verboseLabel": "Includes the bonus generated by the partial OCEANE buyback" } } }, "localname": "FinanceIncomeConvertibleDebt", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlowsParenthetical", "http://www.genfit.com/role/ConsolidatedStatementsofOperationsParenthetical" ], "xbrltype": "monetaryItemType" }, "gnft_FinanceIncomeFromRenegotiationOfDebt": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Finance income from renegotiation of debt", "label": "Finance income from renegotiation of debt", "terseLabel": "Finance income from renegotiation of debt" } } }, "localname": "FinanceIncomeFromRenegotiationOfDebt", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_FinancialAssetsVariations": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial Assets, Variations", "label": "Financial Assets, Variations", "totalLabel": "Financial Assets, Variations" } } }, "localname": "FinancialAssetsVariations", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_FinancialIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial income and expenses [abstract]", "label": "Financial Income And Expenses [Abstract]", "terseLabel": "Financial Income And Expenses [Abstract]" } } }, "localname": "FinancialIncomeAndExpensesAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_FinancialInvestments": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 4.0, "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Financial Investments", "label": "Financial Investments", "terseLabel": "Financial Investments" } } }, "localname": "FinancialInvestments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_FinancialInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Financial investments", "label": "Financial investments [Member]", "terseLabel": "Financial investments" } } }, "localname": "FinancialInvestmentsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "gnft_FirstYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "First Year", "label": "First Year [Member]", "terseLabel": "First Year" } } }, "localname": "FirstYearMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_FixedAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixed Assets.", "label": "Fixed Assets [Member]", "terseLabel": "Fixed Assets" } } }, "localname": "FixedAssetsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_FixturesAndFittingsPremisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fixtures And Fittings Premises", "label": "Fixtures And Fittings Premises [Member]", "terseLabel": "Fixtures And Fittings Premises" } } }, "localname": "FixturesAndFittingsPremisesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_FluctuationInCurrencyUSDToEUR": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fluctuation In Currency, USD to EUR", "label": "Fluctuation In Currency, USD to EUR", "terseLabel": "Fluctuation in currency (in percent)" } } }, "localname": "FluctuationInCurrencyUSDToEUR", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ForeignExchangeRatesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rates line items.", "label": "Foreign Exchange Rates [Line Items]", "terseLabel": "Foreign Exchange Rates [Line Items]" } } }, "localname": "ForeignExchangeRatesLineItems", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "stringItemType" }, "gnft_ForeignExchangeRatesTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Foreign exchange rates table.", "label": "Foreign Exchange Rates [Table]", "terseLabel": "Foreign Exchange Rates [Table]" } } }, "localname": "ForeignExchangeRatesTable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "stringItemType" }, "gnft_FredericDESDOUITSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Frederic DESDOUITS.", "label": "Frederic D E S D O U I T S [Member]", "terseLabel": "Frederic D E S D O U I T S [Member]" } } }, "localname": "FredericDESDOUITSMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_FreeSharesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Free shares.", "label": "Free Shares [Member]", "terseLabel": "Free Shares" } } }, "localname": "FreeSharesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "gnft_FurnitureAndITEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture and IT equipment.", "label": "Furniture And I T Equipment [Member]", "terseLabel": "Furniture and IT Equipment" } } }, "localname": "FurnitureAndITEquipmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_FurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture.", "label": "Furniture [Member]", "terseLabel": "Furniture [Member]" } } }, "localname": "FurnitureMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "gnft_GainLossOnBuybackOfDebtInstrument": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain (Loss) On Buyback Of Debt Instrument", "label": "Gain (Loss) On Buyback Of Debt Instrument", "terseLabel": "Recognition of financial gain before tax" } } }, "localname": "GainLossOnBuybackOfDebtInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_GainLossOnDisposalOfPropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Gain loss on disposal of property, plant, and equipment.", "label": "Gain Loss On Disposal Of Property Plant And Equipment [Member]", "terseLabel": "Gain / (loss) on disposal of property, plant & equipment" } } }, "localname": "GainLossOnDisposalOfPropertyPlantAndEquipmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_GenfitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genfit", "label": "Genfit [Member]", "terseLabel": "Genfit" } } }, "localname": "GenfitMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_GenosciencePharmaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Genoscience Pharma", "label": "Genoscience Pharma [Member]", "terseLabel": "Genoscience Pharma" } } }, "localname": "GenosciencePharmaMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_GovernmentGrantNetOfFees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Government Grant, Net Of Fees", "label": "Government Grant, Net Of Fees", "terseLabel": "Government grant, net of fees" } } }, "localname": "GovernmentGrantNetOfFees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_GovernmentGrantsAndSubsidiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Government grants and subsidies.", "label": "Government Grants And Subsidies [Member]", "terseLabel": "Government Grants And Subsidies [Member]" } } }, "localname": "GovernmentGrantsAndSubsidiesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_GrantDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Grant date", "label": "Grant date", "terseLabel": "Grant date" } } }, "localname": "GrantDate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "dateItemType" }, "gnft_GrantsReceivables": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 5.0, "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Grants receivables.", "label": "Grants Receivables", "terseLabel": "Grants Receivables" } } }, "localname": "GrantsReceivables", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_IFRS19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IFRS 19", "label": "IFRS 19 [Member]", "terseLabel": "IFRS 19" } } }, "localname": "IFRS19Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "gnft_IFRS38Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "IFRS 38", "label": "IFRS 38 [Member]", "terseLabel": "IFRS 38" } } }, "localname": "IFRS38Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "gnft_ImpactAttributableToDeferredTaxAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impact Attributable To Deferred Tax Assets", "label": "Impact Attributable To Deferred Tax Assets [Member]", "terseLabel": "Impact Attributable To Deferred Tax Assets [Member]" } } }, "localname": "ImpactAttributableToDeferredTaxAssetsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnft_ImpactAttributableToDeferredTaxLiabilitiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Impact Attributable To Deferred Tax Liabilities", "label": "Impact Attributable To Deferred Tax Liabilities [Member]", "terseLabel": "Impact Attributable To Deferred Tax Liabilities [Member]" } } }, "localname": "ImpactAttributableToDeferredTaxLiabilitiesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnft_ImpactOnSubcontractingCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impact On Subcontracting Costs", "label": "Impact On Subcontracting Costs", "terseLabel": "Impact On Subcontracting Costs" } } }, "localname": "ImpactOnSubcontractingCosts", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ImpairmentReorganizationOfVacantPremises": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Impairment, Reorganization Of Vacant Premises", "label": "Impairment, Reorganization Of Vacant Premises", "terseLabel": "Reorganization of vacant premises" } } }, "localname": "ImpairmentReorganizationOfVacantPremises", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_IncreaseDecreaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase Decrease", "label": "Increase Decrease [Axis]", "terseLabel": "Increase Decrease [Axis]" } } }, "localname": "IncreaseDecreaseAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_IncreaseDecreaseDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase Decrease [Domain]", "label": "Increase Decrease [Domain]", "terseLabel": "Increase Decrease [Domain]" } } }, "localname": "IncreaseDecreaseDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_IncreaseDecreaseInFinancialAssetsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Financial Assets", "label": "Increase Decrease In Financial Assets [Axis]", "terseLabel": "Increase Decrease In Financial Assets [Axis]" } } }, "localname": "IncreaseDecreaseInFinancialAssetsAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "gnft_IncreaseDecreaseInFinancialAssetsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Financial Assets [Domain]", "label": "Increase Decrease In Financial Assets [Domain]", "terseLabel": "Increase Decrease In Financial Assets [Domain]" } } }, "localname": "IncreaseDecreaseInFinancialAssetsDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromServicePaidToEmployees": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees", "label": "Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees", "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from service paid to employees" } } }, "localname": "IncreaseDecreaseInNetDefinedBenefitLiabilityAssetResultingFromServicePaidToEmployees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_IncreaseDecreaseInProvisionClosingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) In Provision Closing Cost", "label": "Increase (Decrease) In Provision Closing Cost", "negatedTerseLabel": "Increase (Decrease) In Provision Closing Cost" } } }, "localname": "IncreaseDecreaseInProvisionClosingCost", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_IncreaseDecreaseOfResearchTaxCreditReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) of Research Tax Credit Receivable", "label": "Increase (Decrease) of Research Tax Credit Receivable", "terseLabel": "Increase (Decrease) of Research Tax Credit Receivable" } } }, "localname": "IncreaseDecreaseOfResearchTaxCreditReceivable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_IncreaseDecreaseRelatedToTaxEffectAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase (Decrease) Related To Tax Effect", "label": "Increase (Decrease) Related To Tax Effect [Abstract]", "terseLabel": "Increase (Decrease) Related To Tax Effect [Abstract]" } } }, "localname": "IncreaseDecreaseRelatedToTaxEffectAbstract", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "stringItemType" }, "gnft_IncreaseDecreaseThroughCapitalIncrease": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) through capital increase.", "label": "Increase Decrease Through Capital Increase", "terseLabel": "Capital increase" } } }, "localname": "IncreaseDecreaseThroughCapitalIncrease", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_IncreaseInInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase In Interest Rate", "label": "Increase In Interest Rate", "terseLabel": "Increase in interest rate (in percent)" } } }, "localname": "IncreaseInInterestRate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_IncreaseInProvisionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase in Provisions", "label": "Increase in Provisions [Member]", "terseLabel": "Increase in Provisions [Member]" } } }, "localname": "IncreaseInProvisionsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_IncreaseInTheDebts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase in the debts", "label": "Increase in the debts", "terseLabel": "Increase in the debts" } } }, "localname": "IncreaseInTheDebts", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_IncreaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Increase", "label": "Increase [Member]", "terseLabel": "Increase" } } }, "localname": "IncreaseMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "gnft_InitialDebt": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Initial debt.", "label": "Initial Debt", "terseLabel": "Initial debt" } } }, "localname": "InitialDebt", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_InitialPublicOfferingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Initial public offering.", "label": "Initial Public Offering [Member]", "terseLabel": "Initial Public Offering" } } }, "localname": "InitialPublicOfferingMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_Installments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Installments.", "label": "Installments", "terseLabel": "Installments" } } }, "localname": "Installments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "stringItemType" }, "gnft_InsurancePremiumToBePaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Insurance premium to be paid", "label": "Insurance Premium To Be Paid", "terseLabel": "Insurance premium to be paid" } } }, "localname": "InsurancePremiumToBePaid", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_InterestBearingCurrentAccountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest bearing current account.", "label": "Interest Bearing Current Account [Member]", "terseLabel": "Interest Bearing Current Account [Member]" } } }, "localname": "InterestBearingCurrentAccountMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "gnft_InterestExpensesForLeases": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest expenses for leases.", "label": "Interest Expenses For Leases", "negatedLabel": "Interest Expenses For Leases", "negatedTerseLabel": "Interest Expenses For Leases" } } }, "localname": "InterestExpensesForLeases", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_InterestRateYearsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Years", "label": "Interest Rate Years [Axis]", "terseLabel": "Interest Rate Years [Axis]" } } }, "localname": "InterestRateYearsAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_InterestRateYearsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Years [Domain]", "label": "Interest Rate Years [Domain]", "terseLabel": "Interest Rate Years [Domain]" } } }, "localname": "InterestRateYearsDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_InterestRateYearsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest Rate Years", "label": "Interest Rate Years [Member]", "terseLabel": "Interest Rate Years [Member]" } } }, "localname": "InterestRateYearsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_InterestReceivedClassifiedAsFinancingActivities": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Interest received classified as financing activities.", "label": "Interest Received Classified As Financing Activities", "terseLabel": "+ Financial interests received" } } }, "localname": "InterestReceivedClassifiedAsFinancingActivities", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gnft_InventoryPurchaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Inventory Purchase Agreement", "label": "Inventory Purchase Agreement [Member]", "terseLabel": "Inventory Purchase Agreement" } } }, "localname": "InventoryPurchaseAgreementMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "domainItemType" }, "gnft_IpsenMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ipsen", "label": "Ipsen [Member]", "terseLabel": "Ipsen" } } }, "localname": "IpsenMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_IssuePricePerShareWarrants": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The issue price per share warrants.", "label": "Issue Price Per Share Warrants", "terseLabel": "Issue price (in EUR per share)" } } }, "localname": "IssuePricePerShareWarrants", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "perShareItemType" }, "gnft_JeanFrancoisMouneyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jean Francois Mouney.", "label": "Jean Francois Mouney [Member]", "terseLabel": "Jean Francois MOUNEY" } } }, "localname": "JeanFrancoisMouneyMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_JeanFranoisTINEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Jean-Fran\u00e7ois TINE", "label": "Jean-Fran\u00e7ois TINE [Member]", "terseLabel": "Jean-Fran\u00e7ois TINE [Member]" } } }, "localname": "JeanFranoisTINEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_KatherineKALINMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Katherine KALIN.", "label": "Katherine K A L I N [Member]", "terseLabel": "Katherine K A L I N [Member]" } } }, "localname": "KatherineKALINMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_KeyManagementPersonnelCompensationAttendanceFees": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": 3.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, attendance fees", "label": "Key management personnel compensation, attendance fees", "terseLabel": "Key management personnel compensation, attendance fees" } } }, "localname": "KeyManagementPersonnelCompensationAttendanceFees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_KeyManagementPersonnelCompensationConsultingFees": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": 7.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, consulting fees", "label": "Key management personnel compensation, consulting fees", "terseLabel": "Key management personnel compensation, consulting fees" } } }, "localname": "KeyManagementPersonnelCompensationConsultingFees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_KeyManagementPersonnelCompensationContributionInKind": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": 4.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, contribution in kind", "label": "Key management personnel compensation, contribution in kind", "terseLabel": "Key management personnel compensation, contribution in kind" } } }, "localname": "KeyManagementPersonnelCompensationContributionInKind", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_KeyManagementPersonnelCompensationDirectorFeesOfSubsidiary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, director fees of subsidiary.", "label": "Key Management Personnel Compensation Director Fees Of Subsidiary", "terseLabel": "Key Management Personnel Compensation Director Fees Of Subsidiary" } } }, "localname": "KeyManagementPersonnelCompensationDirectorFeesOfSubsidiary", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_KeyManagementPersonnelCompensationFixedCompensationFees": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": 1.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, fixed compensation fees", "label": "Key management personnel compensation, fixed compensation fees", "terseLabel": "Key management personnel compensation, fixed compensation fees" } } }, "localname": "KeyManagementPersonnelCompensationFixedCompensationFees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_KeyManagementPersonnelCompensationVariableCompensationFees": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": 2.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation, variable compensation fees", "label": "Key management personnel compensation, variable compensation fees", "terseLabel": "Key management personnel compensation, variable compensation fees" } } }, "localname": "KeyManagementPersonnelCompensationVariableCompensationFees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_KeyManagementPersonnelCompensationemployerContributions": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": 6.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Key management personnel compensation,employer contributions", "label": "Key management personnel compensation,employer contributions", "terseLabel": "Key management personnel compensation,employer contributions" } } }, "localname": "KeyManagementPersonnelCompensationemployerContributions", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "gnft_LabcorpMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Labcorp", "label": "Labcorp [Member]", "terseLabel": "Labcorp" } } }, "localname": "LabcorpMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "domainItemType" }, "gnft_LeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lease.", "label": "Lease [Member]", "terseLabel": "Lease" } } }, "localname": "LeaseMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "gnft_LeasedEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Leased equipment.", "label": "Leased Equipment [Member]", "terseLabel": "Leased equipment" } } }, "localname": "LeasedEquipmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_LicenceFeesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "licence fees", "label": "licence fees [Axis]", "terseLabel": "licence fees [Axis]" } } }, "localname": "LicenceFeesAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "stringItemType" }, "gnft_LicenceFeesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "licence fees [Domain]", "label": "licence fees [Domain]", "terseLabel": "licence fees [Domain]" } } }, "localname": "LicenceFeesDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "domainItemType" }, "gnft_LicenseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Agreements", "label": "License Agreements [Member]", "terseLabel": "License Agreements" } } }, "localname": "LicenseAgreementsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "domainItemType" }, "gnft_LicensingAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Licensing Agreement", "label": "Licensing Agreement [Member]", "terseLabel": "Licensing Agreement" } } }, "localname": "LicensingAgreementMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "domainItemType" }, "gnft_LifeExpectancyDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life expectancy description.", "label": "Life Expectancy Description", "terseLabel": "Life expectancy" } } }, "localname": "LifeExpectancyDescription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "stringItemType" }, "gnft_LiquidityContractNet": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 2.0, "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Liquidity contract net.", "label": "Liquidity Contract Net", "terseLabel": "Liquidity Contract Net", "verboseLabel": "Liquidity account, cash balance" } } }, "localname": "LiquidityContractNet", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_LiquidityContractVariations": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 1.0, "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Liquidity Contract, Variations", "label": "Liquidity Contract, Variations", "terseLabel": "Liquidity Contract, Variations" } } }, "localname": "LiquidityContractVariations", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_LoansAndReceivablesVariations": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 3.0, "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Loans And Receivables, Variations", "label": "Loans And Receivables, Variations", "terseLabel": "Loans And Receivables, Variations" } } }, "localname": "LoansAndReceivablesVariations", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_LoansGrantedInContextOfCOVID19Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Loans Granted in Context of COVID-19", "label": "Loans Granted in Context of COVID-19 [Member]", "terseLabel": "Loans Granted in Context of COVID-19" } } }, "localname": "LoansGrantedInContextOfCOVID19Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_LongTermDepositsAndGuarantees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long-term deposits and guarantees.", "label": "Long Term Deposits And Guarantees", "terseLabel": "Long Term Deposits And Guarantees" } } }, "localname": "LongTermDepositsAndGuarantees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_LongTermDepositsAndGuaranteesVariations": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 2.0, "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Long Term Deposits And Guarantees, Variations", "label": "Long Term Deposits And Guarantees, Variations", "terseLabel": "Long Term Deposits And Guarantees, Variations" } } }, "localname": "LongTermDepositsAndGuaranteesVariations", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_MaleMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Male.", "label": "Male [Member]", "terseLabel": "Male [Member]" } } }, "localname": "MaleMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_ManagementBoardMeetingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Management board meeting date.", "label": "Management Board Meeting Date", "terseLabel": "Date of the Management Board meeting" } } }, "localname": "ManagementBoardMeetingDate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "dateItemType" }, "gnft_MarketingAndCommercialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Marketing and commercial.", "label": "Marketing And Commercial [Member]", "terseLabel": "Marketing And Commercial [Member]" } } }, "localname": "MarketingAndCommercialMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_MaximumAmountToBePaidIfAnyFurtherAmountsToBePaidAsConditionalAdvance": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum amount to be paid if any further amounts to be paid as conditional advance.", "label": "Maximum Amount To Be Paid If Any Further Amounts To Be Paid As Conditional Advance", "terseLabel": "Maximum amount to be paid if any further amounts to be paid as conditional advance" } } }, "localname": "MaximumAmountToBePaidIfAnyFurtherAmountsToBePaidAsConditionalAdvance", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_MaximumCommitmentAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Maximum commitment amount.", "label": "Maximum Commitment Amount", "terseLabel": "Maximum commitment amount" } } }, "localname": "MaximumCommitmentAmount", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_MaximumDilutionOfConvertibleInstrumentsPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum Dilution Of Convertible Instruments, Percentage", "label": "Maximum Dilution Of Convertible Instruments, Percentage", "terseLabel": "Maximum dilution of convertible instruments, percentage" } } }, "localname": "MaximumDilutionOfConvertibleInstrumentsPercentage", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_NatixisPGEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Natixis PGE", "label": "Natixis PGE [Member]", "terseLabel": "Natixis PGE [Member]" } } }, "localname": "NatixisPGEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_NatureOfReveivablesAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of reveivables", "label": "Nature of reveivables [Axis]", "terseLabel": "Nature of reveivables [Axis]" } } }, "localname": "NatureOfReveivablesAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "stringItemType" }, "gnft_NatureOfReveivablesDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nature of reveivables [Domain]", "label": "Nature of reveivables [Domain]", "terseLabel": "Nature of reveivables [Domain]" } } }, "localname": "NatureOfReveivablesDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "domainItemType" }, "gnft_NetCashAdjustmentPayment": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Net cash adjustment payment", "label": "Net cash adjustment payment", "terseLabel": "Net cash adjustment payment" } } }, "localname": "NetCashAdjustmentPayment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NewBuildingMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "New building.", "label": "New Building [Member]", "terseLabel": "New Building" } } }, "localname": "NewBuildingMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_NonCurrentAssetsByGeographical": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Non Current Assets By Geographical", "label": "Non Current Assets By Geographical", "terseLabel": "Non Current Assets By Geographical" } } }, "localname": "NonCurrentAssetsByGeographical", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NonRefundableUpfrontPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Non-refundable upfront payment.", "label": "Non Refundable Upfront Payment", "terseLabel": "Non-refundable upfront payment" } } }, "localname": "NonRefundableUpfrontPayment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NonRepayableMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Non Repayable", "label": "Non Repayable [Member]", "terseLabel": "Non Repayable" } } }, "localname": "NonRepayableMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_NoncurrentGrantsReceivables": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncurrent grants receivables.", "label": "Noncurrent Grants Receivables", "negatedLabel": "Noncurrent Grants Receivables" } } }, "localname": "NoncurrentGrantsReceivables", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NoncurrentLiquidityContractNet": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncurrent Liquidity Contract Net", "label": "Noncurrent Liquidity Contract Net", "terseLabel": "Noncurrent Liquidity Contract Net" } } }, "localname": "NoncurrentLiquidityContractNet", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NoncurrentProvisionClosingCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncurrent provision closing cost.", "label": "Noncurrent Provision Closing Cost", "terseLabel": "Non-current provision closing cost" } } }, "localname": "NoncurrentProvisionClosingCost", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NoncurrentResearchTaxCredit": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncurrent research tax credit.", "label": "Noncurrent Research Tax Credit", "terseLabel": "Noncurrent Research Tax Credit" } } }, "localname": "NoncurrentResearchTaxCredit", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NoncurrentSocialSecurityCostsReceivables": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Noncurrent social security costs receivables.", "label": "Noncurrent Social Security Costs Receivables", "terseLabel": "Noncurrent Social Security Costs Receivables" } } }, "localname": "NoncurrentSocialSecurityCostsReceivables", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_NumberOfBankLoans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Bank Loans", "label": "Number Of Bank Loans", "terseLabel": "Number Of Bank Loans" } } }, "localname": "NumberOfBankLoans", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "gnft_NumberOfBiannualInstallments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Biannual Installments", "label": "Number Of Biannual Installments", "terseLabel": "Number of biannual installments" } } }, "localname": "NumberOfBiannualInstallments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_NumberOfCoFoundersHoldShareCapitalOfRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of co-founders hold share capital of related party.", "label": "Number Of Co Founders Hold Share Capital Of Related Party", "terseLabel": "Number of co-founders hold share capital of related party" } } }, "localname": "NumberOfCoFoundersHoldShareCapitalOfRelatedParty", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_NumberOfCommercialBanks": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Commercial Banks", "label": "Number Of Commercial Banks", "terseLabel": "Number Of Commercial Banks" } } }, "localname": "NumberOfCommercialBanks", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "decimalItemType" }, "gnft_NumberOfConvertibleAndExchangeableBondsForNewOrExistingShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Convertible And Exchangeable Bonds For New Or Existing Shares", "label": "Number Of Convertible And Exchangeable Bonds For New Or Existing Shares", "terseLabel": "Number of convertible and exchangeable bonds for new or existing shares" } } }, "localname": "NumberOfConvertibleAndExchangeableBondsForNewOrExistingShares", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfDebtInstrumentsIssuedSubjectToConversion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Debt Instruments Issued Subject To Conversion", "label": "Number Of Debt Instruments Issued Subject To Conversion", "terseLabel": "New O C E AN E shares (in shares)" } } }, "localname": "NumberOfDebtInstrumentsIssuedSubjectToConversion", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_NumberOfEmployeesHoldShareCapitalOfRelatedParty": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of employees hold share capital of related party.", "label": "Number Of Employees Hold Share Capital Of Related Party", "terseLabel": "Number of employees hold share capital of related party" } } }, "localname": "NumberOfEmployeesHoldShareCapitalOfRelatedParty", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_NumberOfFreeSharesAcquried": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of free shares acquried", "label": "Number of free shares acquried", "terseLabel": "Number of free shares acquried" } } }, "localname": "NumberOfFreeSharesAcquried", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfOtherEquityInstrumentsAwardedInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement", "label": "Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement", "terseLabel": "Number Of Other Equity Instruments Awarded In Share Based Payment Arrangement" } } }, "localname": "NumberOfOtherEquityInstrumentsAwardedInShareBasedPaymentArrangement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToCompanyRDProgramm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to Company R&D programm", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to Company R&D programm", "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to NSIA diagnostic" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToCompanyRDProgramm", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to Development Of Elafibranor In P B C And Elative Clinical", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to Development Of Elafibranor In P B C And Elative Clinical", "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to Development Of Elafibranor In P B C And Elative Clinical" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfTheGNS561Program": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to development of the GNS561 program", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to development of the GNS561 program", "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to development of the GNS561 program" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToDevelopmentOfTheGNS561Program", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToNTZProgram": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to NTZ Program", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to NTZ Program", "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to NTZ Program" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToNTZProgram", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToPBCAndELATIVE": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to PBC and ELATIVE", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to PBC and ELATIVE", "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to PBC and ELATIVE" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToPBCAndELATIVE", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToTheProductPipelineOfTheCompany": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments exercisable in share-based payment arrangement relating to the product pipeline of the Company", "label": "Number of other equity instruments exercisable in share-based payment arrangement relating to the product pipeline of the Company", "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement relating to the product pipeline of the Company" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInShareBasedPaymentArrangementRelatingToTheProductPipelineOfTheCompany", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfOtherEquityInstrumentsSubscribedInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of other equity instruments subscribed in share based payment arrangement.", "label": "Number Of Other Equity Instruments Subscribed In Share Based Payment Arrangement", "terseLabel": "Total number of BSAAR subscribed", "verboseLabel": "Total number of AGA subscribed (in shares)" } } }, "localname": "NumberOfOtherEquityInstrumentsSubscribedInShareBasedPaymentArrangement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "gnft_NumberOfQuarterlyPayments": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Quarterly Payments", "label": "Number Of Quarterly Payments", "terseLabel": "Number of quarterly payments," } } }, "localname": "NumberOfQuarterlyPayments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_NumberOfQuarterlyPaymentsAmortizationAndInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Quarterly Payments, Amortization And Interest", "label": "Number Of Quarterly Payments, Amortization And Interest", "terseLabel": "Number of quarterly payments, amortization and interest" } } }, "localname": "NumberOfQuarterlyPaymentsAmortizationAndInterest", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_NumberOfSegment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of segment.", "label": "Number Of Segment", "terseLabel": "Number of segment" } } }, "localname": "NumberOfSegment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "integerItemType" }, "gnft_NumberOfSegmentInformation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Segment Information", "label": "Number Of Segment Information", "terseLabel": "Number Of Segment Information" } } }, "localname": "NumberOfSegmentInformation", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "fileNumberItemType" }, "gnft_NumberOfShareOptionsSubscribedInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options subscribed in share based payment arrangement.", "label": "Number Of Share Options Subscribed In Share Based Payment Arrangement", "terseLabel": "Total number of SO subscribed" } } }, "localname": "NumberOfShareOptionsSubscribedInShareBasedPaymentArrangement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "gnft_NumberOfShareOptionsVestedShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share options vested share based payment arrangement.", "label": "Number Of Share Options Vested Share Based Payment Arrangement", "terseLabel": "Total number of SO definitively vested" } } }, "localname": "NumberOfShareOptionsVestedShareBasedPaymentArrangement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "gnft_NumberOfShareWarrantsRemainingInShareBasedPaymentArrangement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of share warrants remaining in share based payment arrangement.", "label": "Number Of Share Warrants Remaining In Share Based Payment Arrangement", "terseLabel": "Total number of BSAAR remaining (in shares)" } } }, "localname": "NumberOfShareWarrantsRemainingInShareBasedPaymentArrangement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfSharesIssuedDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Shares Issued During Period", "label": "Number Of Shares Issued During Period", "terseLabel": "Number of shares issued during period (in shares)" } } }, "localname": "NumberOfSharesIssuedDuringPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfSharesNonIncludedInTheComputationOfDilutedEarningsPerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share", "label": "Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share", "terseLabel": "Number Of Shares Non Included In The Computation Of Diluted Earnings Per Share" } } }, "localname": "NumberOfSharesNonIncludedInTheComputationOfDilutedEarningsPerShare", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfSharesRecordedAsDeductionFromEquity": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares recorded as deduction from equity.", "label": "Number Of Shares Recorded As Deduction From Equity", "terseLabel": "Number of shares recorded as deduction from equity (in shares)" } } }, "localname": "NumberOfSharesRecordedAsDeductionFromEquity", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfSharesVested": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares vested.", "label": "Number Of Shares Vested", "terseLabel": "Number of shares vested (in shares)" } } }, "localname": "NumberOfSharesVested", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfSharesWithDoubleVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares with double voting rights.", "label": "Number Of Shares With Double Voting Rights", "terseLabel": "Number of shares in entity held to entitle double voting rights (in shares)" } } }, "localname": "NumberOfSharesWithDoubleVotingRights", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfTreasuryShares": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/EquityAdditionalInformationDetails": { "order": 2.0, "parentTag": "ifrs-full_NumberOfSharesOutstanding", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of Treasury shares", "label": "Number of Treasury shares", "terseLabel": "Treasury shares" } } }, "localname": "NumberOfTreasuryShares", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_NumberOfYearsOfSuccessivePlan": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of years of successive plan.", "label": "Number Of Years Of Successive Plan", "terseLabel": "Number of years of successive plan" } } }, "localname": "NumberOfYearsOfSuccessivePlan", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_OCEANESMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "OCEANES", "label": "OCEANES [Member]", "terseLabel": "OCEANES" } } }, "localname": "OCEANESMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "domainItemType" }, "gnft_ObligationsUnderFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Obligations under finance leases.", "label": "Obligations Under Finance Leases [Member]", "terseLabel": "Obligations Under Finance Leases [Member]" } } }, "localname": "ObligationsUnderFinanceLeasesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "gnft_ObligationsUnderLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Obligations under leases.", "label": "Obligations Under Leases [Member]", "terseLabel": "Obligations Under Leases [Member]" } } }, "localname": "ObligationsUnderLeasesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "domainItemType" }, "gnft_OfficersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Officers.", "label": "Officers [Member]", "terseLabel": "Officers", "verboseLabel": "Officers [Member]" } } }, "localname": "OfficersMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_OperatingExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating expense.", "label": "Operating Expense [Abstract]", "terseLabel": "Operating Expense [Abstract]" } } }, "localname": "OperatingExpenseAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_OtherExpenseByNatureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other expense by nature.", "label": "Other Expense By Nature [Member]", "terseLabel": "Other expenses (maintenance, fees, travel, taxes)" } } }, "localname": "OtherExpenseByNatureMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_OtherFinancialLoansAndBorrowingsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other financial loans and borrowings.", "label": "Other Financial Loans And Borrowings [Member]", "terseLabel": "Other Financial Loans And Borrowings [Member]" } } }, "localname": "OtherFinancialLoansAndBorrowingsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "domainItemType" }, "gnft_OtherInvestments": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 5.0, "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Investments", "label": "Other Investments", "terseLabel": "Other Investments" } } }, "localname": "OtherInvestments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_OtherInvestmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other investments", "label": "Other investments [Member]", "terseLabel": "Other investments" } } }, "localname": "OtherInvestmentsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "gnft_OtherInvestmentsNumberOfUnitsOfSubscription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Investments - Number of units of subscription", "label": "Other Investments - Number of units of subscription", "terseLabel": "Other Investments - Number of units of subscription" } } }, "localname": "OtherInvestmentsNumberOfUnitsOfSubscription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "integerItemType" }, "gnft_OtherInvestmentsPercentageOfSubscriptionPaid": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Investments - Percentage of Subscription paid", "label": "Other Investments - Percentage of Subscription paid", "terseLabel": "Other Investments - Percentage of Subscription paid" } } }, "localname": "OtherInvestmentsPercentageOfSubscriptionPaid", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "percentItemType" }, "gnft_OtherInvestmentsRemainingSubscription": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Investments - Remaining subscription", "label": "Other Investments - Remaining subscription", "terseLabel": "Other Investments - Remaining subscription" } } }, "localname": "OtherInvestmentsRemainingSubscription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_OtherInvestmentsSubscriptionPaid": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Other Investments - Subscription paid", "label": "Other Investments - Subscription paid", "terseLabel": "Other Investments - Subscription paid" } } }, "localname": "OtherInvestmentsSubscriptionPaid", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_OtherLoansAndBorrowings": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Other loans and borrowings.", "label": "Other Loans And Borrowings", "terseLabel": "Other Loans And Borrowings", "verboseLabel": "TOTAL - Other loans and borrowings" } } }, "localname": "OtherLoansAndBorrowings", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_OtherMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other.", "label": "Other [Member]", "terseLabel": "Other [Member]" } } }, "localname": "OtherMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_OtherOperatingIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other Operating Income", "label": "Other Operating Income [Member]", "terseLabel": "Other Operating Income [Member]" } } }, "localname": "OtherOperatingIncomeMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_OtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other payables.", "label": "Other Payables [Member]", "terseLabel": "Other Payables [Member]" } } }, "localname": "OtherPayablesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "gnft_OtherRemunerationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other remuneration.", "label": "Other Remuneration [Member]", "terseLabel": "Other Remuneration" } } }, "localname": "OtherRemunerationMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_OutstandingLoans": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Outstanding loans.", "label": "Outstanding Loans", "terseLabel": "Bank loan outstanding" } } }, "localname": "OutstandingLoans", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "monetaryItemType" }, "gnft_OwnedEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owned equipment.", "label": "Owned Equipment [Member]", "terseLabel": "Owned equipment" } } }, "localname": "OwnedEquipmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_PCASGroupMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PCAS Group.", "label": "P C A S Group [Member]", "terseLabel": "PCAS Group" } } }, "localname": "PCASGroupMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_PSEMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "PSE", "label": "PSE [Member]", "terseLabel": "PSE" } } }, "localname": "PSEMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_PartialRecognitionOfDeferredRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Partial recognition of deferred revenue", "label": "Partial recognition of deferred revenue", "terseLabel": "Partial recognition of deferred revenue" } } }, "localname": "PartialRecognitionOfDeferredRevenue", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "monetaryItemType" }, "gnft_PaymentForBuybackOfDebtInstrument": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment for partial buy back of debt instrument.", "label": "Payment For Buyback Of Debt Instrument", "terseLabel": "Payment for partial buyback" } } }, "localname": "PaymentForBuybackOfDebtInstrument", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_PaymentFromCollaborationUpFrontCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payment from collaboration, up-front cash payment", "label": "Payment from collaboration, up-front cash payment", "terseLabel": "Payment from collaboration, up-front cash payment" } } }, "localname": "PaymentFromCollaborationUpFrontCashPayment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "monetaryItemType" }, "gnft_PercentageOfDiscountOfBondDebtAtEffectiveInterestRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of discount of bond debt at effective interest rate.", "label": "Percentage Of Discount Of Bond Debt At Effective Interest Rate", "terseLabel": "Proportion of discount of bond debt at effective interest rate (as a percent)" } } }, "localname": "PercentageOfDiscountOfBondDebtAtEffectiveInterestRate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfDoubleVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of double voting rights.", "label": "Percentage Of Double Voting Rights", "terseLabel": "Percentage of double voting rights" } } }, "localname": "PercentageOfDoubleVotingRights", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToCompanysRDProgramPortfolio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Exercisable Instruments Relating To Company's R&D program portfolio", "label": "Percentage Of Exercisable Instruments Relating To Company's R&D program portfolio", "terseLabel": "Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToCompanysRDProgramPortfolio", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfCompanyPipeline": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercisable instruments relating to the development of the company's pipeline.", "label": "Percentage Of Exercisable Instruments Relating To Development Of Company Pipeline", "terseLabel": "Percentage of exercisable instruments relating to the development of company pipeline" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfCompanyPipeline", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercisable instruments relating to the development of elafibranor in pbc and the elative clinical.", "label": "Percentage Of Exercisable Instruments Relating To Development Of Elafibranor In P B C And Elative Clinical", "terseLabel": "Percentage of exercisable instruments relating to the development of elafibranor in pbc and elative clinical" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfElafibranorInPBCAndElativeClinical", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheDevelopmentOfTheGNS561Program": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Exercisable Instruments Relating To Development Of The development of the GNS561 program", "label": "Percentage Of Exercisable Instruments Relating To Development Of The development of the GNS561 program", "terseLabel": "Percentage of exercisable instruments relating to development of the product pipeline of the company" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheDevelopmentOfTheGNS561Program", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate20October2024": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024", "label": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024", "terseLabel": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 20 october 2024" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate20October2024", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate31March2024": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 31 march 2024", "label": "Percentage Of Exercisable Instruments Relating To Development Of The Product Pipeline Of The Company Evaluation date 31 march 2024", "terseLabel": "Percentage of exercisable instruments relating to development of the product pipeline of the company" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToDevelopmentOfTheProductPipelineOfTheCompanyEvaluationDate31March2024", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToNI4DiagnosticsTechnology": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of exercisable instruments relating to the ni4 diagnostics technology.", "label": "Percentage Of Exercisable Instruments Relating To N I4 Diagnostics Technology", "terseLabel": "Percentage of exercisable instruments relating to NI4 diagnostics technology" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToNI4DiagnosticsTechnology", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToTheDevelopmentOfNTZAndTheACLFFranchise": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Exercisable Instruments Relating To The Development Of NTZ And The ACLF Franchise", "label": "Percentage Of Exercisable Instruments Relating To The Development Of NTZ And The ACLF Franchise", "terseLabel": "Percentage of exercisable instruments relating to the development of NTZ and the ACLF franchise" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToTheDevelopmentOfNTZAndTheACLFFranchise", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfExercisableInstrumentsRelatingToTheNIS4DiagnosticTechnology": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage Of Exercisable Instruments Relating To The NIS4 Diagnostic Technology", "label": "Percentage Of Exercisable Instruments Relating To The NIS4 Diagnostic Technology", "terseLabel": "Percentage of exercisable instruments relating to the NIS4 diagnostic technology" } } }, "localname": "PercentageOfExercisableInstrumentsRelatingToTheNIS4DiagnosticTechnology", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfFairValueInAssetValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of fair value in asset value", "label": "Percentage of fair value in asset value", "terseLabel": "Percentage of fair value in asset value" } } }, "localname": "PercentageOfFairValueInAssetValue", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfPaymentOfCouponsRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of payment of coupons rate.", "label": "Percentage Of Payment Of Coupons Rate", "terseLabel": "Proportion of payment of coupons rate (as a percent)" } } }, "localname": "PercentageOfPaymentOfCouponsRate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_PercentageOfProfitExceedingLimitOffsettingTaxableProfit": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of profit exceeding limit offsetting taxable profit.", "label": "Percentage Of Profit Exceeding Limit Offsetting Taxable Profit", "terseLabel": "Percentage of profit exceeding limit offsetting taxable profit" } } }, "localname": "PercentageOfProfitExceedingLimitOffsettingTaxableProfit", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "percentItemType" }, "gnft_PerformanceConditionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance conditions.", "label": "Performance Conditions [Member]", "terseLabel": "Performance Conditions" } } }, "localname": "PerformanceConditionsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "gnft_PerformanceConditionsPlanFourMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance conditions plan four.", "label": "Performance Conditions Plan Four [Member]", "terseLabel": "Performance Conditions Plan Four" } } }, "localname": "PerformanceConditionsPlanFourMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "xbrltype": "domainItemType" }, "gnft_PerformanceConditionsPlanOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance conditions plan one.", "label": "Performance Conditions Plan One [Member]", "terseLabel": "SOD 2020 SOC2020 SOUS2020" } } }, "localname": "PerformanceConditionsPlanOneMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_PerformanceConditionsPlanThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance conditions plan three.", "label": "Performance Conditions Plan Three [Member]", "terseLabel": "Performance Conditions Plan Three" } } }, "localname": "PerformanceConditionsPlanThreeMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "xbrltype": "domainItemType" }, "gnft_PerformanceConditionsPlanTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Performance conditions plan two.", "label": "Performance Conditions Plan Two [Member]", "terseLabel": "Performance Conditions Plan Two" } } }, "localname": "PerformanceConditionsPlanTwoMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails" ], "xbrltype": "domainItemType" }, "gnft_PhilippeMOONSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Philippe MOONS.", "label": "Philippe M O O N S [Member]", "terseLabel": "Philippe M O O N S [Member]" } } }, "localname": "PhilippeMOONSMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_PopulationDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Population description.", "label": "Population Description", "terseLabel": "Population Description" } } }, "localname": "PopulationDescription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "stringItemType" }, "gnft_PremisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Premises.", "label": "Premises [Member]", "terseLabel": "Premises" } } }, "localname": "PremisesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "xbrltype": "domainItemType" }, "gnft_PretGarantiParLEtatPGEBancaireMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pret Garanti Par L etat (PGE) Bancaire", "label": "Pret Garanti Par L etat (PGE) Bancaire [Member]", "terseLabel": "Pret Garanti Par L etat (PGE) Bancaire" } } }, "localname": "PretGarantiParLEtatPGEBancaireMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_PriceOfSharesAtAllocation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of shares at allocation.", "label": "Price Of Shares At Allocation", "terseLabel": "Price of the share at the time of allocation" } } }, "localname": "PriceOfSharesAtAllocation", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "gnft_ProbabilityOfContinuedPresenceDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Probability of continued presence description.", "label": "Probability Of Continued Presence Description", "terseLabel": "Probability of continued presence in the company at retirement age" } } }, "localname": "ProbabilityOfContinuedPresenceDescription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "stringItemType" }, "gnft_ProceedsFromSubscriptionOrExerciseOfShareWarrants": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds from subscription or exercise of share warrants.", "label": "Proceeds From Subscription Or Exercise Of Share Warrants", "terseLabel": "+ Proceeds from subscription / exercise of share warrants" } } }, "localname": "ProceedsFromSubscriptionOrExerciseOfShareWarrants", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gnft_PropertyPlantAndEquipmentByFinanceLeaseStatusAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment by finance lease status.", "label": "Property Plant And Equipment By Finance Lease Status [Axis]", "terseLabel": "Property Plant And Equipment By Finance Lease Status" } } }, "localname": "PropertyPlantAndEquipmentByFinanceLeaseStatusAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_PropertyPlantAndEquipmentByFinanceLeaseStatusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment by finance lease status.", "label": "Property Plant And Equipment By Finance Lease Status [Member]", "terseLabel": "Property Plant And Equipment By Finance Lease Status Member" } } }, "localname": "PropertyPlantAndEquipmentByFinanceLeaseStatusMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_PropertyPlantAndEquipmentSubjectToFinanceLeasesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Property plant and equipment subject to finance leases.", "label": "Property Plant And Equipment Subject To Finance Leases [Member]", "terseLabel": "Assets under finance lease contracts" } } }, "localname": "PropertyPlantAndEquipmentSubjectToFinanceLeasesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_ProportionOfLoanGuaranteedByTheFrenchGovernment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proportion Of Loan Guaranteed By The French Government", "label": "Proportion Of Loan Guaranteed By The French Government", "terseLabel": "Proportion of loan guaranteed by the French government (in percent)" } } }, "localname": "ProportionOfLoanGuaranteedByTheFrenchGovernment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ProportionOfTradingPeriodOverNominalValueOfOCEANEs": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Proportion Of Trading Period Over Nominal Value Of OCEANEs", "label": "Proportion Of Trading Period Over Nominal Value Of OCEANEs", "terseLabel": "Proportion of trading period over nominal value of OCEANEs (in percent)" } } }, "localname": "ProportionOfTradingPeriodOverNominalValueOfOCEANEs", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "gnft_ProvisionForCharges": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails": { "order": 1.0, "parentTag": "ifrs-full_CurrentProvisions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision for charges", "label": "Provision for charges", "terseLabel": "Provision for charges [Line Items]" } } }, "localname": "ProvisionForCharges", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ProvisionForLitigation": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails": { "order": 2.0, "parentTag": "ifrs-full_CurrentProvisions", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision for litigation", "label": "Provision for litigation", "terseLabel": "Provision for litigation [Line Items]" } } }, "localname": "ProvisionForLitigation", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ProvisionPension": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Provision, Pension", "label": "Provision, Pension", "terseLabel": "Pension provision" } } }, "localname": "ProvisionPension", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RESOLVEITTrialMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "RESOLVE-IT trial", "label": "RESOLVE-IT trial [Member]", "terseLabel": "RESOLVE-IT trial" } } }, "localname": "RESOLVEITTrialMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_RawMaterialsAndConsumablesUsedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Raw materials and consumables used.", "label": "Raw Materials And Consumables Used [Member]", "terseLabel": "Raw materials & consumables used" } } }, "localname": "RawMaterialsAndConsumablesUsedMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_ReceiptsOfRefundableAndConditionalAdvances": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receipts of refundable and conditional advances.", "label": "Receipts Of Refundable And Conditional Advances", "terseLabel": "Refundable and conditional advances, Receipts" } } }, "localname": "ReceiptsOfRefundableAndConditionalAdvances", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RedeemableWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Redeemable warrants.", "label": "Redeemable Warrants [Member]", "terseLabel": "Redeemable Warrants" } } }, "localname": "RedeemableWarrantsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "gnft_ReferenceSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reference share price.", "label": "Reference Share Price", "terseLabel": "Reference share price" } } }, "localname": "ReferenceSharePrice", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "perShareItemType" }, "gnft_RefundableAndConditionalAdvances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Refundable and conditional advances.", "label": "Refundable And Conditional Advances", "terseLabel": "TOTAL - Refundable and conditional advances" } } }, "localname": "RefundableAndConditionalAdvances", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RefundableAndConditionalAdvancesAmountAllocated": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Refundable and conditional advances amount allocated.", "label": "Refundable And Conditional Advances Amount Allocated", "terseLabel": "Refundable and conditional advances, Total amount allocated" } } }, "localname": "RefundableAndConditionalAdvancesAmountAllocated", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RefundableAndConditionalAdvancesGrantDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refundable and conditional advances grant date.", "label": "Refundable And Conditional Advances Grant Date", "terseLabel": "Refundable and conditional advances, Grant date" } } }, "localname": "RefundableAndConditionalAdvancesGrantDate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "dateItemType" }, "gnft_RefundableAndConditionalAdvancesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Refundable and conditional advances.", "label": "Refundable And Conditional Advances [Member]", "terseLabel": "Refundable And Conditional Advances [Member]" } } }, "localname": "RefundableAndConditionalAdvancesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "domainItemType" }, "gnft_RefundableAndConditionalAdvancesNetBookValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Refundable and conditional advances net book value.", "label": "Refundable And Conditional Advances Net Book Value", "terseLabel": "Refundable and conditional advances, Net book value" } } }, "localname": "RefundableAndConditionalAdvancesNetBookValue", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RelatedPartyTransactionCost": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Related party transaction cost.", "label": "Related Party Transaction Cost", "terseLabel": "Technology transfers cost" } } }, "localname": "RelatedPartyTransactionCost", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RenegotiationCostsEstimated": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Renegotiation costs estimated.", "label": "Renegotiation Costs Estimated", "terseLabel": "Renegotiation costs estimated" } } }, "localname": "RenegotiationCostsEstimated", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RenegotiationCostsRecognized": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Renegotiation costs recognized.", "label": "Renegotiation Costs Recognized", "terseLabel": "Renegotiation costs recognized" } } }, "localname": "RenegotiationCostsRecognized", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RenegotiationFeesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Renegotiation Fees", "label": "Renegotiation Fees [Member]", "terseLabel": "Renegotiation Fees" } } }, "localname": "RenegotiationFeesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_RentalPaymentObligationUnderLeaseAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Rental payment obligation under lease agreement.", "label": "Rental Payment Obligation Under Lease Agreement", "terseLabel": "Rental payment obligation under the lease agreement" } } }, "localname": "RentalPaymentObligationUnderLeaseAgreement", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ReorganizationAndReductionInForce": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ReorganizationAndReductionInForce", "label": "ReorganizationAndReductionInForce", "terseLabel": "ReorganizationAndReductionInForce" } } }, "localname": "ReorganizationAndReductionInForce", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "xbrltype": "textBlockItemType" }, "gnft_ReorganizationAndRestructuringExpenses": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "order": 4.0, "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "This amount represents a transfer of expenses relating to employee training expenses.", "label": "Reorganization And Restructuring Expenses", "negatedLabel": "Reorganization And Restructuring Expenses" } } }, "localname": "ReorganizationAndRestructuringExpenses", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ReorganizationCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Reorganization costs.", "label": "Reorganization Costs", "terseLabel": "Reorganization costs" } } }, "localname": "ReorganizationCosts", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RepaymentsOfLoansAndBorrowings": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net value between the amount repaid on loans and the accrued interest on loans.", "label": "Repayments Of Loans And Borrowings", "negatedLabel": "- Repayments of loans and borrowings" } } }, "localname": "RepaymentsOfLoansAndBorrowings", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "gnft_RepaymentsOfRefundableAndConditionalAdvances": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Repayments of refundable and conditional advances.", "label": "Repayments Of Refundable And Conditional Advances", "terseLabel": "Refundable and conditional advances, Repayments" } } }, "localname": "RepaymentsOfRefundableAndConditionalAdvances", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research and development expense, general and administrative expense, marketing and market access expense and other operating income and expense.", "label": "Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense", "negatedTotalLabel": "Research And Development Expense General And Administrative Expense Marketing And Market Access Expense And Other Operating Income And Expense" } } }, "localname": "ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and development.", "label": "Research And Development [Member]", "terseLabel": "Research And Development [Member]" } } }, "localname": "ResearchAndDevelopmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_ResearchAndLaboratoryEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research and laboratory equipment.", "label": "Research And Laboratory Equipment [Member]", "terseLabel": "Research and Laboratory Equipment" } } }, "localname": "ResearchAndLaboratoryEquipmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails" ], "xbrltype": "domainItemType" }, "gnft_ResearchTaxCredit": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research tax credit.", "label": "Research Tax Credit", "terseLabel": "Research Tax Credit" } } }, "localname": "ResearchTaxCredit", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ResearchTaxCreditCarryforwardPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research Tax Credit, Carryforward Period", "label": "Research Tax Credit, Carryforward Period", "terseLabel": "Research tax credit, carryforward period (in years)" } } }, "localname": "ResearchTaxCreditCarryforwardPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_ResearchTaxCreditDisputeReversal": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Research tax credit dispute reversal.", "label": "Research Tax Credit Dispute Reversal", "terseLabel": "Research tax credit dispute reversal" } } }, "localname": "ResearchTaxCreditDisputeReversal", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ResearchTaxCreditLitigationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Research Tax Credit Litigation", "label": "Research Tax Credit Litigation [Member]", "terseLabel": "Research tax credit litigation" } } }, "localname": "ResearchTaxCreditLitigationMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_ResearchTaxCreditReceivable": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 2.0, "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Research Tax Credit Receivable", "label": "Research Tax Credit Receivable", "terseLabel": "Research Tax Credit Receivable" } } }, "localname": "ResearchTaxCreditReceivable", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RestructuringAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring", "label": "Restructuring [Axis]", "terseLabel": "Restructuring [Axis]" } } }, "localname": "RestructuringAxis", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "gnft_RestructuringDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Restructuring [Domain]", "label": "Restructuring [Domain]", "terseLabel": "Restructuring [Domain]" } } }, "localname": "RestructuringDomain", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_RetirementAge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Retirement age", "label": "Retirement age", "terseLabel": "Retirement age" } } }, "localname": "RetirementAge", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_ReturnToWorkBonusesTrainingsBusinessStartUpAssistanceAndOtherBenefitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Return-To-Work Bonuses, Trainings, Business Start-Up Assistance And Other Benefits", "label": "Return-To-Work Bonuses, Trainings, Business Start-Up Assistance And Other Benefits [Member]", "terseLabel": "Return-to-Work Bonuses, Trainings, Business Start-Up Assistance and Other Benefits" } } }, "localname": "ReturnToWorkBonusesTrainingsBusinessStartUpAssistanceAndOtherBenefitsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_RevenueByDestination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue By Destination", "label": "Revenue By Destination", "terseLabel": "Revenue By Destination" } } }, "localname": "RevenueByDestination", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "pureItemType" }, "gnft_RevenueFromCollaborationUpFrontCashPayment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from collaboration, up-front cash payment", "label": "Revenue from collaboration, up-front cash payment", "terseLabel": "Revenue from collaboration, up-front cash payment" } } }, "localname": "RevenueFromCollaborationUpFrontCashPayment", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RevenueFromContractsWithCustomersNumberOfPerformanceObligations": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Contracts With Customers, Number Of Performance Obligations", "label": "Revenue From Contracts With Customers, Number Of Performance Obligations", "terseLabel": "Number of Performance Obligations" } } }, "localname": "RevenueFromContractsWithCustomersNumberOfPerformanceObligations", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_RevenueFromContractsWithCustomersPotentialMilestonePayments": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue From Contracts With Customers, Potential Milestone Payments", "label": "Revenue From Contracts With Customers, Potential Milestone Payments", "terseLabel": "Revenue from collaboration, potential milestone payments" } } }, "localname": "RevenueFromContractsWithCustomersPotentialMilestonePayments", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RevenueFromContractsWithCustomersValueAddedTaxes": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue From Contracts With Customers, Value Added Taxes", "label": "Revenue From Contracts With Customers, Value Added Taxes", "terseLabel": "Payment from collaboration, up-front cash payment, VAT" } } }, "localname": "RevenueFromContractsWithCustomersValueAddedTaxes", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RevenueFromFranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From France", "label": "Revenue From France [Member]", "terseLabel": "Revenue From France" } } }, "localname": "RevenueFromFranceMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_RevenueFromOtherCountriesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revenue From Other Countries", "label": "Revenue From Other Countries [Member]", "terseLabel": "Revenue From Other Countries" } } }, "localname": "RevenueFromOtherCountriesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_RevenueFromSalesOfInventories": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from sales of inventories", "label": "Revenue from sales of inventories", "terseLabel": "Revenue from sales of inventories" } } }, "localname": "RevenueFromSalesOfInventories", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RevenueOnSupplyOfDrugProductRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue on supply of drug product recognized.", "label": "Revenue On Supply Of Drug Product Recognized", "terseLabel": "Revenue on supply of drug product recognized" } } }, "localname": "RevenueOnSupplyOfDrugProductRecognized", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RevenueRemainingPerformanceObligationVariableConsiderationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount", "terseLabel": "Milestone payments" } } }, "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RevenueRemainingPerformanceObligationVariableContingentConsiderationAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue, Remaining Performance Obligation, Variable Contingent Consideration Amount", "label": "Revenue, Remaining Performance Obligation, Variable Contingent Consideration Amount", "terseLabel": "Contingent milestone payments" } } }, "localname": "RevenueRemainingPerformanceObligationVariableContingentConsiderationAmount", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ReversalImpairmentOfRightsRelatedOfLeasedPremisesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reversal Impairment Of Rights Related Of Leased Premises", "label": "Reversal Impairment Of Rights Related Of Leased Premises [Member]", "terseLabel": "Reversal Impairment Of Rights Related Of Leased Premises" } } }, "localname": "ReversalImpairmentOfRightsRelatedOfLeasedPremisesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_ReversalImpairmentOfRightsRelatedToLeasedEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reversal Impairment Of Rights Related To Leased Equipment", "label": "Reversal Impairment Of Rights Related To Leased Equipment [Member]", "terseLabel": "Reversal Impairment Of Rights Related To Leased Equipment" } } }, "localname": "ReversalImpairmentOfRightsRelatedToLeasedEquipmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_ReversalOfAmortizationAndImpairmentLossRelatedToFixedAssetsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reversal Of Amortization And Impairment Loss Related To Fixed Assets", "label": "Reversal Of Amortization And Impairment Loss Related To Fixed Assets [Member]", "terseLabel": "Reversal Of Amortization And Impairment Loss Related To Fixed Assets" } } }, "localname": "ReversalOfAmortizationAndImpairmentLossRelatedToFixedAssetsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_ReversalOfProvisionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reversal Of Provision", "label": "Reversal Of Provision [Member]", "terseLabel": "Reversal Of Provision" } } }, "localname": "ReversalOfProvisionMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "gnft_RevisedTermsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revised terms", "label": "Revised terms [Member]", "terseLabel": "Revised terms" } } }, "localname": "RevisedTermsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_RevisedTurnoverRateAssumption": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Revised turnover rate assumption.", "label": "Revised Turnover Rate Assumption", "terseLabel": "Revised turnover rate" } } }, "localname": "RevisedTurnoverRateAssumption", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_RightsOfUseLeasedPremisedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rights of use leased premised.", "label": "Rights Of Use Leased Premised [Member]", "terseLabel": "Rights of Use of Leased Premised" } } }, "localname": "RightsOfUseLeasedPremisedMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_RoyaltiesOnCommercialSalesRecognized": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Royalties on commercial sales recognized.", "label": "Royalties On Commercial Sales Recognized", "terseLabel": "Royalties on commercial sales recognized" } } }, "localname": "RoyaltiesOnCommercialSalesRecognized", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_RoyaltyIncomePercentOfCollaborativeSales": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Royalty income, Percent Of Collaborative Sales", "label": "Royalty income, Percent Of Collaborative Sales", "terseLabel": "Royalty income, percent of collaborative sales" } } }, "localname": "RoyaltyIncomePercentOfCollaborativeSales", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "percentItemType" }, "gnft_SO1Et22016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 1 et 2 2016.", "label": "S O1 Et22016 [Member]", "terseLabel": "SO US 2016" } } }, "localname": "SO1Et22016Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SO1Et22017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 1 et 2 2017.", "label": "S O1 Et22017 [Member]", "terseLabel": "SO 1 et 2 2017" } } }, "localname": "SO1Et22017Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SO20161Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2016-1.", "label": "S O20161 [Member]", "terseLabel": "S O20161 [Member]" } } }, "localname": "SO20161Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SO20162Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2016-2.", "label": "S O20162 [Member]", "terseLabel": "S O20162 [Member]" } } }, "localname": "SO20162Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SO2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2016", "label": "SO 2016 [Member]", "terseLabel": "SO 2016" } } }, "localname": "SO2016Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SO20171Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2017-1.", "label": "S O20171 [Member]", "terseLabel": "S O20171 [Member]" } } }, "localname": "SO20171Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SO20172Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2017-2.", "label": "S O20172 [Member]", "terseLabel": "S O20172 [Member]" } } }, "localname": "SO20172Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SO2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2017", "label": "SO 2017 [Member]", "terseLabel": "SO 2017" } } }, "localname": "SO2017Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SO2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2018.", "label": "S O2018 [Member]", "terseLabel": "S O2018 [Member]" } } }, "localname": "SO2018Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SO2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2019.", "label": "S O2019 [Member]", "terseLabel": "S O2019 [Member]" } } }, "localname": "SO2019Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SO2019USMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO 2019 - US.", "label": "S O2019 U S [Member]", "verboseLabel": "S O2019 U S [Member]" } } }, "localname": "SO2019USMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SO2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "S O 2020", "label": "S O 2020 [Member]", "terseLabel": "S O 2020" } } }, "localname": "SO2020Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SO2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "S O 2021", "label": "S O 2021 [Member]", "terseLabel": "S O 2021" } } }, "localname": "SO2021Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOC2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO C 2020.", "label": "S O C2020 [Member]", "terseLabel": "S O C2020 [Member]" } } }, "localname": "SOC2020Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOC2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO C2021", "label": "SO C2021 [Member]", "terseLabel": "SO C2021 [Member]" } } }, "localname": "SOC2021Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOC2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO C2022", "label": "SO C2022 [Member]", "terseLabel": "SO C2022" } } }, "localname": "SOC2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOCH2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO CH 2022", "label": "SO CH 2022 [Member]", "terseLabel": "SO CH 2022" } } }, "localname": "SOCH2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOD2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO D 2020.", "label": "S O D2020 [Member]", "terseLabel": "S O D2020 [Member]" } } }, "localname": "SOD2020Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOD2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO D 2021", "label": "SO D 2021 [Member]", "terseLabel": "SO D 2021 [Member]" } } }, "localname": "SOD2021Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOD2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO D 2022", "label": "SO D 2022 [Member]", "terseLabel": "SO D 2022" } } }, "localname": "SOD2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO.", "label": "S O [Member]", "terseLabel": "S O" } } }, "localname": "SOMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOSU2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO SU 2022", "label": "SO SU 2022 [Member]", "terseLabel": "SO SU 2022" } } }, "localname": "SOSU2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS12019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "S O US 1 2019", "label": "S O US 1 2019 [Member]", "terseLabel": "S O US 1 2019" } } }, "localname": "SOUS12019Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 1.", "label": "S O U S1 [Member]", "terseLabel": "SO US 1" } } }, "localname": "SOUS1Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS20161Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2016-1.", "label": "S O U S20161 [Member]", "terseLabel": "S O U S20161 [Member]" } } }, "localname": "SOUS20161Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS20162Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2016-2.", "label": "S O U S20162 [Member]", "terseLabel": "S O U S20162 [Member]" } } }, "localname": "SOUS20162Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2016Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2016.", "label": "S O U S2016 [Member]", "verboseLabel": "SO US 2016" } } }, "localname": "SOUS2016Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS20171Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2017-1.", "label": "S O U S20171 [Member]", "terseLabel": "S O U S20171 [Member]" } } }, "localname": "SOUS20171Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS20172Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2017-2.", "label": "S O U S20172 [Member]", "terseLabel": "S O U S20172 [Member]" } } }, "localname": "SOUS20172Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2017Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2017.", "label": "S O U S2017 [Member]", "verboseLabel": "SO US 2017" } } }, "localname": "SOUS2017Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2018Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2018.", "label": "S O U S2018 [Member]", "terseLabel": "S O U S2018 [Member]" } } }, "localname": "SOUS2018Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2019.", "label": "S O U S2019 [Member]", "terseLabel": "S O U S2019 [Member]" } } }, "localname": "SOUS2019Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2020Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2020.", "label": "S O U S2020 [Member]", "terseLabel": "S O U S2020 [Member]" } } }, "localname": "SOUS2020Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2021Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2021", "label": "SO US 2021 [Member]", "terseLabel": "SO US 2021 [Member]" } } }, "localname": "SOUS2021Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2022Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2022", "label": "SO US 2022 [Member]", "terseLabel": "SO US 2022" } } }, "localname": "SOUS2022Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS22019Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "S O US 2 2019", "label": "S O US 2 2019 [Member]", "terseLabel": "S O US 2 2019" } } }, "localname": "SOUS22019Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUS2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SO US 2.", "label": "S O U S2 [Member]", "terseLabel": "SO US 2" } } }, "localname": "SOUS2Member", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SOUSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SOUS.", "label": "S O U S [Member]", "terseLabel": "SO US" } } }, "localname": "SOUSMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "gnft_SalePriceClinicalTrialPhase": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sale Price, Clinical Trial Phase", "label": "Sale Price, Clinical Trial Phase", "terseLabel": "Sale price, clinical trial phase" } } }, "localname": "SalePriceClinicalTrialPhase", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ScientificEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Scientific equipment.", "label": "Scientific Equipment [Member]", "terseLabel": "Scientific Equipment [Member]" } } }, "localname": "ScientificEquipmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "gnft_SegmentInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Segment information [Abstract]", "label": "Segment information [Abstract]" } } }, "localname": "SegmentInformationAbstract", "nsuri": "http://www.genfit.com/20221231", "xbrltype": "stringItemType" }, "gnft_SeniorStaffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Senior staff.", "label": "Senior Staff [Member]", "terseLabel": "Senior Staff [Member]" } } }, "localname": "SeniorStaffMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheCHFAgainstTheEuroExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The CHF Against The Euro Explanatory", "label": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The CHF Against The Euro Explanatory [Text Block]", "terseLabel": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The CHF Against The Euro Explanatory" } } }, "localname": "SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheCHFAgainstTheEuroExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementTables" ], "xbrltype": "textBlockItemType" }, "gnft_SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sensitivity of cash and cash equivalents and expenses to variation of ten percent of the US dollars against the euro explanatory.", "label": "Sensitivity Of Cash And Cash Equivalents And Expenses To Variation Of Ten Percent Of The U S Dollars Against The Euro Explanatory [Text Block]", "terseLabel": "Summary of Sensitivity of Cash and Cash Equivalents and Expenses to Variation of Ten Percent of the US Dollars Against the Euro" } } }, "localname": "SensitivityOfCashAndCashEquivalentsAndExpensesToVariationOfTenPercentOfTheUSDollarsAgainstTheEuroExplanatoryTextBlock", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementTables" ], "xbrltype": "textBlockItemType" }, "gnft_ServicesRelatedToResearchAndDevelopmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Services related to research and development.", "label": "Services Related To Research And Development [Member]", "terseLabel": "Services Related To Research And Development [Member]" } } }, "localname": "ServicesRelatedToResearchAndDevelopmentMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_ShareBasedCompensationAcquisitionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based compensation acquisition period.", "label": "Share Based Compensation Acquisition Period", "terseLabel": "Acquisition period" } } }, "localname": "ShareBasedCompensationAcquisitionPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "gnft_ShareCapitalAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Share capital amount.", "label": "Share Capital Amount", "terseLabel": "Share capital amount" } } }, "localname": "ShareCapitalAmount", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "gnft_SharePricePeriodToDetermineVolatilityAssumptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share price period to determine volatility assumptions.", "label": "Share Price Period To Determine Volatility Assumptions", "terseLabel": "Share price period to determine volatility assumptions prior to grant date" } } }, "localname": "SharePricePeriodToDetermineVolatilityAssumptions", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_ShareWarrantsExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share warrants exercise period.", "label": "Share Warrants Exercise Period", "terseLabel": "End of exercise period" } } }, "localname": "ShareWarrantsExercisePeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "stringItemType" }, "gnft_ShareWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share warrants.", "label": "Share Warrants [Member]", "terseLabel": "Share Warrants" } } }, "localname": "ShareWarrantsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "gnft_ShareWarrantsSubscriptionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share warrants subscription period.", "label": "Share Warrants Subscription Period", "terseLabel": "Subscription period" } } }, "localname": "ShareWarrantsSubscriptionPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "xbrltype": "stringItemType" }, "gnft_SharebasedCompensationAnnualExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of share-based compensation annual expense.", "label": "Sharebased Compensation Annual Expense", "terseLabel": "Share-based compensation annual expense" } } }, "localname": "SharebasedCompensationAnnualExpense", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "monetaryItemType" }, "gnft_ShareholderMeetingDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder meeting date.", "label": "Shareholder Meeting Date", "terseLabel": "Date of the Shareholders meeting" } } }, "localname": "ShareholderMeetingDate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "dateItemType" }, "gnft_ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder Paid-in and Registered Period for Double Voting Rights", "label": "Shareholder Paid-in and Registered Period for Double Voting Rights", "terseLabel": "Shareholder paid-in and registered period for double voting rights (in years)" } } }, "localname": "ShareholderPaidInAndRegisteredPeriodForDoubleVotingRights", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "durationItemType" }, "gnft_SharesAuthorized": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shares authorized.", "label": "Shares Authorized", "terseLabel": "Shares authorized (in shares)" } } }, "localname": "SharesAuthorized", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "gnft_ShortTermDepositsAndGuarantees": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Short-term deposits and guarantees.", "label": "Short Term Deposits And Guarantees", "terseLabel": "Short Term Deposits And Guarantees" } } }, "localname": "ShortTermDepositsAndGuarantees", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "gnft_SocialSecurityCostsReceivables": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 3.0, "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Social security costs receivables.", "label": "Social Security Costs Receivables", "terseLabel": "Social Security Costs Receivables" } } }, "localname": "SocialSecurityCostsReceivables", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "gnft_StaffMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Staff.", "label": "Staff [Member]", "terseLabel": "Staff [Member]" } } }, "localname": "StaffMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "domainItemType" }, "gnft_StateGuaranteedLoansNumberOfFinancialInstitutions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "State-Guaranteed Loans, Number of Financial Institutions", "label": "State-Guaranteed Loans, Number of Financial Institutions", "terseLabel": "Number of French banks" } } }, "localname": "StateGuaranteedLoansNumberOfFinancialInstitutions", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "integerItemType" }, "gnft_StockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Options.", "label": "Stock Options [Member]", "terseLabel": "Stock Options" } } }, "localname": "StockOptionsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "gnft_SubsidizedLoanBpifranceMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Subsidized Loan, Bpifrance", "label": "Subsidized Loan, Bpifrance [Member]", "terseLabel": "Subsidized Loan" } } }, "localname": "SubsidizedLoanBpifranceMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_TaxEffectOfAdjustmentsWithoutTaxIncidence": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 5.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect Of Adjustments Without Tax Incidence", "label": "Tax Effect Of Adjustments Without Tax Incidence", "negatedTerseLabel": "Tax Effect Of Adjustments Without Tax Incidence", "terseLabel": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense" } } }, "localname": "TaxEffectOfAdjustmentsWithoutTaxIncidence", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTemporaryDifferences": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 8.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Temporary Differences", "label": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Temporary Differences", "negatedTerseLabel": "Tax Effect Of Non-Recognition Of Deferred Tax Assets Related To Temporary Differences", "terseLabel": "Deferred tax expense (income) relating to origination and reversal of temporary differences" } } }, "localname": "TaxEffectOfNonRecognitionOfDeferredTaxAssetsRelatedToTemporaryDifferences", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TaxEffectOfPermanentDifferences": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 3.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect Of Permanent Differences", "label": "Tax Effect Of Permanent Differences", "negatedTerseLabel": "Tax Effect Of Permanent Differences", "terseLabel": "Tax Effect Of Permanent Differences" } } }, "localname": "TaxEffectOfPermanentDifferences", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TaxEffectOfRecognitionOfDeferredTaxAssetsAgainstDeferredTaxLiabilities": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 1.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities", "label": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities", "negatedTerseLabel": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities", "terseLabel": "Tax Effect Of Recognition Of Deferred Tax Assets Against Deferred Tax Liabilities" } } }, "localname": "TaxEffectOfRecognitionOfDeferredTaxAssetsAgainstDeferredTaxLiabilities", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TaxEffectOfRenegotiationOfConvertibleDebt": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 10.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect Of Renegotiation Of Convertible Debt", "label": "Tax Effect Of Renegotiation Of Convertible Debt", "negatedTerseLabel": "Tax Effect Of Renegotiation Of Convertible Debt", "terseLabel": "Tax Effect Of Renegotiation Of Convertible Debt" } } }, "localname": "TaxEffectOfRenegotiationOfConvertibleDebt", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TaxEffectOfTaxCredits": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 7.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Effect Of Tax Credits", "label": "Tax Effect Of Tax Credits", "negatedTerseLabel": "Tax Effect Of Tax Credits", "terseLabel": "Tax Effect Of Tax Credits" } } }, "localname": "TaxEffectOfTaxCredits", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TaxLossCarriedForwardUsedToOffsetTaxableProfits": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Tax Loss Carried Forward Used To Offset Taxable Profits", "label": "Tax Loss Carried Forward Used To Offset Taxable Profits", "terseLabel": "Tax loss carried forward used to offset taxable profits" } } }, "localname": "TaxLossCarriedForwardUsedToOffsetTaxableProfits", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TaxableProfitWithinOneYear": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Taxable profit within one year.", "label": "Taxable Profit Within One Year", "terseLabel": "Taxable profit limit" } } }, "localname": "TaxableProfitWithinOneYear", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TemporaryDifferenceFromPostemploymentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Temporary difference from postemployments.", "label": "Temporary Difference From Postemployments [Member]", "terseLabel": "Temporary difference from postemployments" } } }, "localname": "TemporaryDifferenceFromPostemploymentsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "domainItemType" }, "gnft_TenPercentDecreaseOfCHFVsEuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ten Percent Decrease Of C H F Vs Euro", "label": "Ten Percent Decrease Of C H F Vs Euro [Member]", "terseLabel": "Ten Percent Decrease Of C H F Vs Euro" } } }, "localname": "TenPercentDecreaseOfCHFVsEuroMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails" ], "xbrltype": "domainItemType" }, "gnft_TenPercentDecreaseOfUSDollarVsEuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "10% decrease of US dollar vs Euro.", "label": "Ten Percent Decrease Of U S Dollar Vs Euro [Member]", "terseLabel": "10% Decrease of US Dollar vs Euro" } } }, "localname": "TenPercentDecreaseOfUSDollarVsEuroMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "domainItemType" }, "gnft_TenPercentIncreaseDecreaseInCHFVsEuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ten Percent Increase Decrease In C H F Vs Euro", "label": "Ten Percent Increase Decrease In C H F Vs Euro [Member]", "terseLabel": "Ten Percent Increase Decrease In C H F Vs Euro" } } }, "localname": "TenPercentIncreaseDecreaseInCHFVsEuroMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails" ], "xbrltype": "domainItemType" }, "gnft_TenPercentIncreaseDecreaseInUSDollarVsEuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ten percent increase decrease in US dollar vs Euro.", "label": "Ten Percent Increase Decrease In U S Dollar Vs Euro [Member]", "terseLabel": "10% Increase (Decrease) in US Dollar vs Euro" } } }, "localname": "TenPercentIncreaseDecreaseInUSDollarVsEuroMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "domainItemType" }, "gnft_TenPercentIncreaseOfCHFVsEuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ten Percent Increase Of C H F Vs Euro", "label": "Ten Percent Increase Of C H F Vs Euro [Member]", "terseLabel": "Ten Percent Increase Of C H F Vs Euro" } } }, "localname": "TenPercentIncreaseOfCHFVsEuroMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails" ], "xbrltype": "domainItemType" }, "gnft_TenPercentIncreaseOfUSDollarVsEuroMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "10% increase of US dollar vs Euro.", "label": "Ten Percent Increase Of U S Dollar Vs Euro [Member]", "terseLabel": "10% Increase of US Dollar vs Euro" } } }, "localname": "TenPercentIncreaseOfUSDollarVsEuroMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "domainItemType" }, "gnft_TermAccountsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Term accounts.", "label": "Term Accounts [Member]", "terseLabel": "Term Accounts [Member]" } } }, "localname": "TermAccountsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "gnft_TermsOfRetirementDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terms of retirement description.", "label": "Terms Of Retirement Description", "terseLabel": "Terms of retirement" } } }, "localname": "TermsOfRetirementDescription", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "stringItemType" }, "gnft_TernsPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Terns Pharmaceuticals.", "label": "Terns Pharmaceuticals [Member]", "terseLabel": "Terns Pharmaceuticals" } } }, "localname": "TernsPharmaceuticalsMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_TheNASHEpidemiologyInstituteTMMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The NASH Epidemiology Institute TM.", "label": "The N A S H Epidemiology Institute T M [Member]", "terseLabel": "The NASH Epidemiology Institute TM" } } }, "localname": "TheNASHEpidemiologyInstituteTMMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_ThirdYearMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Third Year", "label": "Third Year [Member]", "terseLabel": "Third Year" } } }, "localname": "ThirdYearMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "gnft_TotalAcquiredAssets": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 2.0, "parentTag": "ifrs-full_NetAssetsLiabilities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total acquired assets", "label": "Total acquired assets", "totalLabel": "Total acquired assets" } } }, "localname": "TotalAcquiredAssets", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TotalAcquiredLiabilities": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 2.0, "parentTag": "gnft_TotalPurchasePrice", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total acquired liabilities", "label": "Total acquired liabilities", "terseLabel": "Total acquired liabilities" } } }, "localname": "TotalAcquiredLiabilities", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TotalPurchasePrice": { "auth_ref": [], "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total purchase price", "label": "Total purchase price", "terseLabel": "Total purchase price" } } }, "localname": "TotalPurchasePrice", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "gnft_TradePayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trade payables.", "label": "Trade Payables [Member]", "terseLabel": "Trade Payables [Member]" } } }, "localname": "TradePayablesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "gnft_TradingPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading period.", "label": "Trading Period", "terseLabel": "Trading period" } } }, "localname": "TradingPeriod", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "durationItemType" }, "gnft_TransitionServicesAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transition Services Agreement", "label": "Transition Services Agreement [Member]", "terseLabel": "Transition Services Agreement" } } }, "localname": "TransitionServicesAgreementMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "domainItemType" }, "gnft_TurnoverRateShareWarrantsGranted": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Turnover rate share warrants granted.", "label": "Turnover Rate Share Warrants Granted", "terseLabel": "Turnover rate" } } }, "localname": "TurnoverRateShareWarrantsGranted", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "percentItemType" }, "gnft_UndertakingForCollectiveInvestmentInTransferableSecuritiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Undertaking for collective investment in transferable securities.", "label": "Undertaking For Collective Investment In Transferable Securities [Member]", "terseLabel": "Undertaking For Collective Investment In Transferable Securities [Member]" } } }, "localname": "UndertakingForCollectiveInvestmentInTransferableSecuritiesMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "gnft_ValuationAssumptionCreditSpread": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation Assumption, Credit Spread", "label": "Valuation Assumption, Credit Spread", "terseLabel": "Credit spread" } } }, "localname": "ValuationAssumptionCreditSpread", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ValuationAssumptionNoRiskRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation Assumption, No-risk Rate", "label": "Valuation Assumption, No-risk Rate", "negatedTerseLabel": "No-risk rate" } } }, "localname": "ValuationAssumptionNoRiskRate", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ValuationAssumptionVolatilityFirstLevel": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation Assumption, Volatility, First Level", "label": "Valuation Assumption, Volatility, First Level", "terseLabel": "Volatility, first level" } } }, "localname": "ValuationAssumptionVolatilityFirstLevel", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ValuationAssumptionVolatilitySecondLevel": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation Assumption, Volatility, Second Level", "label": "Valuation Assumption, Volatility, Second Level", "terseLabel": "Volatility, second level" } } }, "localname": "ValuationAssumptionVolatilitySecondLevel", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "gnft_ValuationMethodUsedInShareBasedPaymentArrangements": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Valuation method used in share based payment arrangements.", "label": "Valuation Method Used In Share Based Payment Arrangements", "terseLabel": "Valuation method used" } } }, "localname": "ValuationMethodUsedInShareBasedPaymentArrangements", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "gnft_VersantisMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Versantis", "label": "Versantis [Member]", "terseLabel": "Versantis" } } }, "localname": "VersantisMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "domainItemType" }, "gnft_XavierGUILLEDESBUTTESMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Xavier GUILLE DES BUTTES.", "label": "Xavier G U I L L E D E S B U T T E S [Member]", "terseLabel": "Xavier G U I L L E D E S B U T T E S [Member]" } } }, "localname": "XavierGUILLEDESBUTTESMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "gnft_Years2028AndThereafterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Years 2028 and thereafter", "label": "Years 2028 and thereafter [Member]", "terseLabel": "Years 2028 and thereafter" } } }, "localname": "Years2028AndThereafterMember", "nsuri": "http://www.genfit.com/20221231", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Accruals": { "auth_ref": [ "r335" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees." } }, "en-us": { "role": { "label": "Accruals", "terseLabel": "Accrued expenses" } } }, "localname": "Accruals", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AccumulatedDepreciationAmortisationAndImpairmentMember": { "auth_ref": [ "r67", "r73", "r124", "r134", "r137" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation, amortisation and impairment. [Refer: Impairment loss; Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation, amortisation and impairment [member]", "terseLabel": "Accumulated Depreciation and Impairment" } } }, "localname": "AccumulatedDepreciationAmortisationAndImpairmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedDepreciationAndAmortisationMember": { "auth_ref": [ "r73", "r340", "r348", "r352", "r353" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated depreciation and amortisation. [Refer: Depreciation and amortisation expense]" } }, "en-us": { "role": { "label": "Accumulated depreciation and amortisation [member]", "terseLabel": "Accumulated Depreciation" } } }, "localname": "AccumulatedDepreciationAndAmortisationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AccumulatedImpairmentMember": { "auth_ref": [ "r206", "r215", "r298", "r311", "r314", "r340", "r348", "r352", "r353" ], "lang": { "en": { "role": { "documentation": "This member stands for accumulated impairment. [Refer: Impairment loss]" } }, "en-us": { "role": { "label": "Accumulated impairment [member]", "terseLabel": "Impairment" } } }, "localname": "AccumulatedImpairmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ActuarialAssumptionOfDiscountRates": { "auth_ref": [ "r343" ], "lang": { "en": { "role": { "documentation": "The discount rate used as the significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Actuarial assumption of discount rates", "terseLabel": "Discount rate (as a percent)" } } }, "localname": "ActuarialAssumptionOfDiscountRates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ActuarialAssumptionOfExpectedRatesOfSalaryIncreases": { "auth_ref": [ "r343" ], "lang": { "en": { "role": { "documentation": "The expected rate of salary increases used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit plans [member]; Defined benefit obligation, at present value; Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Actuarial assumption of expected rates of salary increases", "terseLabel": "Salary growth rate (as a percent)" } } }, "localname": "ActuarialAssumptionOfExpectedRatesOfSalaryIncreases", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ActuarialAssumptionOfRetirementAge2019": { "auth_ref": [ "r343" ], "lang": { "en": { "role": { "documentation": "The retirement age used as a significant actuarial assumption to determine the present value of a defined benefit obligation. [Refer: Defined benefit obligation, at present value; Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Actuarial assumption of retirement age", "terseLabel": "Retirement age" } } }, "localname": "ActuarialAssumptionOfRetirementAge2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_AdjustedWeightedAverageShares": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating diluted earnings per share", "terseLabel": "Weighted average number of ordinary shares used in calculating diluted earnings (loss) per share (in shares)" } } }, "localname": "AdjustedWeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables": { "auth_ref": [ "r358" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for decrease (increase) in trade and other receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other receivables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for decrease (increase) in trade and other receivables", "terseLabel": "Decrease (increase) in trade receivables and other assets" } } }, "localname": "AdjustmentsForDecreaseIncreaseInTradeAndOtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForDepreciationAndAmortisationExpense": { "auth_ref": [ "r357" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for depreciation and amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Depreciation and amortisation expense; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for depreciation and amortisation expense", "terseLabel": "+ Depreciation and amortization on tangible and intangible assets" } } }, "localname": "AdjustmentsForDepreciationAndAmortisationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForFinanceIncomeCost": { "auth_ref": [ "r358" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 7.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Adjustments for net finance income or cost to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Finance income (cost); Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for finance income (cost)", "negatedLabel": "+ Net finance expenses (revenue)" } } }, "localname": "AdjustmentsForFinanceIncomeCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncomeTaxExpense": { "auth_ref": [ "r143" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 8.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for income tax expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for income tax expense", "terseLabel": "+ Income tax expense (benefit)" } } }, "localname": "AdjustmentsForIncomeTaxExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables": { "auth_ref": [ "r358" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for increase (decrease) in trade and other payables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Trade and other payables; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for increase (decrease) in trade and other payables", "terseLabel": "(Decrease) increase in trade payables and other liabilities" } } }, "localname": "AdjustmentsForIncreaseDecreaseInTradeAndOtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets": { "auth_ref": [ "r354" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for losses (gains) on disposal of non-current assets to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Non-current assets; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for losses (gains) on disposal of non-current assets", "terseLabel": "- Gain on disposal of property, plant and equipment" } } }, "localname": "AdjustmentsForLossesGainsOnDisposalOfNoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForProvisions": { "auth_ref": [ "r357" ], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "order": 5.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for provisions to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Provisions; Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for provisions", "negatedLabel": "Adjustments for provisions" } } }, "localname": "AdjustmentsForProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile profit (loss) [abstract]", "terseLabel": "Adjustments to reconcile profit (loss) [abstract]" } } }, "localname": "AdjustmentsForReconcileProfitLossAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_AdjustmentsForSharebasedPayments": { "auth_ref": [ "r357" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Adjustments for share-based payments", "terseLabel": "+ Expenses related to share-based compensation" } } }, "localname": "AdjustmentsForSharebasedPayments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Advances": { "auth_ref": [ "r332", "r335" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of advances received representing contract liabilities for performance obligations satisfied at a point in time. [Refer: Contract liabilities; Performance obligations satisfied at point in time [member]]" } }, "en-us": { "role": { "label": "Advances received, representing contract liabilities for performance obligations satisfied at point in time", "terseLabel": "Advances received" } } }, "localname": "Advances", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AggregatedMeasurementMember": { "auth_ref": [ "r132", "r136", "r171" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated measurement [member]", "terseLabel": "Aggregated measurement [member]" } } }, "localname": "AggregatedMeasurementMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AggregatedTimeBandsMember": { "auth_ref": [ "r26", "r182", "r186", "r188", "r210", "r247", "r248", "r249", "r255", "r280", "r300", "r302" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated time bands. It also represents the standard value for the 'Maturity' axis if no other member is used." } }, "en-us": { "role": { "label": "Aggregated time bands [member]", "terseLabel": "Aggregated time bands [member]" } } }, "localname": "AggregatedTimeBandsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AllLevelsOfFairValueHierarchyMember": { "auth_ref": [ "r82", "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used." } }, "en-us": { "role": { "label": "All levels of fair value hierarchy [member]", "terseLabel": "All levels of fair value hierarchy [member]" } } }, "localname": "AllLevelsOfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AmountsPayableRelatedPartyTransactions": { "auth_ref": [ "r97", "r100" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts payable resulting from related party transactions. [Refer: Related parties [member]]" } }, "en-us": { "role": { "label": "Amounts payable, related party transactions", "terseLabel": "Amounts payable, related party transactions" } } }, "localname": "AmountsPayableRelatedPartyTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ApplicableTaxRate": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "The applicable income tax rate." } }, "en-us": { "role": { "label": "Applicable tax rate", "terseLabel": "Applicable tax rate" } } }, "localname": "ApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_AssetRecognisedForExpectedReimbursementContingentLiabilitiesInBusinessCombination": { "auth_ref": [ "r204", "r205" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that have been recognised for the expected reimbursement of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Expected reimbursement, contingent liabilities in business combination; Business combinations [member]]" } }, "en-us": { "role": { "label": "Asset recognised for expected reimbursement, contingent liabilities in business combination", "terseLabel": "Asset recognised for expected reimbursement, contingent liabilities in business combination" } } }, "localname": "AssetRecognisedForExpectedReimbursementContingentLiabilitiesInBusinessCombination", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CommitmentsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Assets": { "auth_ref": [ "r22", "r171", "r172", "r173", "r235", "r239" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits." } }, "en-us": { "role": { "label": "Assets", "totalLabel": "Total - Assets" } } }, "localname": "Assets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_AssociatesMember": { "auth_ref": [ "r98", "r107", "r109", "r170", "r259", "r262" ], "lang": { "en": { "role": { "documentation": "This member stands for the entities over which the investor has significant influence." } }, "en-us": { "role": { "label": "Associates [member]", "terseLabel": "Associates [member]" } } }, "localname": "AssociatesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AtFairValueMember": { "auth_ref": [ "r132", "r136", "r171" ], "lang": { "en": { "role": { "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date." } }, "en-us": { "role": { "label": "At fair value [member]", "terseLabel": "Fair value" } } }, "localname": "AtFairValueMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_AverageEffectiveTaxRate": { "auth_ref": [ "r60" ], "lang": { "en": { "role": { "documentation": "The tax expense (income) divided by the accounting profit. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Average effective tax rate", "terseLabel": "Average effective tax rate" } } }, "localname": "AverageEffectiveTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_AverageForeignExchangeRate": { "auth_ref": [ "r330" ], "lang": { "en": { "role": { "documentation": "The average exchange rate used by the entity. Exchange rate is the ratio of exchange for two currencies." } }, "en-us": { "role": { "label": "Average foreign exchange rate", "terseLabel": "Average foreign exchange rate", "verboseLabel": "Euros equivalent to USD or CHF" } } }, "localname": "AverageForeignExchangeRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_AverageNumberOfEmployees": { "auth_ref": [ "r330" ], "lang": { "en": { "role": { "documentation": "The average number of personnel employed by the entity during a period." } }, "en-us": { "role": { "label": "Average number of employees", "terseLabel": "Average number of employees" } } }, "localname": "AverageNumberOfEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_BasicEarningsLossPerShare": { "auth_ref": [ "r110", "r111" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)." } }, "en-us": { "role": { "label": "Basic earnings (loss) per share", "terseLabel": "Basic earnings (loss) per share (\u20ac/share)", "verboseLabel": "Basic earnings (loss) per share" } } }, "localname": "BasicEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_BenefitsPaidOrPayable": { "auth_ref": [ "r104" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of benefits paid or payable for retirement benefit plans." } }, "en-us": { "role": { "label": "Benefits paid or payable", "terseLabel": "Benefits paid or payable" } } }, "localname": "BenefitsPaidOrPayable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BorrowingCostsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Borrowing costs [abstract]", "terseLabel": "Borrowing costs [abstract]" } } }, "localname": "BorrowingCostsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_Borrowings": { "auth_ref": [ "r332" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of outstanding funds that the entity is obligated to repay." } }, "en-us": { "role": { "label": "Borrowings", "terseLabel": "New debt recognized" } } }, "localname": "Borrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_BorrowingsAdjustmentToInterestRateBasis": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "The adjustment to the basis (reference rate) used for calculation of the interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, adjustment to interest rate basis", "terseLabel": "Borrowings, adjustment to interest rate basis" } } }, "localname": "BorrowingsAdjustmentToInterestRateBasis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BorrowingsByNameAxis": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Borrowings by name [axis]", "terseLabel": "Borrowings by name [axis]" } } }, "localname": "BorrowingsByNameAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BorrowingsByNameMember": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "This member stands for all borrowings when disaggregated by name. It also represents the standard value for the 'Borrowings by name' axis if no other member is used. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings by name [member]", "terseLabel": "Borrowings by name [member]" } } }, "localname": "BorrowingsByNameMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_BorrowingsInterestRate": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "The interest rate on borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, interest rate", "terseLabel": "Interest rate (in percent)", "verboseLabel": "Annual nominal interest rate (in percent)" } } }, "localname": "BorrowingsInterestRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_BorrowingsMaturity": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "The maturity of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Borrowings, maturity", "terseLabel": "Debt maturity date" } } }, "localname": "BorrowingsMaturity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_BottomOfRangeMember": { "auth_ref": [ "r175", "r195", "r249", "r295", "r296", "r362" ], "lang": { "en": { "role": { "documentation": "This member stands for the bottom of a range." } }, "en-us": { "role": { "label": "Bottom of range [member]", "terseLabel": "Bottom of Range" } } }, "localname": "BottomOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CapitalRequirementsAxis": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Capital requirements [axis]", "terseLabel": "Capital requirements [axis]" } } }, "localname": "CapitalRequirementsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CapitalRequirementsMember": { "auth_ref": [ "r7" ], "lang": { "en": { "role": { "documentation": "This member stands for capital requirements that the entity is subject to. It also represents the standard value for the 'Capital requirements' axis if no other member is used." } }, "en-us": { "role": { "label": "Capital requirements [member]", "terseLabel": "Capital requirements [member]" } } }, "localname": "CapitalRequirementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis": { "auth_ref": [ "r67", "r71", "r124", "r127", "r133", "r134", "r135", "r136", "r137", "r206", "r215", "r216", "r365", "r366" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]", "terseLabel": "Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount [axis]" } } }, "localname": "CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CarryingAmountMember": { "auth_ref": [ "r71", "r127", "r133", "r135", "r136", "r206", "r215", "r216", "r311", "r313" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised in the statement of financial position (after deducting any accumulated depreciation or amortisation and accumulated impairment losses). It also represents the standard value for the 'Carrying amount, accumulated depreciation, amortisation and impairment and gross carrying amount' axis if no other member is used. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Carrying amount [member]", "terseLabel": "Carrying amount [member]" } } }, "localname": "CarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Cash": { "auth_ref": [ "r359" ], "calculation": { "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails": { "order": 2.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits. [Refer: Cash on hand]" } }, "en-us": { "role": { "label": "Cash", "terseLabel": "Cash" } } }, "localname": "Cash", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalents": { "auth_ref": [ "r15", "r144", "r165" ], "calculation": { "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 6.0, "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]" } }, "en-us": { "role": { "label": "Cash and cash equivalents", "periodEndLabel": "Cash and cash equivalents at the end of the period", "periodStartLabel": "Cash and cash equivalents at the beginning of the period", "terseLabel": "Cash and cash equivalents", "totalLabel": "Total cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails", "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashAndCashEquivalentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash and cash equivalents [abstract]", "terseLabel": "Cash and cash equivalents [abstract]" } } }, "localname": "CashAndCashEquivalentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivities": { "auth_ref": [ "r138", "r146" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity." } }, "en-us": { "role": { "label": "Cash flows from (used in) financing activities", "totalLabel": "Net cash flows provided by (used in ) financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) financing activities [abstract]", "terseLabel": "Cash flows from financing activities" } } }, "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivities": { "auth_ref": [ "r138", "r146" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents." } }, "en-us": { "role": { "label": "Cash flows from (used in) investing activities", "totalLabel": "Net cash flows provided by (used in ) investment activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) investing activities [abstract]", "terseLabel": "Cash flows from investment activities" } } }, "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivities": { "auth_ref": [ "r138", "r146" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Cash flows from (used in) operating activities", "totalLabel": "Net cash flows provided by (used in) in operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from (used in) operating activities [abstract]", "terseLabel": "Cash flows from operating activities" } } }, "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "stringItemType" }, "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital": { "auth_ref": [ "r292", "r358" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The cash inflow (outflow) from the entity's operations before changes in working capital." } }, "en-us": { "role": { "label": "Cash flows from (used in) operations before changes in working capital", "totalLabel": "Operating cash flows before change in working capital" } } }, "localname": "CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CashTransferred": { "auth_ref": [ "r203" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value, at acquisition date, of cash transferred as consideration in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Cash transferred", "terseLabel": "Cash transferred" } } }, "localname": "CashTransferred", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CategoriesOfRelatedPartiesAxis": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Categories of related parties [axis]", "terseLabel": "Categories of related parties [axis]" } } }, "localname": "CategoriesOfRelatedPartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ChangesInEquity": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) in equity", "terseLabel": "Increase in equity" } } }, "localname": "ChangesInEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ChangesInOtherProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in other provisions [abstract]" } } }, "localname": "ChangesInOtherProvisionsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialAssetsAxis": { "auth_ref": [ "r224", "r225", "r246", "r256", "r257", "r258" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial assets [axis]", "terseLabel": "Classes of financial assets [axis]" } } }, "localname": "ClassesOfFinancialAssetsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsAxis": { "auth_ref": [ "r215", "r217", "r219", "r220" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of financial instruments [axis]", "terseLabel": "Classes of financial instruments [axis]" } } }, "localname": "ClassesOfFinancialInstrumentsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfFinancialInstrumentsMember": { "auth_ref": [ "r215", "r217", "r219", "r220" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial instruments. Financial instruments are contracts that give rise to a financial asset of one entity and a financial liability or equity instrument of another entity. It also represents the standard value for the 'Classes of financial instruments' axis if no other member is used. [Refer: Financial assets; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial instruments, class [member]", "terseLabel": "Financial instruments, class [member]" } } }, "localname": "ClassesOfFinancialInstrumentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClassesOfIntangibleAssetsAndGoodwillAxis": { "auth_ref": [ "r350" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets and goodwill [axis]", "terseLabel": "Classes of intangible assets and goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsAndGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of intangible assets other than goodwill [axis]", "terseLabel": "Classes of intangible assets other than goodwill [axis]" } } }, "localname": "ClassesOfIntangibleAssetsOtherThanGoodwillAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of property, plant and equipment [axis]", "terseLabel": "Classes of property, plant and equipment [axis]" } } }, "localname": "ClassesOfPropertyPlantAndEquipmentAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfProvisionsAxis": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of other provisions [axis]", "terseLabel": "Classes of other provisions [axis]" } } }, "localname": "ClassesOfProvisionsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalAxis": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Classes of share capital [axis]", "terseLabel": "Classes of share capital [axis]" } } }, "localname": "ClassesOfShareCapitalAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ClassesOfShareCapitalMember": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used." } }, "en-us": { "role": { "label": "Share capital [member]", "terseLabel": "Share capital [member]" } } }, "localname": "ClassesOfShareCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ClosingForeignExchangeRate": { "auth_ref": [ "r330" ], "lang": { "en": { "role": { "documentation": "The spot exchange rate at the end of the reporting period. Exchange rate is the ratio of exchange for two currencies. Spot exchange rate is the exchange rate for immediate delivery." } }, "en-us": { "role": { "label": "Closing foreign exchange rate", "terseLabel": "Closing foreign exchange rate", "verboseLabel": "Closing foreign exchange rate" } } }, "localname": "ClosingForeignExchangeRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_ComponentsOfEquityAxis": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Components of equity [axis]", "terseLabel": "Components of equity [axis]" } } }, "localname": "ComponentsOfEquityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_ComprehensiveIncome": { "auth_ref": [ "r1", "r40", "r151", "r153", "r162", "r294" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of change in equity resulting from transactions and other events, other than those changes resulting from transactions with owners in their capacity as owners." } }, "en-us": { "role": { "label": "Comprehensive income", "totalLabel": "Total comprehensive income (loss)" } } }, "localname": "ComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToNoncontrollingInterests": { "auth_ref": [ "r1", "r43" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss_1": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to non-controlling interests. [Refer: Comprehensive income; Non-controlling interests]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to non-controlling interests", "terseLabel": "Comprehensive income, attributable to non-controlling interests" } } }, "localname": "ComprehensiveIncomeAttributableToNoncontrollingInterests", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComprehensiveIncomeAttributableToOwnersOfParent": { "auth_ref": [ "r1", "r44" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss_1": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of comprehensive income attributable to owners of the parent. [Refer: Comprehensive income]" } }, "en-us": { "role": { "label": "Comprehensive income, attributable to owners of parent", "terseLabel": "Attributable to owners of the Company" } } }, "localname": "ComprehensiveIncomeAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ComputerEquipmentMember": { "auth_ref": [ "r339" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing computer equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Computer equipment [member]", "terseLabel": "Computer equipment [member]" } } }, "localname": "ComputerEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ComputerSoftwareMember": { "auth_ref": [ "r284" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing computer software. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Computer software [member]", "terseLabel": "Computer software [member]", "verboseLabel": "Software" } } }, "localname": "ComputerSoftwareMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ConstructionInProgressMember": { "auth_ref": [ "r339" ], "lang": { "en": { "role": { "documentation": "This member stands for expenditure capitalised during the construction of items of property, plant and equipment that are not yet available for use (ie not yet in the location and condition necessary for it to be capable of operating in the manner intended by the management). [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Construction in progress [member]", "terseLabel": "Construction in progress [member]" } } }, "localname": "ConstructionInProgressMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ConsumerLoansMember": { "auth_ref": [ "r299", "r303", "r305" ], "lang": { "en": { "role": { "documentation": "This member stands for loans that are made to individuals for personal use." } }, "en-us": { "role": { "label": "Loans to consumers [member]", "terseLabel": "Loans to consumers [member]" } } }, "localname": "ConsumerLoansMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContingentLiabilityForGuaranteesMember": { "auth_ref": [ "r347" ], "lang": { "en": { "role": { "documentation": "This member stands for a contingent liability for guarantees. [Refer: Contingent liabilities [member]; Guarantees [member]]" } }, "en-us": { "role": { "label": "Contingent liability for guarantees [member]", "terseLabel": "Contingent liability for guarantees [member]" } } }, "localname": "ContingentLiabilityForGuaranteesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ContractLiabilities": { "auth_ref": [ "r177", "r180" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of an entity\u2019s obligation to transfer goods or services to a customer for which the entity has received consideration (or the amount is due) from the customer." } }, "en-us": { "role": { "label": "Contract liabilities", "terseLabel": "Contract liabilities" } } }, "localname": "ContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember": { "auth_ref": [ "r285" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets representing copyrights, patents and other industrial property rights, service and operating rights. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Copyrights, patents and other industrial property rights, service and operating rights [member]", "terseLabel": "Patents" } } }, "localname": "CopyrightsPatentsAndOtherIndustrialPropertyRightsServiceAndOperatingRightsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CounterpartiesAxis": { "auth_ref": [ "r229" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Counterparties [axis]", "terseLabel": "Counterparties [axis]" } } }, "localname": "CounterpartiesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CounterpartiesMember": { "auth_ref": [ "r229" ], "lang": { "en": { "role": { "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used." } }, "en-us": { "role": { "label": "Counterparties [member]", "terseLabel": "Counterparties [member]" } } }, "localname": "CounterpartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_CumulativeEffectAtDateOfInitialApplicationAxis": { "auth_ref": [ "r328" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Cumulative effect at date of initial application [axis]", "terseLabel": "Cumulative effect at date of initial application [axis]" } } }, "localname": "CumulativeEffectAtDateOfInitialApplicationAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentAssets": { "auth_ref": [ "r27", "r158", "r294" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]" } }, "en-us": { "role": { "label": "Current assets", "totalLabel": "Total - Current assets" } } }, "localname": "CurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets [abstract]", "terseLabel": "Current assets" } } }, "localname": "CurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentContractLiabilities": { "auth_ref": [ "r177" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Current contract liabilities", "terseLabel": "Deferred income" } } }, "localname": "CurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentContractLiabilitiesForPerformanceObligationsSatisfiedOverTime": { "auth_ref": [ "r332", "r335" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current contract liabilities for performance obligations satisfied over time. [Refer: Contract liabilities for performance obligations satisfied over time]" } }, "en-us": { "role": { "label": "Current contract liabilities for performance obligations satisfied over time", "terseLabel": "Upfront payment received" } } }, "localname": "CurrentContractLiabilitiesForPerformanceObligationsSatisfiedOverTime", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentDeferredIncomeIncludingCurrentContractLiabilities": { "auth_ref": [ "r332", "r335" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current deferred income including current contract liabilities. [Refer: Deferred income including contract liabilities]" } }, "en-us": { "role": { "label": "Current deferred income including current contract liabilities", "verboseLabel": "Deferred income current" } } }, "localname": "CurrentDeferredIncomeIncludingCurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentDeferredIncomeOtherThanCurrentContractLiabilities": { "auth_ref": [ "r332", "r335" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current deferred income other than current contract liabilities. [Refer: Deferred income other than contract liabilities]" } }, "en-us": { "role": { "label": "Current deferred income other than current contract liabilities", "terseLabel": "Current deferred income and revenue" } } }, "localname": "CurrentDeferredIncomeOtherThanCurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentExciseTaxPayables": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 3.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current excise tax payables. [Refer: Excise tax payables]" } }, "en-us": { "role": { "label": "Current excise tax payables", "terseLabel": "Current excise tax payables" } } }, "localname": "CurrentExciseTaxPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilities": { "auth_ref": [ "r28", "r160", "r294" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have an unconditional right to defer settlement for at least twelve months after the reporting period.\nEffective 2023-01-01: The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period." } }, "en-us": { "role": { "label": "Current liabilities", "totalLabel": "Total - Current liabilities" } } }, "localname": "CurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities [abstract]", "terseLabel": "Current liabilities" } } }, "localname": "CurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_CurrentLoansAndReceivables": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current loans and receivables. [Refer: Loans and receivables]" } }, "en-us": { "role": { "label": "Current loans and receivables", "terseLabel": "Current loans and receivables" } } }, "localname": "CurrentLoansAndReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current notes and debentures issued and the current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]" } }, "en-us": { "role": { "label": "Current notes and debentures issued and current portion of non-current notes and debentures issued", "terseLabel": "Current convertible loans" } } }, "localname": "CurrentNotesAndDebenturesIssuedAndCurrentPortionOfNoncurrentNotesAndDebenturesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 5.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } }, "en-us": { "role": { "label": "Current payables on social security and taxes other than income tax", "terseLabel": "Current payables on social security and taxes other than income tax" } } }, "localname": "CurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentProvisions": { "auth_ref": [ "r17" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 3.0, "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0 }, "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Current provisions", "terseLabel": "Current provisions", "totalLabel": "Current provisions" } } }, "localname": "CurrentProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentServiceCostNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r78" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from employee service in the current period. [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Increase in net defined benefit liability (asset) resulting from current service cost", "terseLabel": "Increase in net defined benefit liability (asset) resulting from current service cost" } } }, "localname": "CurrentServiceCostNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTaxLiabilitiesCurrent": { "auth_ref": [ "r18" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 4.0, "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of current tax liabilities. [Refer: Current tax liabilities]" } }, "en-us": { "role": { "label": "Current tax liabilities, current", "terseLabel": "Other current tax liabilities" } } }, "localname": "CurrentTaxLiabilitiesCurrent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentTradeReceivables": { "auth_ref": [ "r269", "r271" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 1.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Current trade receivables", "terseLabel": "Current trade receivables" } } }, "localname": "CurrentTradeReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentValueAddedTaxPayables": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 1.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current value added tax payables. [Refer: Value added tax payables]" } }, "en-us": { "role": { "label": "Current value added tax payables", "terseLabel": "Current value added tax payables" } } }, "localname": "CurrentValueAddedTaxPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_CurrentValueAddedTaxReceivables": { "auth_ref": [ "r333" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 4.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current value added tax receivables. [Refer: Value added tax receivables]" } }, "en-us": { "role": { "label": "Current value added tax receivables", "terseLabel": "Current value added tax receivables" } } }, "localname": "CurrentValueAddedTaxReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DateOfAcquisition2013": { "auth_ref": [ "r200" ], "lang": { "en": { "role": { "documentation": "The date on which the acquirer obtains control of the acquiree in a business combination." } }, "en-us": { "role": { "label": "Date of acquisition", "terseLabel": "Date of acquisition" } } }, "localname": "DateOfAcquisition2013", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "dateItemType" }, "ifrs-full_DebtInstrumentsHeld": { "auth_ref": [ "r332" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of instruments representing indebtedness held by the entity." } }, "en-us": { "role": { "label": "Debt instruments held", "terseLabel": "Carrying value debt at amortized cost" } } }, "localname": "DebtInstrumentsHeld", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DebtSecurities": { "auth_ref": [ "r332" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of instruments issued by the entity that represent indebtedness." } }, "en-us": { "role": { "label": "Debt instruments issued", "terseLabel": "Aggregate nominal amount" } } }, "localname": "DebtSecurities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The amount of deductible temporary differences for which no deferred tax asset is recognised in the statement of financial position. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Deductible temporary differences for which no deferred tax asset is recognised", "terseLabel": "Temporary differences" } } }, "localname": "DeductibleTemporaryDifferencesForWhichNoDeferredTaxAssetIsRecognised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredIncomeIncludingContractLiabilities": { "auth_ref": [ "r332", "r335" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, including contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Deferred income including contract liabilities", "terseLabel": "Deferred income including contract liabilities" } } }, "localname": "DeferredIncomeIncludingContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredIncomeOtherThanContractLiabilities": { "auth_ref": [ "r332", "r335" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities representing income that has been received (or the amount is due) but is not yet earned, other than contract liabilities. [Refer: Contract liabilities]" } }, "en-us": { "role": { "label": "Deferred income other than contract liabilities", "terseLabel": "Deferred income other than contract liabilities" } } }, "localname": "DeferredIncomeOtherThanContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxAssets": { "auth_ref": [ "r19", "r23", "r62" ], "calculation": { "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails": { "order": 2.0, "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes recoverable in future periods in respect of: (a) deductible temporary differences; (b) the carryforward of unused tax losses; and (c) the carryforward of unused tax credits. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Deferred tax assets", "periodEndLabel": "Deferred tax assets", "periodStartLabel": "Deferred tax assets", "terseLabel": "Deferred tax assets" } } }, "localname": "DeferredTaxAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxExpenseIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred tax expense (income) [abstract]", "terseLabel": "Deferred tax expense (income) [abstract]" } } }, "localname": "DeferredTaxExpenseIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DeferredTaxExpenseIncomeRecognisedInProfitOrLoss": { "auth_ref": [ "r63" ], "lang": { "en": { "role": { "documentation": "The amount of tax expense or income relating to changes in deferred tax liabilities and deferred tax assets, recognised in profit or loss. [Refer: Deferred tax assets; Deferred tax expense (income); Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Deferred tax expense (income) recognised in profit or loss", "negatedTerseLabel": "Impact on the profit/loss", "terseLabel": "Impact on the profit/loss" } } }, "localname": "DeferredTaxExpenseIncomeRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilities": { "auth_ref": [ "r19", "r23", "r62" ], "calculation": { "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails": { "order": 1.0, "parentTag": "ifrs-full_DeferredTaxLiabilityAsset", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amounts of income taxes payable in future periods in respect of taxable temporary differences. [Refer: Temporary differences [member]]" } }, "en-us": { "role": { "label": "Deferred tax liabilities", "negatedPeriodEndLabel": "Deferred tax liabilities", "negatedPeriodStartLabel": "Deferred tax liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "DeferredTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxLiabilityAsset": { "auth_ref": [ "r62" ], "calculation": { "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax liabilities or assets. [Refer: Deferred tax liabilities; Deferred tax assets]" } }, "en-us": { "role": { "label": "Deferred tax liability (asset)", "negatedPeriodEndLabel": "Deferred tax liability (asset)", "negatedPeriodStartLabel": "Deferred tax liability (asset)", "negatedTerseLabel": "Deferred tax liability (asset)", "terseLabel": "Deferred tax liability (asset)" } } }, "localname": "DeferredTaxLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity": { "auth_ref": [ "r58" ], "lang": { "en": { "role": { "documentation": "The amount of deferred tax related to items credited (charged) directly to equity. [Refer: Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Deferred tax relating to items credited (charged) directly to equity", "negatedTerseLabel": "Impact on equity", "terseLabel": "Impact on equity" } } }, "localname": "DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DefinedBenefitPlansAxis": { "auth_ref": [ "r76" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Defined benefit plans [axis]", "terseLabel": "Defined benefit plans [axis]" } } }, "localname": "DefinedBenefitPlansAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DefinedBenefitPlansMember": { "auth_ref": [ "r76" ], "lang": { "en": { "role": { "documentation": "This member stands for post-employment benefit plans other than defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods. It also represents the standard value for the 'Defined benefit plans' axis if no other member is used." } }, "en-us": { "role": { "label": "Defined benefit plans [member]", "terseLabel": "Defined benefit plans [member]" } } }, "localname": "DefinedBenefitPlansMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_DepreciationExpense": { "auth_ref": [ "r330" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives." } }, "en-us": { "role": { "label": "Depreciation expense", "negatedTerseLabel": "Depreciation" } } }, "localname": "DepreciationExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DerivativeFinancialLiabilitiesUndiscountedCashFlows": { "auth_ref": [ "r222" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of contractual undiscounted cash flows in relation to derivative financial liabilities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Derivative financial liabilities, undiscounted cash flows", "terseLabel": "TOTAL" } } }, "localname": "DerivativeFinancialLiabilitiesUndiscountedCashFlows", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEarningsPerShareExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for earnings per share.\nEffective 2023-01-01: The description of the entity's material accounting policy information for earnings per share." } }, "en-us": { "role": { "label": "Description of accounting policy for earnings per share [text block]", "terseLabel": "Earnings (loss) per share" } } }, "localname": "DescriptionOfAccountingPolicyForEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment.\nEffective 2023-01-01: The description of the entity's material accounting policy information for employee benefits. Employee benefits are all forms of consideration given by an entity in exchange for services rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Description of accounting policy for employee benefits [text block]", "terseLabel": "Description of accounting policy for employee benefits [text block]" } } }, "localname": "DescriptionOfAccountingPolicyForEmployeeBenefitsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForExpensesExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for expenses.\nEffective 2023-01-01: The description of the entity's material accounting policy information for expenses." } }, "en-us": { "role": { "label": "Description of accounting policy for expenses [text block]", "terseLabel": "Classification of operating expenses" } } }, "localname": "DescriptionOfAccountingPolicyForExpensesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for financial liabilities. [Refer: Financial liabilities]\nEffective 2023-01-01: The description of the entity's material accounting policy information for financial liabilities. [Refer: Financial liabilities]" } }, "en-us": { "role": { "label": "Description of accounting policy for financial liabilities [text block]", "terseLabel": "Loans and borrowings" } } }, "localname": "DescriptionOfAccountingPolicyForFinancialLiabilitiesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for foreign currency translation.\nEffective 2023-01-01: The description of the entity's material accounting policy information for foreign currency translation." } }, "en-us": { "role": { "label": "Description of accounting policy for foreign currency translation [text block]", "terseLabel": "Foreign currency" } } }, "localname": "DescriptionOfAccountingPolicyForForeignCurrencyTranslationExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the impairment of assets.\nEffective 2023-01-01: The description of the entity's material accounting policy information for the impairment of assets." } }, "en-us": { "role": { "label": "Description of accounting policy for impairment of assets [text block]", "terseLabel": "Impairment of tangible assets, intangible assets and goodwill" } } }, "localname": "DescriptionOfAccountingPolicyForImpairmentOfAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIncomeTaxExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for income tax.\nEffective 2023-01-01: The description of the entity's material accounting policy information for income tax." } }, "en-us": { "role": { "label": "Description of accounting policy for income tax [text block]", "terseLabel": "Income tax" } } }, "localname": "DescriptionOfAccountingPolicyForIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]\nEffective 2023-01-01: The description of the entity's material accounting policy information for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Description of accounting policy for intangible assets other than goodwill [text block]", "terseLabel": "Intangible assets" } } }, "localname": "DescriptionOfAccountingPolicyForIntangibleAssetsOtherThanGoodwillExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForIssuedCapitalExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for issued capital. [Refer: Issued capital]\nEffective 2023-01-01: The description of the entity's material accounting policy information for issued capital. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Description of accounting policy for issued capital [text block]", "terseLabel": "Equity" } } }, "localname": "DescriptionOfAccountingPolicyForIssuedCapitalExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/Equity", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForLeasesExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time.\nEffective 2023-01-01: The description of the entity's material accounting policy information for leases. A lease is an agreement whereby the lessor conveys to the lessee in return for a payment or series of payments the right to use an asset for an agreed period of time." } }, "en-us": { "role": { "label": "Description of accounting policy for leases [text block]", "terseLabel": "Leases" } } }, "localname": "DescriptionOfAccountingPolicyForLeasesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForMeasuringInventories": { "auth_ref": [ "r87" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy for measuring inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Description of accounting policy for measuring inventories [text block]", "terseLabel": "Inventories" } } }, "localname": "DescriptionOfAccountingPolicyForMeasuringInventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for the offsetting of financial instruments. [Refer: Financial instruments, class [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for the offsetting of financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for offsetting of financial instruments [text block]", "terseLabel": "Financial instruments" } } }, "localname": "DescriptionOfAccountingPolicyForOffsettingOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for property, plant and equipment. [Refer: Property, plant and equipment]\nEffective 2023-01-01: The description of the entity's material accounting policy information for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Description of accounting policy for property, plant and equipment [text block]", "terseLabel": "Property, plant and equipment" } } }, "localname": "DescriptionOfAccountingPolicyForPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForProvisionsExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for provisions. [Refer: Provisions]\nEffective 2023-01-01: The description of the entity's material accounting policy information for provisions. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Description of accounting policy for provisions [text block]", "terseLabel": "Provisions" } } }, "localname": "DescriptionOfAccountingPolicyForProvisionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForRecognitionOfRevenue": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for recognising revenue. [Refer: Revenue]\nEffective 2023-01-01: The description of the entity's material accounting policy information for recognising revenue. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Description of accounting policy for recognition of revenue [text block]", "terseLabel": "Revenues from ongoing activities under client agreements" } } }, "localname": "DescriptionOfAccountingPolicyForRecognitionOfRevenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for research and development expense. [Refer: Research and development expense]\nEffective 2023-01-01: The description of the entity's material accounting policy information for research and development expense. [Refer: Research and development expense]" } }, "en-us": { "role": { "label": "Description of accounting policy for research and development expense [text block]", "terseLabel": "Research and development expenses" } } }, "localname": "DescriptionOfAccountingPolicyForResearchAndDevelopmentExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpense", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSegmentReportingExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for segment reporting.\nEffective 2023-01-01: The description of the entity's material accounting policy information for segment reporting." } }, "en-us": { "role": { "label": "Description of accounting policy for segment reporting [text block]", "terseLabel": "Operating segments" } } }, "localname": "DescriptionOfAccountingPolicyForSegmentReportingExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]\nEffective 2023-01-01: The description of the entity's material accounting policy information for transactions in which the entity: (a) receives goods or services from the supplier of those goods or services (including an employee) in a share-based payment arrangement; or (b) incurs an obligation to settle the transaction with the supplier in a share-based payment arrangement when another group entity receives those goods or services. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of accounting policy for share-based payment transactions [text block]", "terseLabel": "Share-based compensation" } } }, "localname": "DescriptionOfAccountingPolicyForSharebasedPaymentTransactionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other payables. [Refer: Trade and other payables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Description of accounting policy for trade and other payables [text block]", "terseLabel": "Trade and other payables" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherPayablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies", "http://www.genfit.com/role/TradeandOtherPayables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory": { "auth_ref": [ "r363", "r364" ], "lang": { "en": { "role": { "documentation": "Expiry date 2023-01-01: The description of the entity's accounting policy for trade and other receivables. [Refer: Trade and other receivables]\nEffective 2023-01-01: The description of the entity's material accounting policy information for trade and other receivables. [Refer: Trade and other receivables]" } }, "en-us": { "role": { "label": "Description of accounting policy for trade and other receivables [text block]", "terseLabel": "Trade and other receivables" } } }, "localname": "DescriptionOfAccountingPolicyForTradeAndOtherReceivablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssets", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents": { "auth_ref": [ "r145" ], "lang": { "en": { "role": { "documentation": "The description of the entity's accounting policy used to determine the components of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Description of accounting policy for determining components of cash and cash equivalents [text block]", "terseLabel": "Cash and cash equivalents" } } }, "localname": "DescriptionOfAccountingPolicyToDetermineComponentsOfCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalents", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [line items]", "terseLabel": "Disclosure of expected impact of initial application of new standards or interpretations [line items]" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the expected impact of the initial application of new standards or interpretations." } }, "en-us": { "role": { "label": "Disclosure of expected impact of initial application of new standards or interpretations [table]", "terseLabel": "Disclosure of expected impact of initial application of new standards or interpretations [table]" } } }, "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfExpectedVolatilityShareOptionsGranted": { "auth_ref": [ "r197" ], "lang": { "en": { "role": { "documentation": "The expected volatility of the share price used to calculate the fair value of the share options granted. Expected volatility is a measure of the amount by which a price is expected to fluctuate during a period. The measure of volatility used in option pricing models is the annualised standard deviation of the continuously compounded rates of return on the share over a period of time." } }, "en-us": { "role": { "label": "Expected volatility, share options granted", "terseLabel": "Expected volatility" } } }, "localname": "DescriptionOfExpectedVolatilityShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfPrimaryReasonsForBusinessCombination": { "auth_ref": [ "r202" ], "lang": { "en": { "role": { "documentation": "The description of the primary reasons for a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Description of primary reasons for business combination", "terseLabel": "Description of primary reasons for business combination" } } }, "localname": "DescriptionOfPrimaryReasonsForBusinessCombination", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DescriptionOfRiskFreeInterestRateShareOptionsGranted": { "auth_ref": [ "r197" ], "lang": { "en": { "role": { "documentation": "The implied yield currently available on zero-coupon government issues of the country in whose currency the exercise price for share options granted is expressed, with a remaining term equal to the expected term of the option being valued (based on the option's remaining contractual life and taking into account the effects of expected early exercise). [Refer: Government [member]]" } }, "en-us": { "role": { "label": "Risk free interest rate, share options granted", "terseLabel": "Risk-free interest rate" } } }, "localname": "DescriptionOfRiskFreeInterestRateShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_DescriptionOfVestingRequirementsForSharebasedPaymentArrangement": { "auth_ref": [ "r190" ], "lang": { "en": { "role": { "documentation": "The description of the vesting requirements for a type of share-based payment arrangement that existed at any time during the period. An entity with substantially similar types of share-based payment arrangements may aggregate this information. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Description of vesting requirements for share-based payment arrangement", "terseLabel": "Vesting period" } } }, "localname": "DescriptionOfVestingRequirementsForSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DilutedEarningsLossPerShare": { "auth_ref": [ "r110", "r111" ], "lang": { "en": { "role": { "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]" } }, "en-us": { "role": { "label": "Diluted earnings (loss) per share", "terseLabel": "Diluted earnings (loss) per share (\u20ac/share)", "verboseLabel": "Diluted earnings (loss) per share" } } }, "localname": "DilutedEarningsLossPerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_DisclosureOfAccountingJudgementsAndEstimatesExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of judgements that management has made in the process of applying the entity's accounting policies that have the most significant effect on amounts recognised in the financial statements along with information about the assumptions that the entity makes about the future, and other major sources of estimation uncertainty at the end of the reporting period, that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Disclosure of accounting judgements and estimates [text block]", "terseLabel": "Use of estimates and judgments" } } }, "localname": "DisclosureOfAccountingJudgementsAndEstimatesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of the basis used for the preparation of the financial statements." } }, "en-us": { "role": { "label": "Disclosure of basis of preparation of financial statements [text block]", "terseLabel": "Basis of Presentation" } } }, "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/BasisofPresentation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfBorrowingsExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of borrowings [text block]", "terseLabel": "Loans and Borrowings" } } }, "localname": "DisclosureOfBorrowingsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowings" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashAndCashEquivalentsExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of cash and cash equivalents. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Disclosure of cash and cash equivalents [text block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "DisclosureOfCashAndCashEquivalentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalents" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfCashFlowStatementExplanatory": { "auth_ref": [ "r147" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for a statement of cash flows." } }, "en-us": { "role": { "label": "Disclosure of cash flow statement [text block]", "terseLabel": "Disclosure of cash flow statement [text block]" } } }, "localname": "DisclosureOfCashFlowStatementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/Cashflowstatement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of classes of share capital [abstract]", "terseLabel": "Disclosure of classes of share capital [abstract]" } } }, "localname": "DisclosureOfClassesOfShareCapitalAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [line items]", "terseLabel": "Disclosure of classes of share capital [line items]" } } }, "localname": "DisclosureOfClassesOfShareCapitalLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfClassesOfShareCapitalTable": { "auth_ref": [ "r36" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to classes of share capital." } }, "en-us": { "role": { "label": "Disclosure of classes of share capital [table]", "terseLabel": "Disclosure of classes of share capital [table]" } } }, "localname": "DisclosureOfClassesOfShareCapitalTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfCommitmentsExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of commitments." } }, "en-us": { "role": { "label": "Disclosure of commitments [text block]", "terseLabel": "Commitments" } } }, "localname": "DisclosureOfCommitmentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/Commitments", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfContingentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of contingent liabilities [abstract]", "terseLabel": "Disclosure of contingent liabilities [abstract]" } } }, "localname": "DisclosureOfContingentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDeferredIncomeExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of deferred income. [Refer: Deferred income including contract liabilities]" } }, "en-us": { "role": { "label": "Disclosure of deferred income [text block]", "terseLabel": "Deferred Income and Revenue" } } }, "localname": "DisclosureOfDeferredIncomeExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenue" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansExplanatory": { "auth_ref": [ "r76" ], "lang": { "en": { "role": { "documentation": "The disclosure of defined benefit plans. [Refer: Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Disclosure of defined benefit plans [text block]", "terseLabel": "Disclosure of defined benefit plans [text block]" } } }, "localname": "DisclosureOfDefinedBenefitPlansExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of defined benefit plans [line items]", "terseLabel": "Disclosure of defined benefit plans [line items]" } } }, "localname": "DisclosureOfDefinedBenefitPlansLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDefinedBenefitPlansTable": { "auth_ref": [ "r76" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to defined benefit plans." } }, "en-us": { "role": { "label": "Disclosure of defined benefit plans [table]", "terseLabel": "Disclosure of defined benefit plans [table]" } } }, "localname": "DisclosureOfDefinedBenefitPlansTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsExplanatory": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about borrowings. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [text block]", "terseLabel": "Other Loans and Borrowings" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [line items]", "terseLabel": "Disclosure of detailed information about borrowings [line items]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBorrowingsTable": { "auth_ref": [ "r362" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of borrowings." } }, "en-us": { "role": { "label": "Disclosure of detailed information about borrowings [table]", "terseLabel": "Disclosure of detailed information about borrowings [table]" } } }, "localname": "DisclosureOfDetailedInformationAboutBorrowingsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofRefundableandConditionalAdvancesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory": { "auth_ref": [ "r207" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about business combination [text block]", "terseLabel": "Disclosure of detailed information about business combination [text block]" } } }, "localname": "DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about intangible assets. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [text block]", "terseLabel": "Schedule of Variations in Intangible Assets" } } }, "localname": "DisclosureOfDetailedInformationAboutIntangibleAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "The disclosure of detailed information about property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [text block]", "terseLabel": "Summary of Variations in Tangible Assets" } } }, "localname": "DisclosureOfDetailedInformationAboutPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEarningsPerShareExplanatory": { "auth_ref": [ "r113" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for earnings per share." } }, "en-us": { "role": { "label": "Disclosure of earnings per share [text block]", "terseLabel": "Earnings (Loss) Per Share" } } }, "localname": "DisclosureOfEarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShare" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory": { "auth_ref": [ "r92" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for the effect of changes in foreign exchange rates." } }, "en-us": { "role": { "label": "Disclosure of effect of changes in foreign exchange rates [text block]", "terseLabel": "Summary of Functional Currency" } } }, "localname": "DisclosureOfEffectOfChangesInForeignExchangeRatesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEmployeeBenefitsExplanatory": { "auth_ref": [ "r86" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for employee benefits." } }, "en-us": { "role": { "label": "Disclosure of employee benefits [text block]", "terseLabel": "Disclosure of employee benefits [text block]" } } }, "localname": "DisclosureOfEmployeeBenefitsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": { "auth_ref": [ "r245" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for operating segments." } }, "en-us": { "role": { "label": "Disclosure of entity's operating segments [text block]", "terseLabel": "Disclosure of entity's operating segments [text block]" } } }, "localname": "DisclosureOfEntitysReportableSegmentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/Operatingsegments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfExpensesByNatureExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of expenses by nature. [Refer: Expenses, by nature]" } }, "en-us": { "role": { "label": "Disclosure of expenses by nature [text block]", "terseLabel": "Operating Expense" } } }, "localname": "DisclosureOfExpensesByNatureExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpense" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueMeasurementExplanatory": { "auth_ref": [ "r174" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for fair value measurement." } }, "en-us": { "role": { "label": "Disclosure of fair value measurement [text block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "DisclosureOfFairValueMeasurementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstruments" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFairValueOfFinancialInstrumentsExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of the fair value of financial instruments. [Refer: Financial instruments, class [member]; At fair value [member]]" } }, "en-us": { "role": { "label": "Disclosure of fair value of financial instruments [text block]", "terseLabel": "Disclosure of financial assets and liabilities carrying values by category and fair values" } } }, "localname": "DisclosureOfFairValueOfFinancialInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinanceIncomeExpenseExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of finance income (cost). [Refer: Finance income (cost)]" } }, "en-us": { "role": { "label": "Disclosure of finance income (cost) [text block]", "terseLabel": "Financial Income and Expenses" } } }, "localname": "DisclosureOfFinanceIncomeExpenseExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpenses", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfFinancialAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of financial assets [line items]", "terseLabel": "Disclosure of financial assets [line items]" } } }, "localname": "DisclosureOfFinancialAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialAssetsTable": { "auth_ref": [ "r226" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to financial assets." } }, "en-us": { "role": { "label": "Disclosure of financial assets [table]", "terseLabel": "Disclosure of financial assets [table]" } } }, "localname": "DisclosureOfFinancialAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about financial instruments [abstract]", "terseLabel": "Disclosure of detailed information about financial instruments [abstract]" } } }, "localname": "DisclosureOfFinancialInstrumentsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfFinancialRiskManagementExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of the entity's financial risk management practices and policies." } }, "en-us": { "role": { "label": "Disclosure of financial risk management [text block]", "terseLabel": "Financial Risks Management" } } }, "localname": "DisclosureOfFinancialRiskManagementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagement" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIncomeTaxExplanatory": { "auth_ref": [ "r65" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for income taxes." } }, "en-us": { "role": { "label": "Disclosure of income tax [text block]", "terseLabel": "Income Tax" } } }, "localname": "DisclosureOfIncomeTaxExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTax" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]", "terseLabel": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [line items]" } } }, "localname": "DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesTable": { "auth_ref": [ "r176" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to amounts recognised in relation to regulatory deferral account balances." } }, "en-us": { "role": { "label": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [table]", "terseLabel": "Disclosure of information about amounts recognised in relation to regulatory deferral account balances [table]" } } }, "localname": "DisclosureOfInformationAboutAmountsRecognisedInRelationToRegulatoryDeferralAccountBalancesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInformationAboutDefinedBenefitPlansAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of information about defined benefit plans [abstract]", "terseLabel": "Disclosure of information about defined benefit plans [abstract]" } } }, "localname": "DisclosureOfInformationAboutDefinedBenefitPlansAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfInformationAboutEmployeesExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about employees." } }, "en-us": { "role": { "label": "Disclosure of information about employees [text block]", "terseLabel": "Summary of Employee Expenses and Number of Employees" } } }, "localname": "DisclosureOfInformationAboutEmployeesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfInformationAboutKeyManagementPersonnelExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of information about key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Disclosure of information about key management personnel [text block]", "terseLabel": "Schedule of Director's Fees and Other Compensation Due and Paid to Non Executive Directors" } } }, "localname": "DisclosureOfInformationAboutKeyManagementPersonnelExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [abstract]", "terseLabel": "Disclosure of detailed information about intangible assets [abstract]" } } }, "localname": "DisclosureOfIntangibleAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsExplanatory": { "auth_ref": [ "r131" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for intangible assets." } }, "en-us": { "role": { "label": "Disclosure of intangible assets [text block]", "terseLabel": "Intangible Assets" } } }, "localname": "DisclosureOfIntangibleAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [line items]", "terseLabel": "Disclosure of detailed information about intangible assets [line items]" } } }, "localname": "DisclosureOfIntangibleAssetsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsTable": { "auth_ref": [ "r128" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of intangible assets." } }, "en-us": { "role": { "label": "Disclosure of detailed information about intangible assets [table]", "terseLabel": "Disclosure of detailed information about intangible assets [table]" } } }, "localname": "DisclosureOfIntangibleAssetsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of intangible assets with indefinite useful life [line items]", "terseLabel": "Disclosure of intangible assets with indefinite useful life [line items]" } } }, "localname": "DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeTable": { "auth_ref": [ "r129" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to intangible assets with an indefinite useful life." } }, "en-us": { "role": { "label": "Disclosure of intangible assets with indefinite useful life [table]", "terseLabel": "Disclosure of intangible assets with indefinite useful life [table]" } } }, "localname": "DisclosureOfIntangibleAssetsWithIndefiniteUsefulLifeTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfLoansAndAdvancesToBanksExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of loans and advances to banks. [Refer: Loans and advances to banks]" } }, "en-us": { "role": { "label": "Disclosure of loans and advances to banks [text block]", "terseLabel": "Summary of Bank Loans" } } }, "localname": "DisclosureOfLoansAndAdvancesToBanksExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis for derivative financial liabilities [line items]", "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [line items]" } } }, "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable": { "auth_ref": [ "r222" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to the maturity analysis for derivative financial liabilities." } }, "en-us": { "role": { "label": "Disclosure of maturity analysis for derivative financial liabilities [table]", "terseLabel": "Disclosure of maturity analysis for derivative financial liabilities [table]" } } }, "localname": "DisclosureOfMaturityAnalysisForDerivativeFinancialLiabilitiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory": { "auth_ref": [ "r77" ], "lang": { "en": { "role": { "documentation": "The disclosure of a net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Disclosure of net defined benefit liability (asset) [text block]", "terseLabel": "Disclosure of net defined benefit liability (asset) [text block]" } } }, "localname": "DisclosureOfNetDefinedBenefitLiabilityAssetExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory": { "auth_ref": [ "r360" ], "lang": { "en": { "role": { "documentation": "The disclosure of the number and weighted average exercise prices of other equity instruments (ie other than share options)." } }, "en-us": { "role": { "label": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]", "terseLabel": "Disclosure of number and weighted average exercise prices of other equity instruments [text block]" } } }, "localname": "DisclosureOfNumberAndWeightedAverageExercisePricesOfOtherEquityInstrumentsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherAssetsExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of other assets. [Refer: Other assets]" } }, "en-us": { "role": { "label": "Disclosure of other assets [text block]", "terseLabel": "Other Assets" } } }, "localname": "DisclosureOfOtherAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherAssets" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherOperatingIncomeExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of other operating income. [Refer: Other operating income (expense)]" } }, "en-us": { "role": { "label": "Disclosure of other operating income [text block]", "terseLabel": "Operating Income" } } }, "localname": "DisclosureOfOtherOperatingIncomeExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingIncome" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory": { "auth_ref": [ "r122" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for other provisions, contingent liabilities and contingent assets." } }, "en-us": { "role": { "label": "Disclosure of other provisions, contingent liabilities and contingent assets [text block]", "terseLabel": "Litigation and Contingent Liabilities" } } }, "localname": "DisclosureOfOtherProvisionsContingentLiabilitiesAndContingentAssetsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LitigationandContingentLiabilities" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfOtherProvisionsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of other provisions [line items]", "terseLabel": "Disclosure of other provisions [line items]" } } }, "localname": "DisclosureOfOtherProvisionsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfOtherProvisionsTable": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to other provisions." } }, "en-us": { "role": { "label": "Disclosure of other provisions [table]", "terseLabel": "Disclosure of other provisions [table]" } } }, "localname": "DisclosureOfOtherProvisionsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [abstract]", "terseLabel": "Disclosure of detailed information about property, plant and equipment [abstract]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentExplanatory": { "auth_ref": [ "r75" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of property, plant and equipment [text block]", "terseLabel": "Property, Plant and Equipment" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipment" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [line items]", "terseLabel": "Disclosure of detailed information about property, plant and equipment [line items]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r72" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to details of property, plant and equipment." } }, "en-us": { "role": { "label": "Disclosure of detailed information about property, plant and equipment [table]", "terseLabel": "Disclosure of detailed information about property, plant and equipment [table]" } } }, "localname": "DisclosureOfPropertyPlantAndEquipmentTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfProvisionsExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of provisions. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Disclosure of provisions [text block]", "terseLabel": "Provisions" } } }, "localname": "DisclosureOfProvisionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/Provisions" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfRelatedPartyExplanatory": { "auth_ref": [ "r101" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for related parties." } }, "en-us": { "role": { "label": "Disclosure of related party [text block]", "terseLabel": "Related Parties" } } }, "localname": "DisclosureOfRelatedPartyExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/RelatedParties", "http://www.genfit.com/role/Statementoffinancialpositioncurrentnoncurrent" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory": { "auth_ref": [ "r84" ], "lang": { "en": { "role": { "documentation": "The disclosure of a sensitivity analysis for significant actuarial assumptions used to determine the present value of a defined benefit obligation. [Refer: Actuarial assumptions [member]; Defined benefit obligation, at present value]" } }, "en-us": { "role": { "label": "Disclosure of sensitivity analysis for actuarial assumptions [text block]", "terseLabel": "Disclosure of sensitivity analysis for actuarial assumptions [text block]" } } }, "localname": "DisclosureOfSensitivityAnalysisForActuarialAssumptionsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/EmployeeBenefitsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory": { "auth_ref": [ "r37" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share capital, reserves and other equity interest." } }, "en-us": { "role": { "label": "Disclosure of share capital, reserves and other equity interest [text block]", "terseLabel": "Equity" } } }, "localname": "DisclosureOfShareCapitalReservesAndOtherEquityInterestExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": { "auth_ref": [ "r189" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of share-based payment arrangements [text block]", "terseLabel": "Disclosure of share-based payment arrangements [text block]" } } }, "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensation" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory": { "auth_ref": [ "r261" ], "lang": { "en": { "role": { "documentation": "The entire disclosure for significant accounting policies applied by the entity." } }, "en-us": { "role": { "label": "Disclosure of significant accounting policies [text block]", "terseLabel": "Disclosure of significant accounting policies [text block]" } } }, "localname": "DisclosureOfSummaryOfSignificantAccountingPoliciesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefits", "http://www.genfit.com/role/Equity", "http://www.genfit.com/role/OtherFinancialAssets", "http://www.genfit.com/role/SummaryofSignificantAccountingPolicies", "http://www.genfit.com/role/TradeandOtherPayables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "The disclosure of types of temporary differences, unused tax losses and unused tax credits. [Refer: Unused tax credits [member]; Unused tax losses [member]; Temporary differences [member]]" } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [text block]", "terseLabel": "Breakdown of deferred taxes by nature" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]", "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [line items]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to temporary differences, unused tax losses and unused tax credits." } }, "en-us": { "role": { "label": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]", "terseLabel": "Disclosure of temporary difference, unused tax losses and unused tax credits [table]" } } }, "localname": "DisclosureOfTemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [abstract]", "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [abstract]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "The disclosure of the general terms and conditions of share-based payment arrangements. [Refer: Share-based payment arrangements [member]]" } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [text block]", "terseLabel": "Summary of Key Terms and Conditions of Share-Based Compensation Based" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensation", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]", "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [line items]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements." } }, "en-us": { "role": { "label": "Disclosure of terms and conditions of share-based payment arrangement [table]", "terseLabel": "Disclosure of terms and conditions of share-based payment arrangement [table]" } } }, "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTradeAndOtherPayablesExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other payables. [Refer: Trade and other payables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other payables [text block]", "terseLabel": "Trade and Other Payables" } } }, "localname": "DisclosureOfTradeAndOtherPayablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTradeAndOtherReceivablesExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of trade and other receivables. [Refer: Trade and other receivables]" } }, "en-us": { "role": { "label": "Disclosure of trade and other receivables [text block]", "terseLabel": "Trade and Other Receivables" } } }, "localname": "DisclosureOfTradeAndOtherReceivablesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of transactions between related parties [abstract]", "terseLabel": "Disclosure of transactions between related parties [abstract]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [line items]", "terseLabel": "Disclosure of transactions between related parties [line items]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTransactionsBetweenRelatedPartiesTable": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to transactions between related parties." } }, "en-us": { "role": { "label": "Disclosure of transactions between related parties [table]", "terseLabel": "Disclosure of transactions between related parties [table]" } } }, "localname": "DisclosureOfTransactionsBetweenRelatedPartiesTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfTreasurySharesExplanatory": { "auth_ref": [ "r326" ], "lang": { "en": { "role": { "documentation": "The disclosure of treasury shares. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Disclosure of treasury shares [text block]", "terseLabel": "Disclosure of treasury shares [text block]" } } }, "localname": "DisclosureOfTreasurySharesExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Disclosure of voluntary change in accounting policy [abstract]", "terseLabel": "Disclosure of voluntary change in accounting policy [abstract]" } } }, "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Disclosure of voluntary change in accounting policy [line items]", "terseLabel": "Disclosure of voluntary change in accounting policy [line items]" } } }, "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisclosureOfVoluntaryChangeInAccountingPolicyTable": { "auth_ref": [ "r148" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to a voluntary change in accounting policy." } }, "en-us": { "role": { "label": "Disclosure of voluntary change in accounting policy [table]", "terseLabel": "Disclosure of voluntary change in accounting policy [table]" } } }, "localname": "DisclosureOfVoluntaryChangeInAccountingPolicyTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_DisposalsIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r125" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in intangible assets other than goodwill resulting from disposals. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Disposals, intangible assets other than goodwill", "negatedLabel": "Decrease" } } }, "localname": "DisposalsIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_DisposalsPropertyPlantAndEquipment": { "auth_ref": [ "r68" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The decrease in property, plant and equipment resulting from disposals. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Disposals, property, plant and equipment", "negatedLabel": "Decrease", "negatedTerseLabel": "Disposals, property, plant and equipment" } } }, "localname": "DisposalsPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings per share [abstract]", "terseLabel": "Basic and diluted earnings (loss) per share" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "ifrs-full_EarningsPerShareExplanatory": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "The disclosure of earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [text block]", "terseLabel": "Summary of Earnings (Loss) Per Share" } } }, "localname": "EarningsPerShareExplanatory", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_EarningsPerShareTable": { "auth_ref": [ "r110" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to earnings per share." } }, "en-us": { "role": { "label": "Earnings per share [table]", "terseLabel": "Earnings per share [table]" } } }, "localname": "EarningsPerShareTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": { "auth_ref": [ "r140", "r141" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]" } }, "en-us": { "role": { "label": "Effect of exchange rate changes on cash and cash equivalents", "terseLabel": "Effects of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EmployeeBenefitsExpense": { "auth_ref": [ "r0", "r55", "r266" ], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The expense of all forms of consideration given by an entity in exchange for a service rendered by employees or for the termination of employment." } }, "en-us": { "role": { "label": "Employee benefits expense", "negatedTotalLabel": "Employee benefits expense" } } }, "localname": "EmployeeBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember": { "auth_ref": [ "r276" ], "lang": { "en": { "role": { "documentation": "This member stands for entering into significant commitments or contingent liabilities. [Refer: Contingent liabilities [member]]" } }, "en-us": { "role": { "label": "Entering into significant commitments or contingent liabilities [member]", "terseLabel": "Renegotiation" } } }, "localname": "EnteringIntoSignificantCommitmentsOrContingentLiabilitiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForAssociatesMember": { "auth_ref": [ "r107", "r109", "r170", "r260", "r263" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Associates' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for associates [member]", "terseLabel": "Entity's total for associates [member]" } } }, "localname": "EntitysTotalForAssociatesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EntitysTotalForRelatedPartiesMember": { "auth_ref": [ "r99" ], "lang": { "en": { "role": { "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used." } }, "en-us": { "role": { "label": "Entity's total for related parties [member]", "terseLabel": "Entity's total for related parties [member]" } } }, "localname": "EntitysTotalForRelatedPartiesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersAdditionalInformationDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersScheduleofDirectorsFeesandOtherCompensationDueandPaidtoNonExecutiveDirectorsDetails", "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Equity": { "auth_ref": [ "r22", "r32", "r150", "r152", "r171", "r172", "r173" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities." } }, "en-us": { "role": { "label": "Equity", "periodEndLabel": "Balance at end of period", "periodStartLabel": "Balance at beginning of period", "terseLabel": "Equity", "totalLabel": "Total - Shareholders' equity" } } }, "localname": "Equity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails", "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [abstract]", "terseLabel": "Shareholders' equity" } } }, "localname": "EquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAndLiabilities": { "auth_ref": [ "r22" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]" } }, "en-us": { "role": { "label": "Equity and liabilities", "totalLabel": "Total - Shareholders' equity & liabilities" } } }, "localname": "EquityAndLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAndLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity and liabilities [abstract]", "terseLabel": "SHAREHOLDERS' EQUITY AND LIABILITIES" } } }, "localname": "EquityAndLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_EquityAttributableToOwnersOfParent": { "auth_ref": [ "r21" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity attributable to the owners of the parent. This specifically excludes non-controlling interest." } }, "en-us": { "role": { "label": "Equity attributable to owners of parent", "totalLabel": "Total equity attributable to owners of parent" } } }, "localname": "EquityAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_EquityAttributableToOwnersOfParentMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for equity attributable to the owners of the parent." } }, "en-us": { "role": { "label": "Equity attributable to owners of parent [member]", "terseLabel": "Total shareholders' equity Group share" } } }, "localname": "EquityAttributableToOwnersOfParentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityInvestmentsMember": { "auth_ref": [ "r299", "r305" ], "lang": { "en": { "role": { "documentation": "This member stands for investments in equity instruments." } }, "en-us": { "role": { "label": "Equity investments [member]", "terseLabel": "Equity investments [member]" } } }, "localname": "EquityInvestmentsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_EquityMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used." } }, "en-us": { "role": { "label": "Equity [member]", "terseLabel": "Equity [member]" } } }, "localname": "EquityMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_ExciseTaxPayables": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 4.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payables related to excise tax." } }, "en-us": { "role": { "label": "Excise tax payables", "terseLabel": "Excise tax payables" } } }, "localname": "ExciseTaxPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ExercisePriceShareOptionsGranted2019": { "auth_ref": [ "r197" ], "lang": { "en": { "role": { "documentation": "The exercise price of share options granted." } }, "en-us": { "role": { "label": "Exercise price, share options granted", "terseLabel": "Excercise price (in EUR per share)" } } }, "localname": "ExercisePriceShareOptionsGranted2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_ExpectedDividendAsPercentageShareOptionsGranted": { "auth_ref": [ "r197" ], "lang": { "en": { "role": { "documentation": "The percentage of an expected dividend used to calculate the fair value of share options granted." } }, "en-us": { "role": { "label": "Expected dividend as percentage, share options granted", "terseLabel": "Expected dividends" } } }, "localname": "ExpectedDividendAsPercentageShareOptionsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ExpenseOfRestructuringActivities": { "auth_ref": [ "r52" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 6.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to restructuring. Restructuring is a programme that is planned and controlled by management and materially changes either the scope of a business undertaken by an entity or the manner in which that business is conducted. Such programmes include: (a) the sale or termination of a line of business; (b) closure of business locations in a country or region or the relocation of activities from one country or region to another; (c) changes in management structure; and (d) fundamental reorganisations that have a material effect on the nature and focus of the entity's operations." } }, "en-us": { "role": { "label": "Expense of restructuring activities", "negatedLabel": "Reorganization and restructuring income (expenses)", "terseLabel": "Expense of restructuring activities" } } }, "localname": "ExpenseOfRestructuringActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FeeAndCommissionExpense": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to fees and commissions." } }, "en-us": { "role": { "label": "Fee and commission expense", "terseLabel": "Fee and commission expense" } } }, "localname": "FeeAndCommissionExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceCosts": { "auth_ref": [ "r46" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": -1.0 }, "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of costs associated with financing activities of the entity." } }, "en-us": { "role": { "label": "Finance costs", "negatedLabel": "Financial expenses", "negatedTerseLabel": "Finance costs", "negatedTotalLabel": "Finance costs" } } }, "localname": "FinanceCosts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncome": { "auth_ref": [ "r337" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncomeCost", "weight": 1.0 }, "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income", "terseLabel": "Financial income", "totalLabel": "Finance income" } } }, "localname": "FinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinanceIncomeCost": { "auth_ref": [ "r337" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income or cost associated with interest and other financing activities of the entity." } }, "en-us": { "role": { "label": "Finance income (cost)", "terseLabel": "Finance income (cost)", "totalLabel": "Financial profit (loss)" } } }, "localname": "FinanceIncomeCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssets": { "auth_ref": [ "r211", "r215", "r216", "r219", "r298" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that are: (a) cash; (b) an equity instrument of another entity; (c) a contractual right: (i) to receive cash or another financial asset from another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially favourable to the entity; or (d) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to receive a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose the entity\u2019s own equity instruments do not include puttable financial instruments classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. [Refer: Financial instruments, class [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial assets", "terseLabel": "Current and non current financial assets" } } }, "localname": "FinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValue": { "auth_ref": [ "r211" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The fair value of financial assets. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, at fair value", "terseLabel": "Fair value of financial assets" } } }, "localname": "FinancialAssetsAtFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsAtFairValueThroughProfitOrLoss": { "auth_ref": [ "r227" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value and for which gains (losses) are recognised in profit or loss. A financial asset shall be measured at fair value through profit or loss unless it is measured at amortised cost or at fair value through other comprehensive income. A gain (loss) on a financial asset measured at fair value shall be recognised in profit or loss unless it is part of a hedging relationship, it is an investment in an equity instrument for which the entity has elected to present gains and losses in other comprehensive income or it is a financial asset measured at fair value through other comprehensive income. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets at fair value through profit or loss", "terseLabel": "Carrying value of Assets at fair value through profit and loss" } } }, "localname": "FinancialAssetsAtFairValueThroughProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome": { "auth_ref": [ "r228" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that are measured at fair value through other comprehensive income. A financial asset shall be measured at fair value through other comprehensive income if both of the following conditions are met: (a) the financial asset is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and (b) the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding. [Refer: At fair value [member]; Financial assets]" } }, "en-us": { "role": { "label": "Financial assets measured at fair value through other comprehensive income", "terseLabel": "Financial assets measured at fair value through other comprehensive income" } } }, "localname": "FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialAssetsMember": { "auth_ref": [ "r224", "r225", "r246", "r256", "r257", "r258" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregated classes of financial assets. It also represents the standard value for the 'Classes of financial assets' axis if no other member is used. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Financial assets, class [member]", "terseLabel": "Financial assets, class [member]" } } }, "localname": "FinancialAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSummaryofCashCashEquivalentsandFinancialAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FinancialLiabilities": { "auth_ref": [ "r211" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that are: (a) a contractual obligation: (i) to deliver cash or another financial asset to another entity; or (ii) to exchange financial assets or financial liabilities with another entity under conditions that are potentially unfavourable to the entity; or (b) a contract that will, or may be, settled in the entity\u2019s own equity instruments and is: (i) a non-derivative for which the entity is, or may be, obliged to deliver a variable number of the entity\u2019s own equity instruments; or (ii) a derivative that will, or may be, settled other than by the exchange of a fixed amount of cash or another financial asset for a fixed number of the entity\u2019s own equity instruments. For this purpose, rights, options or warrants to acquire a fixed number of the entity\u2019s own equity instruments for a fixed amount of any currency are equity instruments if the entity offers the rights, options or warrants pro rata to all of its existing owners of the same class of its own non-derivative equity instruments. Also, for those purposes the entity\u2019s own equity instruments do not include puttable financial instruments that are classified as equity instruments in accordance with paragraphs 16A-16B of IAS 32, instruments that impose on the entity an obligation to deliver to another party a pro rata share of the net assets of the entity only on liquidation and are classified as equity instruments in accordance with paragraphs 16C-16D of IAS 32, or instruments that are contracts for the future receipt or delivery of the entity\u2019s own equity instruments. As an exception, an instrument that meets the definition of a financial liability is classified as an equity instrument if it has all the features and meets the conditions in paragraphs 16A-16B or paragraphs 16C-16D of IAS 32. [Refer: Financial instruments, class [member]; Financial assets; Derivatives [member]]" } }, "en-us": { "role": { "label": "Financial liabilities", "terseLabel": "Financial liabilities" } } }, "localname": "FinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FinancialLiabilitiesAtFairValue": { "auth_ref": [ "r211" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The fair value of financial liabilities. [Refer: At fair value [member]; Financial liabilities]" } }, "en-us": { "role": { "label": "Financial liabilities, at fair value", "terseLabel": "Fair value of financial liabilities" } } }, "localname": "FinancialLiabilitiesAtFairValue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_FixedInterestRateMember": { "auth_ref": [ "r361" ], "lang": { "en": { "role": { "documentation": "This member stands for a fixed interest rate. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Fixed interest rate [member]", "terseLabel": "Annual Nominal Interest Rate" } } }, "localname": "FixedInterestRateMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_FixturesAndFittingsMember": { "auth_ref": [ "r278" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing fixtures and fittings that are not permanently attached to real property. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Fixtures and fittings [member]", "terseLabel": "Fixtures and fittings [member]", "verboseLabel": "Fittings, Fittings and Improvements" } } }, "localname": "FixturesAndFittingsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ForeignExchangeRatesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Foreign exchange rates [abstract]", "terseLabel": "Foreign exchange rates [abstract]" } } }, "localname": "ForeignExchangeRatesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r80" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The decrease (increase) in a net defined benefit liability (asset) resulting from the remeasurement of that net defined benefit liability (asset). [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income", "terseLabel": "Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income" } } }, "localname": "GainLossOnRemeasurementOfNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationBeforeTax": { "auth_ref": [ "r49" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The gains (losses) recognised in other comprehensive income on exchange differences on the translation of financial statements of foreign operations, before tax, before reclassification adjustments. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Gains (losses) on exchange differences on translation of foreign operations, before tax", "terseLabel": "Exchange gains on trade receivables" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss": { "auth_ref": [ "r8", "r90" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of exchange differences recognised in profit or loss that arise from foreign currency transactions, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: At fair value [member]; Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Foreign exchange gain (loss)", "terseLabel": "Foreign exchange gain (loss)" } } }, "localname": "GainsLossesOnExchangeDifferencesOnTranslationRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialIncomeandExpensesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GeneralAndAdministrativeExpense": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 5.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 }, "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "order": 2.0, "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to general and administrative activities of the entity." } }, "en-us": { "role": { "label": "General and administrative expense", "negatedLabel": "General and administrative expenses", "terseLabel": "General and administrative expense" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GovernmentGrants": { "auth_ref": [ "r332" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of assistance by government in the form of transfers of resources to an entity in return for past or future compliance with certain conditions relating to the operating activities of the entity, recognised as deferred income. They exclude those forms of government assistance that cannot reasonably have a value placed upon them and transactions with government that cannot be distinguished from the normal trading transactions of the entity. [Refer: Deferred income other than contract liabilities; Government [member]]" } }, "en-us": { "role": { "label": "Government grants", "terseLabel": "Government grants" } } }, "localname": "GovernmentGrants", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_GrossCarryingAmountMember": { "auth_ref": [ "r67", "r124", "r134", "r137", "r206", "r216", "r219", "r298", "r365", "r366" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount at which an asset is recognised before deducting any accumulated depreciation (amortisation) and accumulated impairment losses thereon. [Refer: Depreciation and amortisation expense; Impairment loss]" } }, "en-us": { "role": { "label": "Gross carrying amount [member]", "terseLabel": "Gross" } } }, "localname": "GrossCarryingAmountMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ImpairmentLoss": { "auth_ref": [ "r116", "r117" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount recognised as a reduction of the carrying amount of an asset or cash-generating unit to its recoverable amount. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Impairment loss", "terseLabel": "Impairment loss" } } }, "localname": "ImpairmentLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment": { "auth_ref": [ "r51", "r70" ], "lang": { "en": { "role": { "documentation": "The amount of impairment loss recognised in profit or loss for property, plant and equipment. [Refer: Impairment loss recognised in profit or loss; Property, plant and equipment]" } }, "en-us": { "role": { "label": "Impairment loss recognised in profit or loss, property, plant and equipment", "terseLabel": "Impairment loss" } } }, "localname": "ImpairmentLossRecognisedInProfitOrLossPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Profit or loss [abstract]", "terseLabel": "Profit or loss [abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_IncomeTaxExpenseContinuingOperations": { "auth_ref": [ "r47", "r57", "r59", "r60", "r105", "r168", "r234" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": -1.0 }, "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The aggregate amount included in the determination of profit (loss) for the period in respect of current tax and deferred tax. [Refer: Current tax expense (income); Deferred tax expense (income)]" } }, "en-us": { "role": { "label": "Tax expense (income)", "negatedLabel": "Income tax benefit (expense)", "negatedTotalLabel": "Tax expense (income)", "terseLabel": "Tax expense (income)" } } }, "localname": "IncomeTaxExpenseContinuingOperations", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncomeTaxesPaidRefundClassifiedAsOperatingActivities": { "auth_ref": [ "r143", "r286" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash flows from income taxes paid or refunded, classified as operating activities. [Refer: Income taxes paid (refund)]" } }, "en-us": { "role": { "label": "Income taxes paid (refund), classified as operating activities", "negatedLabel": "Income tax paid" } } }, "localname": "IncomeTaxesPaidRefundClassifiedAsOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember": { "auth_ref": [ "r328" ], "lang": { "en": { "role": { "documentation": "This member stands for the financial effect of changes in accounting policy for cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application [member]", "terseLabel": "Decrease due to changes in accounting policy required by IFRSs, cumulative effect at date of initial application" } } }, "localname": "IncreaseDecreaseDueToChangesInAccountingPolicyRequiredByIFRSsCumulativeEffectAtDateOfInitialApplicationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": { "auth_ref": [ "r144" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]" } }, "en-us": { "role": { "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes", "totalLabel": "Increase (decrease) in cash and cash equivalents" } } }, "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by a decrease in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in defined benefit obligation due to reasonably possible decrease in actuarial assumption", "terseLabel": "Impact/present value of the undertaking" } } }, "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleDecreaseInActuarialAssumption", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption": { "auth_ref": [ "r83" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in a defined benefit obligation that would have been caused by an increase in a significant actuarial assumption that was reasonably possible at the end of the reporting period. [Refer: Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in defined benefit obligation due to reasonably possible increase in actuarial assumption", "terseLabel": "Impact/present value of the undertaking" } } }, "localname": "IncreaseDecreaseInDefinedBenefitObligationDueToReasonablyPossibleIncreaseInActuarialAssumption", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInIntangibleAssetsAndGoodwill": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets and goodwill. [Refer: Intangible assets and goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) in intangible assets and goodwill", "terseLabel": "Increase (decrease) in intangible assets and goodwill" } } }, "localname": "IncreaseDecreaseInIntangibleAssetsAndGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseInNumberOfSharesOutstanding": { "auth_ref": [ "r35" ], "lang": { "en": { "role": { "documentation": "The increase (decrease) in the number of shares outstanding. [Refer: Number of shares outstanding]" } }, "en-us": { "role": { "label": "Increase (decrease) in number of shares outstanding", "terseLabel": "Capital increase (shares)" } } }, "localname": "IncreaseDecreaseInNumberOfSharesOutstanding", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "sharesItemType" }, "ifrs-full_IncreaseDecreaseInWorkingCapital": { "auth_ref": [ "r358" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in working capital." } }, "en-us": { "role": { "label": "Increase (decrease) in working capital", "negatedTotalLabel": "Change in working capital", "terseLabel": "Increase in capital" } } }, "localname": "IncreaseDecreaseInWorkingCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughAppropriationOfRetainedEarnings": { "auth_ref": [ "r327" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from the appropriation of retained earnings. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Increase (decrease) through appropriation of retained earnings, equity", "terseLabel": "Allocation of prior period profit (loss)" } } }, "localname": "IncreaseDecreaseThroughAppropriationOfRetainedEarnings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r126" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from net exchange differences arising on the translation of the financial statements from the functional currency into a different presentation currency, including the translation of a foreign operation into the presentation currency of the reporting entity. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through net exchange differences, intangible assets other than goodwill", "terseLabel": "Translation adjustments" } } }, "localname": "IncreaseDecreaseThroughNetExchangeDifferencesIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r342" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes", "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from other changes" } } }, "localname": "IncreaseDecreaseThroughOtherChangesNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": { "auth_ref": [ "r4" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through share-based payment transactions, equity", "terseLabel": "Share-based compensation" } } }, "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersAndOtherChangesEquity": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from changes that the entity does not separately disclose in the same statement or note. [Refer: Equity]" } }, "en-us": { "role": { "label": "Increase (decrease) through other changes, equity", "negatedTerseLabel": "Increase (decrease) through other changes, equity", "terseLabel": "Other movements" } } }, "localname": "IncreaseDecreaseThroughTransfersAndOtherChangesEquity", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in intangible assets other than goodwill resulting from transfers. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Increase (decrease) through transfers, intangible assets other than goodwill", "terseLabel": "Reclassification" } } }, "localname": "IncreaseDecreaseThroughTransfersIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IncreaseDecreaseThroughTreasuryShareTransactions": { "auth_ref": [ "r5" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in equity resulting from treasury share transactions. [Refer: Equity; Treasury shares]" } }, "en-us": { "role": { "label": "Increase (decrease) through treasury share transactions, equity", "terseLabel": "Treasury shares" } } }, "localname": "IncreaseDecreaseThroughTreasuryShareTransactions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwill": { "auth_ref": [ "r332" ], "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 4.0, "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of intangible assets and goodwill held by the entity. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill", "terseLabel": "Intangible assets and goodwill" } } }, "localname": "IntangibleAssetsAndGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsAndGoodwillMember": { "auth_ref": [ "r350" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets and goodwill. It also represents the standard value for the 'Classes of intangible assets and goodwill' axis if no other member is used. [Refer: Goodwill; Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets and goodwill [member]", "terseLabel": "Intangible assets and goodwill [member]" } } }, "localname": "IntangibleAssetsAndGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r10", "r127" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill", "periodEndLabel": "Intangible assets other than goodwill Period End", "periodStartLabel": "Intangible assets other than goodwill Period Start", "terseLabel": "Intangible assets" } } }, "localname": "IntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IntangibleAssetsOtherThanGoodwillMember": { "auth_ref": [ "r128", "r282", "r297" ], "lang": { "en": { "role": { "documentation": "This member stands for intangible assets other than goodwill. It also represents the standard value for the 'Classes of intangible assets other than goodwill' axis if no other member is used. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Intangible assets other than goodwill [member]", "terseLabel": "Intangible assets other than goodwill [member]" } } }, "localname": "IntangibleAssetsOtherThanGoodwillMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestExpense": { "auth_ref": [ "r167", "r233", "r240" ], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense arising from interest." } }, "en-us": { "role": { "label": "Interest expense", "negatedLabel": "Interest expense", "negatedTerseLabel": "Interest expense" } } }, "localname": "InterestExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestExpenseIncomeNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r79" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from the passage of time. [Refer: Interest expense; Net defined benefit liability (asset)]" } }, "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)", "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from interest expense (income)" } } }, "localname": "InterestExpenseIncomeNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPaidClassifiedAsFinancingActivities": { "auth_ref": [ "r142" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 6.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for interest paid, classified as financing activities." } }, "en-us": { "role": { "label": "Interest paid, classified as financing activities", "negatedLabel": "- Financial interests paid (including finance lease)" } } }, "localname": "InterestPaidClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestPayable": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of interest recognised as a liability." } }, "en-us": { "role": { "label": "Interest payable", "terseLabel": "Convertible bond, yearly interest" } } }, "localname": "InterestPayable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InterestRateRiskMember": { "auth_ref": [ "r230", "r250", "r251", "r252", "r253" ], "lang": { "en": { "role": { "documentation": "This member stands for the type of risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Interest rate risk [member]", "terseLabel": "Interest Rate Risk" } } }, "localname": "InterestRateRiskMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_InterestRateTypesMember": { "auth_ref": [ "r361" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of interest rates. It also represents the standard value for the 'Types of interest rates' axis if no other member is used. [Refer: Interest rate risk [member]]" } }, "en-us": { "role": { "label": "Interest rate types [member]", "terseLabel": "Interest rate types [member]" } } }, "localname": "InterestRateTypesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Inventories": { "auth_ref": [ "r13", "r88", "r269" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current inventories. [Refer: Inventories]" } }, "en-us": { "role": { "label": "Current inventories", "terseLabel": "Inventories" } } }, "localname": "Inventories", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_InvestmentAccountedForUsingEquityMethod": { "auth_ref": [ "r12", "r169", "r236" ], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 6.0, "parentTag": "gnft_FinancialAssetsVariations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of investments accounted for using the equity method. The equity method is a method of accounting whereby the investment is initially recognised at cost and adjusted thereafter for the post-acquisition change in the investor's share of net assets of the investee. The investor's profit or loss includes its share of the profit or loss of the investee. The investor's other comprehensive income includes its share of the other comprehensive income of the investee. [Refer: At cost [member]]" } }, "en-us": { "role": { "label": "Investments accounted for using equity method", "terseLabel": "Investments accounted for using equity method" } } }, "localname": "InvestmentAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapital": { "auth_ref": [ "r272" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital issued." } }, "en-us": { "role": { "label": "Issued capital", "terseLabel": "Share capital" } } }, "localname": "IssuedCapital", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_IssuedCapitalMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing issued capital." } }, "en-us": { "role": { "label": "Issued capital [member]", "terseLabel": "Share capital" } } }, "localname": "IssuedCapitalMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_IssuedCapitalOrdinaryShares": { "auth_ref": [ "r334" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The nominal value of capital arising from issuing ordinary shares. [Refer: Issued capital]" } }, "en-us": { "role": { "label": "Issued capital, ordinary shares", "terseLabel": "Issued capital, ordinary shares" } } }, "localname": "IssuedCapitalOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensation": { "auth_ref": [ "r96" ], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation", "totalLabel": "Key management personnel compensation" } } }, "localname": "KeyManagementPersonnelCompensation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationPostemploymentBenefits": { "auth_ref": [ "r94" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of post-employment benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, post-employment benefits", "terseLabel": "Key management personnel compensation, post-employment benefits" } } }, "localname": "KeyManagementPersonnelCompensationPostemploymentBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationSharebasedPayment": { "auth_ref": [ "r95" ], "calculation": { "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails": { "order": 5.0, "parentTag": "ifrs-full_KeyManagementPersonnelCompensation", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of share-based payments. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, share-based payment", "terseLabel": "Key management personnel compensation, share-based payment" } } }, "localname": "KeyManagementPersonnelCompensationSharebasedPayment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_KeyManagementPersonnelCompensationShorttermEmployeeBenefits": { "auth_ref": [ "r93" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of compensation to key management personnel in the form of short-term employee benefits. [Refer: Key management personnel of entity or parent [member]]" } }, "en-us": { "role": { "label": "Key management personnel compensation, short-term employee benefits", "terseLabel": "Key management personnel compensation, short-term employee benefits" } } }, "localname": "KeyManagementPersonnelCompensationShorttermEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CompensationofCorporateOfficersSummaryofCompensationPaidtoOfficersDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LaterThanFiveYearsMember": { "auth_ref": [ "r186", "r188", "r255", "r300", "r301", "r304" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than five years." } }, "en-us": { "role": { "label": "Later than five years [member]", "terseLabel": "Later than five years" } } }, "localname": "LaterThanFiveYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanFourYearsAndNotLaterThanFiveYearsMember": { "auth_ref": [ "r186", "r188", "r255", "r300", "r304", "r330" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than four years and not later than five years." } }, "en-us": { "role": { "label": "Later than four years and not later than five years [member]", "terseLabel": "Later than four years and not later than five years" } } }, "localname": "LaterThanFourYearsAndNotLaterThanFiveYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearAndNotLaterThanTwoYearsMember": { "auth_ref": [ "r186", "r188", "r255", "r300", "r304", "r330" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year and not later than two years." } }, "en-us": { "role": { "label": "Later than one year and not later than two years [member]", "terseLabel": "Later than one year and not later than two years" } } }, "localname": "LaterThanOneYearAndNotLaterThanTwoYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanOneYearMember": { "auth_ref": [ "r25", "r310", "r312" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than one year." } }, "en-us": { "role": { "label": "Later than one year [member]", "terseLabel": "Beyond" } } }, "localname": "LaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanThreeYearsAndNotLaterThanFourYearsMember": { "auth_ref": [ "r186", "r188", "r255", "r300", "r304", "r330" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than three years and not later than four years." } }, "en-us": { "role": { "label": "Later than three years and not later than four years [member]", "terseLabel": "Later than three years and not later than four years" } } }, "localname": "LaterThanThreeYearsAndNotLaterThanFourYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LaterThanTwoYearsAndNotLaterThanThreeYearsMember": { "auth_ref": [ "r186", "r188", "r255", "r300", "r304", "r330" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of later than two years and not later than three years." } }, "en-us": { "role": { "label": "Later than two years and not later than three years [member]", "terseLabel": "Later than two years and not later than three years" } } }, "localname": "LaterThanTwoYearsAndNotLaterThanThreeYearsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LeaseLiabilities": { "auth_ref": [ "r184" ], "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 2.0, "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities related to the entity's leases. Lease is a contract, or part of a contract, that conveys the right to use an underlying asset for a period of time in exchange for consideration." } }, "en-us": { "role": { "label": "Lease liabilities", "terseLabel": "Lease liabilities" } } }, "localname": "LeaseLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Level1OfFairValueHierarchyMember": { "auth_ref": [ "r82", "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date." } }, "en-us": { "role": { "label": "Level 1 of fair value hierarchy [member]", "terseLabel": "Level 1" } } }, "localname": "Level1OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level2OfFairValueHierarchyMember": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly." } }, "en-us": { "role": { "label": "Level 2 of fair value hierarchy [member]", "terseLabel": "Level 2" } } }, "localname": "Level2OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_Level3OfFairValueHierarchyMember": { "auth_ref": [ "r172" ], "lang": { "en": { "role": { "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability." } }, "en-us": { "role": { "label": "Level 3 of fair value hierarchy [member]", "terseLabel": "Level 3" } } }, "localname": "Level3OfFairValueHierarchyMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_LevelsOfFairValueHierarchyAxis": { "auth_ref": [ "r82", "r172" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Levels of fair value hierarchy [axis]", "terseLabel": "Levels of fair value hierarchy [axis]" } } }, "localname": "LevelsOfFairValueHierarchyAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_LiabilityAssetOfDefinedBenefitPlans": { "auth_ref": [ "r77" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deficit or surplus in a defined benefit plan, adjusted for any effect of limiting a net defined benefit asset to the asset ceiling. [Refer: Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Net defined benefit liability (asset)", "periodEndLabel": "Defined benefit obligation, ending balance", "periodStartLabel": "Defined benefit obligation, beginning balance", "terseLabel": "Net defined benefit liability (asset)" } } }, "localname": "LiabilityAssetOfDefinedBenefitPlans", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LicenceFeeIncome": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from licence fees." } }, "en-us": { "role": { "label": "Licence fee income", "terseLabel": "Licence fee income" } } }, "localname": "LicenceFeeIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LoansAndReceivables": { "auth_ref": [ "r265" ], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": 1.0, "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-derivative financial assets with fixed or determinable payments that are not quoted in an active market, other than: (a) those that the entity intends to sell immediately or in the near term, which shall be classified as held for trading, and those that the entity, upon initial recognition, designates as at fair value through profit or loss; (b) those that the entity, upon initial recognition, designates as available for sale; or (c) those for which the holder may not recover substantially all of its initial investment, other than because of credit deterioration, which shall be classified as available for sale. An interest acquired in a pool of assets that are not loans or receivables (for example, an interest in a mutual fund or a similar fund) is not a loan or receivable. [Refer: Derivative financial assets]" } }, "en-us": { "role": { "label": "Loans and receivables", "terseLabel": "Loans and receivables" } } }, "localname": "LoansAndReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_LossesOnDisposalsOfPropertyPlantAndEquipment": { "auth_ref": [ "r53" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The losses on the disposal of property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Losses on disposals of property, plant and equipment", "terseLabel": "Losses on disposals of property, plant and equipment" } } }, "localname": "LossesOnDisposalsOfPropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriod", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_MaterialIncomeAndExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Material income and expense [abstract]", "terseLabel": "Operating expenses and other operating income (expenses)" } } }, "localname": "MaterialIncomeAndExpenseAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "ifrs-full_MaturityAnalysisForNonderivativeFinancialLiabilities": { "auth_ref": [ "r221" ], "lang": { "en": { "role": { "documentation": "The disclosure of a maturity analysis for non-derivative financial liabilities (including issued financial guarantee contracts) that shows the remaining contractual maturities. [Refer: Derivative financial liabilities]" } }, "en-us": { "role": { "label": "Disclosure of maturity analysis for non-derivative financial liabilities [text block]", "terseLabel": "Summary of Maturities of Financial Liabilities" } } }, "localname": "MaturityAnalysisForNonderivativeFinancialLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsTables" ], "xbrltype": "textBlockItemType" }, "ifrs-full_MaturityAxis": { "auth_ref": [ "r26", "r182", "r186", "r188", "r210", "r223", "r247", "r248", "r249", "r255", "r280", "r300" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Maturity [axis]", "terseLabel": "Maturity [axis]" } } }, "localname": "MaturityAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MeasurementAxis": { "auth_ref": [ "r132", "r136", "r171" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Measurement [axis]", "terseLabel": "Measurement [axis]" } } }, "localname": "MeasurementAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_MiscellaneousAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Miscellaneous assets [abstract]", "terseLabel": "Miscellaneous assets [abstract]" } } }, "localname": "MiscellaneousAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_NameOfAcquiree": { "auth_ref": [ "r199" ], "lang": { "en": { "role": { "documentation": "The name of the business or businesses that the acquirer obtains control of in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Name of acquiree", "terseLabel": "Name of acquiree" } } }, "localname": "NameOfAcquiree", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NetAssetsLiabilities": { "auth_ref": [ "r293", "r330" ], "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets less the amount of liabilities." } }, "en-us": { "role": { "label": "Assets (liabilities)", "totalLabel": "Assets (liabilities)" } } }, "localname": "NetAssetsLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetDeferredTaxAssets": { "auth_ref": [ "r338" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax assets net of deferred tax liabilities, when the absolute amount of deferred tax assets is greater than the absolute amount of deferred tax liabilities. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax assets", "terseLabel": "Deferred tax assets" } } }, "localname": "NetDeferredTaxAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetDeferredTaxLiabilities": { "auth_ref": [ "r338" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of deferred tax liabilities net of deferred tax assets, when the absolute amount of deferred tax liabilities is greater than the absolute amount of deferred tax assets. [Refer: Deferred tax assets; Deferred tax liabilities]" } }, "en-us": { "role": { "label": "Net deferred tax liabilities", "terseLabel": "Deferred tax liabilities" } } }, "localname": "NetDeferredTaxLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeGain": { "auth_ref": [ "r331", "r346" ], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 2.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The net gain arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange gain", "terseLabel": "Net foreign exchange gain" } } }, "localname": "NetForeignExchangeGain", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NetForeignExchangeLoss": { "auth_ref": [ "r331", "r346" ], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 3.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The net loss arising from exchange differences recognised in profit or loss, excluding those arising on financial instruments measured at fair value through profit or loss in accordance with IFRS 9. [Refer: Foreign exchange gain (loss)]" } }, "en-us": { "role": { "label": "Net foreign exchange loss", "negatedLabel": "Net foreign exchange loss", "negatedTerseLabel": "Net foreign exchange loss" } } }, "localname": "NetForeignExchangeLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NewIFRSsAxis": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "New IFRSs [axis]", "terseLabel": "New IFRSs [axis]" } } }, "localname": "NewIFRSsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NewIFRSsMember": { "auth_ref": [ "r149" ], "lang": { "en": { "role": { "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "New IFRSs [member]", "terseLabel": "New IFRSs [member]" } } }, "localname": "NewIFRSsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [axis]", "terseLabel": "Non-adjusting events after reporting period [axis]" } } }, "localname": "NonadjustingEventsAfterReportingPeriodAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NonadjustingEventsMember": { "auth_ref": [ "r56" ], "lang": { "en": { "role": { "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used." } }, "en-us": { "role": { "label": "Non-adjusting events after reporting period [member]", "terseLabel": "Non-adjusting events after reporting period [member]" } } }, "localname": "NonadjustingEventsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncontrollingInterests": { "auth_ref": [ "r20", "r154", "r156" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Equity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of equity in a subsidiary not attributable, directly or indirectly, to a parent. [Refer: Subsidiaries [member]]" } }, "en-us": { "role": { "label": "Non-controlling interests", "terseLabel": "Non-controlling interests" } } }, "localname": "NoncontrollingInterests", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncontrollingInterestsMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for equity in a subsidiary not attributable, directly or indirectly, to the parent." } }, "en-us": { "role": { "label": "Non-controlling interests [member]", "terseLabel": "Non-controlling interests" } } }, "localname": "NoncontrollingInterestsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_NoncurrentAssets": { "auth_ref": [ "r27", "r159", "r294" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Non-current assets", "totalLabel": "Total - Non-current assets" } } }, "localname": "NoncurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets [abstract]", "terseLabel": "Non-current assets" } } }, "localname": "NoncurrentAssetsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts": { "auth_ref": [ "r243" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets and rights arising under insurance contracts. [Refer: Deferred tax assets; Financial instruments, class [member]; Non-current assets; Types of insurance contracts [member]]" } }, "en-us": { "role": { "label": "Non-current assets other than financial instruments, deferred tax assets, post-employment benefit assets, and rights arising under insurance contracts", "terseLabel": "Post-employment benefit expense, defined benefit plans impact on deferred tax assets" } } }, "localname": "NoncurrentAssetsOtherThanFinancialInstrumentsDeferredTaxAssetsPostemploymentBenefitAssetsAndRightsArisingUnderInsuranceContracts", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities": { "auth_ref": [ "r332", "r335" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current deferred income including non-current contract liabilities. [Refer: Deferred income including contract liabilities]" } }, "en-us": { "role": { "label": "Non-current deferred income including non-current contract liabilities", "verboseLabel": "Deferred income non-current" } } }, "localname": "NoncurrentDeferredIncomeIncludingNoncurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities": { "auth_ref": [ "r332", "r335" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current deferred income other than non-current contract liabilities. [Refer: Deferred income other than contract liabilities]" } }, "en-us": { "role": { "label": "Non-current deferred income other than non-current contract liabilities", "terseLabel": "Non-current deferred income and revenue" } } }, "localname": "NoncurrentDeferredIncomeOtherThanNoncurrentContractLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentExciseTaxPayables": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current excise tax payables. [Refer: Excise tax payables]" } }, "en-us": { "role": { "label": "Non-current excise tax payables", "terseLabel": "Non-current excise tax payables" } } }, "localname": "NoncurrentExciseTaxPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilities": { "auth_ref": [ "r28", "r161", "r294" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 2.0, "parentTag": "ifrs-full_EquityAndLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]" } }, "en-us": { "role": { "label": "Non-current liabilities", "totalLabel": "Total - Non-current liabilities" } } }, "localname": "NoncurrentLiabilities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentLiabilitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities [abstract]", "terseLabel": "Non-current liabilities" } } }, "localname": "NoncurrentLiabilitiesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentLoansAndReceivables": { "auth_ref": [ "r265" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current loans and receivables. [Refer: Loans and receivables]" } }, "en-us": { "role": { "label": "Non-current loans and receivables", "terseLabel": "Non-current loans and receivables" } } }, "localname": "NoncurrentLoansAndReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentPayables": { "auth_ref": [ "r16" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 }, "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current trade payables and non-current other payables. [Refer: Other non-current payables; Non-current trade payables]" } }, "en-us": { "role": { "label": "Trade and other non-current payables", "terseLabel": "Non-current trade and other payables", "totalLabel": "Total trade and other non-current payables" } } }, "localname": "NoncurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other non-current payables [abstract]", "terseLabel": "Trade and other payables - Non current" } } }, "localname": "NoncurrentPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_NoncurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 2.0, "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current payables on social security and taxes other than incomes tax. [Refer: Payables on social security and taxes other than income tax]" } }, "en-us": { "role": { "label": "Non-current payables on social security and taxes other than income tax", "terseLabel": "Non-current payables on social security and taxes other than income tax" } } }, "localname": "NoncurrentPayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentPayablesToTradeSuppliers": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current amount of payment due to suppliers for goods and services used in the entity's business. [Refer: Trade payables]" } }, "en-us": { "role": { "label": "Non-current trade payables", "terseLabel": "Non-current trade payables" } } }, "localname": "NoncurrentPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current notes and debentures issued. [Refer: Notes and debentures issued]" } }, "en-us": { "role": { "label": "Non-current portion of non-current notes and debentures issued", "terseLabel": "Non-current convertible loans" } } }, "localname": "NoncurrentPortionOfNoncurrentNotesAndDebenturesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentPortionOfOtherNoncurrentBorrowings": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The non-current portion of non-current other borrowings. [Refer: Other borrowings]" } }, "en-us": { "role": { "label": "Non-current portion of other non-current borrowings", "terseLabel": "Other non-current loans and borrowings" } } }, "localname": "NoncurrentPortionOfOtherNoncurrentBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentProvisions": { "auth_ref": [ "r17" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions, including provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Non-current provisions", "terseLabel": "Support costs related to reduction in force plan implemented" } } }, "localname": "NoncurrentProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentProvisionsForEmployeeBenefits": { "auth_ref": [ "r31" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current provisions for employee benefits. [Refer: Provisions for employee benefits]" } }, "en-us": { "role": { "label": "Non-current provisions for employee benefits", "terseLabel": "Non-current employee benefits" } } }, "localname": "NoncurrentProvisionsForEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentReceivables": { "auth_ref": [ "r14", "r30" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 }, "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current trade receivables and non-current other receivables. [Refer: Non-current trade receivables; Other non-current receivables]" } }, "en-us": { "role": { "label": "Trade and other non-current receivables", "terseLabel": "Non-current trade and other receivables", "totalLabel": "Total trade and other non-current receivables" } } }, "localname": "NoncurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentTradeReceivables": { "auth_ref": [ "r271" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 1.0, "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Non-current trade receivables", "terseLabel": "Non-current trade receivables" } } }, "localname": "NoncurrentTradeReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentValueAddedTaxPayables": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current value added tax payables. [Refer: Value added tax payables]" } }, "en-us": { "role": { "label": "Non-current value added tax payables", "terseLabel": "Non-current value added tax payables" } } }, "localname": "NoncurrentValueAddedTaxPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NoncurrentValueAddedTaxReceivables": { "auth_ref": [ "r333" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 4.0, "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current value added tax receivables. [Refer: Value added tax receivables]" } }, "en-us": { "role": { "label": "Non-current value added tax receivables", "terseLabel": "Non-current value added tax receivables" } } }, "localname": "NoncurrentValueAddedTaxReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotLaterThanOneYearMember": { "auth_ref": [ "r24", "r186", "r188", "r255", "r300", "r304" ], "lang": { "en": { "role": { "documentation": "This member stands for a time band of not later than one year." } }, "en-us": { "role": { "label": "Not later than one year [member]", "terseLabel": "Within 1 Year" } } }, "localname": "NotLaterThanOneYearMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofAssumptionsUsedforEmployeesfortheMeasurementofRetirementIndemnitytoEmployeesDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofMaturitiesofFinancialLiabilitiesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_NotesAndDebenturesIssued": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of notes and debentures issued by the entity." } }, "en-us": { "role": { "label": "Notes and debentures issued", "terseLabel": "Notes and debentures issued", "verboseLabel": "Notes and debentures issued" } } }, "localname": "NotesAndDebenturesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofConvertibleBondsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NotionalAmount": { "auth_ref": [ "r330" ], "lang": { "en": { "role": { "documentation": "The nominal or face amount of a financial instrument, used to calculate payments made on that instrument." } }, "en-us": { "role": { "label": "Notional amount", "terseLabel": "Notional amount" } } }, "localname": "NotionalAmount", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBondsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_NumberOfEmployees": { "auth_ref": [ "r330" ], "lang": { "en": { "role": { "documentation": "The number of personnel employed by the entity at a date." } }, "en-us": { "role": { "label": "Number of employees", "terseLabel": "Number of employees" } } }, "localname": "NumberOfEmployees", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": { "auth_ref": [ "r198", "r360" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments granted in share-based payment arrangement", "terseLabel": "Number of other equity instruments granted in share-based payment arrangement" } } }, "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement": { "auth_ref": [ "r360" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercisable in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments exercisable in share-based payment arrangement", "terseLabel": "Number of other equity instruments exercisable in share-based payment arrangement" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisableInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement": { "auth_ref": [ "r360" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) exercised or vested in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments exercised or vested in share-based payment arrangement", "terseLabel": "Number of instruments exercised (in shares)", "verboseLabel": "Total number of AGA definitively vested (in shares)" } } }, "localname": "NumberOfOtherEquityInstrumentsExercisedOrVestedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r360" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments forfeited in share-based payment arrangement", "terseLabel": "Total number of BSAAR voided (in shares)", "totalLabel": "Total number of BSAAR voided" } } }, "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement": { "auth_ref": [ "r360" ], "lang": { "en": { "role": { "documentation": "The number of other equity instruments (ie other than share options) outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of other equity instruments outstanding in share-based payment arrangement", "terseLabel": "Total number of BSAAR subscribed (in shares)" } } }, "localname": "NumberOfOtherEquityInstrumentsOutstandingInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfOutstandingShareOptions": { "auth_ref": [ "r191", "r193", "r195" ], "lang": { "en": { "role": { "documentation": "The number of share options outstanding in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options outstanding in share-based payment arrangement", "terseLabel": "Total number of SO remaining" } } }, "localname": "NumberOfOutstandingShareOptions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": { "auth_ref": [ "r192" ], "lang": { "en": { "role": { "documentation": "The number of share options forfeited in a share-based payment arrangement." } }, "en-us": { "role": { "label": "Number of share options forfeited in share-based payment arrangement", "terseLabel": "Total number of SO voided" } } }, "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails" ], "xbrltype": "decimalItemType" }, "ifrs-full_NumberOfSharesIssued": { "auth_ref": [ "r327" ], "calculation": { "http://www.genfit.com/role/EquityAdditionalInformationDetails": { "order": 1.0, "parentTag": "ifrs-full_NumberOfSharesOutstanding", "weight": 1.0 } }, "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity." } }, "en-us": { "role": { "label": "Number of shares issued", "terseLabel": "New shares created (in shares)", "verboseLabel": "Issuance of new shares (in shares)" } } }, "localname": "NumberOfSharesIssued", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesIssuedAndFullyPaid": { "auth_ref": [ "r33" ], "lang": { "en": { "role": { "documentation": "The number of shares issued by the entity, for which full payment has been received." } }, "en-us": { "role": { "label": "Number of shares issued and fully paid", "terseLabel": "Number of shares issued and fully paid" } } }, "localname": "NumberOfSharesIssuedAndFullyPaid", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_NumberOfSharesOutstanding": { "auth_ref": [ "r35" ], "calculation": { "http://www.genfit.com/role/EquityAdditionalInformationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en": { "role": { "documentation": "The number of shares that have been authorised and issued, reduced by treasury shares held. [Refer: Treasury shares]" } }, "en-us": { "role": { "label": "Number of shares outstanding", "periodEndLabel": "Balance at end of period (in shares)", "periodStartLabel": "Balance at beginning of period (in shares)", "terseLabel": "Number of shares outstanding", "totalLabel": "Total number of shares comprising the share capital (in shares)" } } }, "localname": "NumberOfSharesOutstanding", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "sharesItemType" }, "ifrs-full_OfficeEquipmentMember": { "auth_ref": [ "r279" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing equipment used to support office functions, not specifically used in the production process. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Office equipment [member]", "terseLabel": "Office equipment" } } }, "localname": "OfficeEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember": { "auth_ref": [ "r328" ], "lang": { "en": { "role": { "documentation": "This member indicates the opening balance before the cumulative effect adjustment in the financial statements at the date of initial application of a new or amended IFRS Standard. It also represents the standard value for the \u2018Cumulative effect at date of initial application\u2019 axis if no other member is used." } }, "en-us": { "role": { "label": "Opening balance before adjustment, cumulative effect at date of initial application [member]", "terseLabel": "Opening balance before adjustment, cumulative effect at date of initial application [member]" } } }, "localname": "OpeningBalanceBeforeAdjustmentCumulativeEffectAtDateOfInitialApplicationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OperatingExpense": { "auth_ref": [ "r337" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of all operating expenses." } }, "en-us": { "role": { "label": "Operating expense", "terseLabel": "Operating expense", "verboseLabel": "Expenses" } } }, "localname": "OperatingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OrdinarySharesMember": { "auth_ref": [ "r110", "r336" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used." } }, "en-us": { "role": { "label": "Ordinary shares [member]", "terseLabel": "Ordinary shares [member]" } } }, "localname": "OrdinarySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherAdjustmentsForNoncashItems": { "auth_ref": [ "r357" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 9.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "Adjustments for non-cash items to reconcile profit (loss) to net cash flow from (used in) operating activities that the entity does not separately disclose in the same statement or note. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Other adjustments for non-cash items", "terseLabel": "+ Other non-cash items" } } }, "localname": "OtherAdjustmentsForNoncashItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherBorrowings": { "auth_ref": [ "r330" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of borrowings that the entity does not separately disclose in the same statement or note. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Other borrowings", "terseLabel": "Other borrowings" } } }, "localname": "OtherBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncome": { "auth_ref": [ "r3", "r39", "r48", "r164" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income and expense (including reclassification adjustments) that is not recognised in profit or loss as required or permitted by IFRSs. [Refer: IFRSs [member]]" } }, "en-us": { "role": { "label": "Other comprehensive income", "terseLabel": "Other comprehensive income (loss)" } } }, "localname": "OtherComprehensiveIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation": { "auth_ref": [ "r29", "r48" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, after reclassification adjustments, related to exchange differences when financial statements of foreign operations are translated. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, exchange differences on translation of foreign operations", "terseLabel": "Exchange differences on translation of foreign operations" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans": { "auth_ref": [ "r29", "r48", "r341" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income, net of tax, related to gains (losses) on remeasurements of defined benefit plans, which comprise actuarial gains and losses; the return on plan assets, excluding amounts included in net interest on the net defined benefit liability (asset); and any change in the effect of the asset ceiling, excluding amounts included in net interest on the net defined benefit liability (asset). [Refer: Other comprehensive income; Defined benefit plans [member]; Plan assets [member]; Net defined benefit liability (asset)] [Contrast: Decrease (increase) in net defined benefit liability (asset) resulting from gain (loss) on remeasurement in other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income, net of tax, gains (losses) on remeasurements of defined benefit plans", "terseLabel": "Actuarial gains and losses net of tax" } } }, "localname": "OtherComprehensiveIncomeNetOfTaxGainsLossesOnRemeasurementsOfDefinedBenefitPlans", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r273", "r274" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "order": 3.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income that will be reclassified to profit or loss, net of tax", "totalLabel": "that are or may be reclassified to profit or loss" } } }, "localname": "OtherComprehensiveIncomeThatWillBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax": { "auth_ref": [ "r273", "r274" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "order": 2.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of other comprehensive income that will not be reclassified to profit or loss, net of tax. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Other comprehensive income that will not be reclassified to profit or loss, net of tax", "totalLabel": "that will never be reclassified to profit or loss" } } }, "localname": "OtherComprehensiveIncomeThatWillNotBeReclassifiedToProfitOrLossNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentAssets": { "auth_ref": [ "r332" ], "calculation": { "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 5.0, "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current assets that the entity does not separately disclose in the same statement or note. [Refer: Current assets]" } }, "en-us": { "role": { "label": "Other current assets", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current other borrowings and the current portion of non-current other borrowings. [Refer: Other borrowings]" } }, "en-us": { "role": { "label": "Other current borrowings and current portion of other non-current borrowings", "terseLabel": "Other current loans and borrowings" } } }, "localname": "OtherCurrentBorrowingsAndCurrentPortionOfOtherNoncurrentBorrowings", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofOtherLoansandBorrowingsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentFinancialAssets": { "auth_ref": [ "r11" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "order": 1.0, "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets; Current financial assets]" } }, "en-us": { "role": { "label": "Other current financial assets", "terseLabel": "Other current financial assets" } } }, "localname": "OtherCurrentFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentNonfinancialAssets": { "auth_ref": [ "r332" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current non-financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Other current non-financial assets", "terseLabel": "Other current assets" } } }, "localname": "OtherCurrentNonfinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/OtherAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentPayables": { "auth_ref": [ "r332" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 2.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other current payables", "terseLabel": "Other current payables" } } }, "localname": "OtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherCurrentReceivables": { "auth_ref": [ "r271" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 6.0, "parentTag": "ifrs-full_TradeAndOtherCurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other current receivables", "terseLabel": "Other current receivables" } } }, "localname": "OtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceCost": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_FinanceCosts", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of finance costs that the entity does not separately disclose in the same statement or note. [Refer: Finance costs]" } }, "en-us": { "role": { "label": "Other finance cost", "negatedLabel": "Other finance cost", "negatedTerseLabel": "Other finance cost" } } }, "localname": "OtherFinanceCost", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinanceIncome": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 4.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of finance income that the entity does not separately disclose in the same statement or note. [Refer: Finance income]" } }, "en-us": { "role": { "label": "Other finance income", "terseLabel": "Other finance income" } } }, "localname": "OtherFinanceIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherFinancialAssets": { "auth_ref": [ "r11" ], "calculation": { "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets that the entity does not separately disclose in the same statement or note. [Refer: Financial assets]" } }, "en-us": { "role": { "label": "Other financial assets", "terseLabel": "Total amount of financial assets", "totalLabel": "Other financial assets" } } }, "localname": "OtherFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIncome": { "auth_ref": [ "r102", "r266", "r267" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other income", "terseLabel": "Other income", "verboseLabel": "Research tax credit (CIR)" } } }, "localname": "OtherIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeScheduleofOtherIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherIntangibleAssetsMember": { "auth_ref": [ "r351" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of intangible assets that the entity does not separately disclose in the same statement or note. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Other intangible assets [member]", "terseLabel": "Other Intangibles" } } }, "localname": "OtherIntangibleAssetsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherNoncurrentFinancialAssets": { "auth_ref": [ "r11" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 1.0, "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0 }, "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails_1": { "order": 2.0, "parentTag": "ifrs-full_OtherFinancialAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current financial assets that the entity does not separately disclose in the same statement or note. [Refer: Other financial assets]" } }, "en-us": { "role": { "label": "Other non-current financial assets", "terseLabel": "Other non-current financial assets" } } }, "localname": "OtherNoncurrentFinancialAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentPayables": { "auth_ref": [ "r332" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 5.0, "parentTag": "ifrs-full_NoncurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of non-current payables that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other non-current payables", "terseLabel": "Other non-current payables", "verboseLabel": "Other non-current payables" } } }, "localname": "OtherNoncurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherNoncurrentReceivables": { "auth_ref": [ "r271" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 6.0, "parentTag": "ifrs-full_NoncurrentReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of non-current other receivables. [Refer: Other receivables]" } }, "en-us": { "role": { "label": "Other non-current receivables", "terseLabel": "Other non-current receivables" } } }, "localname": "OtherNoncurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherOperatingIncomeExpense": { "auth_ref": [ "r337" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 4.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 }, "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "order": 5.0, "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other operating income (expense)", "terseLabel": "Other operating income (expense)" } } }, "localname": "OtherOperatingIncomeExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherPayables": { "auth_ref": [ "r332" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 5.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "Amounts payable that the entity does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other payables", "terseLabel": "Other payables" } } }, "localname": "OtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherProvisions": { "auth_ref": [ "r31", "r118" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of provisions other than provisions for employee benefits. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other provisions", "terseLabel": "Other provisions" } } }, "localname": "OtherProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherProvisionsMember": { "auth_ref": [ "r121" ], "lang": { "en": { "role": { "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other provisions [member]", "terseLabel": "Other provisions [member]" } } }, "localname": "OtherProvisionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_OtherReceivables": { "auth_ref": [ "r271" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 6.0, "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount receivable by the entity that it does not separately disclose in the same statement or note." } }, "en-us": { "role": { "label": "Other receivables", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherRevenue": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "ifrs-full_Revenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from sources that the entity does not separately disclose in the same statement or note. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Other revenue", "terseLabel": "Other income" } } }, "localname": "OtherRevenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/DeferredIncomeandRevenueDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherReversalsOfProvisions": { "auth_ref": [ "r54" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of reversals of provisions that the entity does not separately disclose in the same statement or note. [Refer: Provisions]" } }, "en-us": { "role": { "label": "Other reversals of provisions", "terseLabel": "Other reversals of provisions" } } }, "localname": "OtherReversalsOfProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherShorttermEmployeeBenefits": { "auth_ref": [ "r345" ], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "order": 2.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense from employee benefits (other than termination benefits), which are expected to be settled wholly within twelve months after the end of the annual reporting period in which the employees render the related services, that the entity does not separately disclose in the same statement or note. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Other short-term employee benefits", "negatedLabel": "Other short-term employee benefits" } } }, "localname": "OtherShorttermEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome": { "auth_ref": [ "r59" ], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 4.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that the entity does not separately disclose in the same statement or note. [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "negatedTerseLabel": "Other tax effects for reconciliation between accounting profit and tax expense (income)", "terseLabel": "Other tax effects for reconciliation between accounting profit and tax expense (income)" } } }, "localname": "OtherTaxEffectsForReconciliationBetweenAccountingProfitAndTaxExpenseIncome", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ParValuePerShare": { "auth_ref": [ "r34" ], "lang": { "en": { "role": { "documentation": "The nominal value per share." } }, "en-us": { "role": { "label": "Par value per share", "terseLabel": "Nominal value (in EUR per share)" } } }, "localname": "ParValuePerShare", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_PastServiceCostNetDefinedBenefitLiabilityAsset": { "auth_ref": [ "r81" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in the net defined benefit liability (asset) resulting from past service cost. Past service cost is the change in the present value of the defined benefit obligation for employee service in prior periods, resulting from a plan amendment (the introduction or withdrawal of, or changes to, a defined benefit plan) or a curtailment (a significant reduction by the entity in the number of employees covered by a plan). [Refer: Net defined benefit liability (asset); Defined benefit plans [member]]" } }, "en-us": { "role": { "label": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost", "terseLabel": "Increase (decrease) in net defined benefit liability (asset) resulting from past service cost" } } }, "localname": "PastServiceCostNetDefinedBenefitLiabilityAsset", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofChangesinPresentValueofDefinedBenefitObligationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 2.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due on social security and taxes other than income tax. Income taxes include all domestic and foreign taxes that are based on taxable profits. Income taxes also include taxes, such as withholding taxes, that are payable by a subsidiary, associate or joint arrangement on distributions to the reporting entity." } }, "en-us": { "role": { "label": "Payables on social security and taxes other than income tax", "terseLabel": "Payables on social security and taxes other than income tax" } } }, "localname": "PayablesOnSocialSecurityAndTaxesOtherThanIncomeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": { "auth_ref": [ "r291" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 5.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]" } }, "en-us": { "role": { "label": "Payments of lease liabilities, classified as financing activities", "negatedLabel": "- Payments on lease debts" } } }, "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PercentageOfReasonablyPossibleDecreaseInActuarialAssumption": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "The reasonably possible percentage of the decrease in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Percentage of reasonably possible decrease in actuarial assumption", "terseLabel": "Percentage of reasonably possible decrease in actuarial assumption", "verboseLabel": "Changes in assumptions/discount rate (as a percent)" } } }, "localname": "PercentageOfReasonablyPossibleDecreaseInActuarialAssumption", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfReasonablyPossibleIncreaseInActuarialAssumption": { "auth_ref": [ "r83" ], "lang": { "en": { "role": { "documentation": "The reasonably possible percentage of the increase in the actuarial assumption used to determine the present value of defined benefit obligation. [Refer: Actuarial assumptions [member]]" } }, "en-us": { "role": { "label": "Percentage of reasonably possible increase in actuarial assumption", "terseLabel": "Changes in assumptions/discount rate (as a percent)" } } }, "localname": "PercentageOfReasonablyPossibleIncreaseInActuarialAssumption", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails", "http://www.genfit.com/role/EmployeeBenefitsSummaryofSensitivityoftheRetirementandPostEmploymentBenefitstoaVariationoftheDiscountRateDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PercentageOfVotingEquityInterestsAcquired": { "auth_ref": [ "r201" ], "lang": { "en": { "role": { "documentation": "The percentage of voting equity interests acquired in a business combination. [Refer: Business combinations [member]]" } }, "en-us": { "role": { "label": "Percentage of voting equity interests acquired", "terseLabel": "Percentage of voting equity interests acquired" } } }, "localname": "PercentageOfVotingEquityInterestsAcquired", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_PerformanceObligationsAxis": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Performance obligations [axis]", "terseLabel": "Performance obligations [axis]" } } }, "localname": "PerformanceObligationsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_PerformanceObligationsMember": { "auth_ref": [ "r181" ], "lang": { "en": { "role": { "documentation": "This member stands for all performance obligations. A performance obligation is a promise in a contract with a customer to transfer to the customer either: (a) a good or service (or a bundle of goods or services) that is distinct; or (b) a series of distinct goods or services that are substantially the same and that have the same pattern of transfer to the customer. This member also represents the standard value for the 'Performance obligations' axis if no other member is used." } }, "en-us": { "role": { "label": "Performance obligations [member]", "terseLabel": "Performance obligations [member]" } } }, "localname": "PerformanceObligationsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsParentheticalDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PerformanceObligationsSatisfiedOverTimeMember": { "auth_ref": [ "r183" ], "lang": { "en": { "role": { "documentation": "This member stands for performance obligations satisfied over time. An entity satisfies a performance obligation over time, if one of the following criteria is met: (a) the customer simultaneously receives and consumes the benefits provided by the entity\u2019s performance as the entity performs; (b) the entity\u2019s performance creates or enhances an asset (for example, work in progress) that the customer controls as the asset is created or enhanced; or (c) the entity\u2019s performance does not create an asset with an alternative use to the entity and the entity has an enforceable right to payment for performance completed to date. [Refer: Performance obligations [member]]" } }, "en-us": { "role": { "label": "Performance obligations satisfied over time [member]", "terseLabel": "Performance obligations satisfied over time" } } }, "localname": "PerformanceObligationsSatisfiedOverTimeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PostemploymentBenefitExpenseDefinedContributionPlans": { "auth_ref": [ "r85" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of post-employment benefit expense relating to defined contribution plans. Defined contribution plans are post-employment benefit plans under which an entity pays fixed contributions into a separate entity (a fund) and will have no legal or constructive obligation to pay further contributions if the fund does not hold sufficient assets to pay all employee benefits relating to employee service in the current and prior periods." } }, "en-us": { "role": { "label": "Post-employment benefit expense, defined contribution plans", "terseLabel": "Defined contribution plan expense" } } }, "localname": "PostemploymentBenefitExpenseDefinedContributionPlans", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PotentialOrdinaryShareTransactionsMember": { "auth_ref": [ "r275" ], "lang": { "en": { "role": { "documentation": "This member stands for potential ordinary share transactions. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Potential ordinary share transactions [member]", "terseLabel": "Potential ordinary share transactions [member]" } } }, "localname": "PotentialOrdinaryShareTransactionsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PreferenceSharesMember": { "auth_ref": [ "r336" ], "lang": { "en": { "role": { "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Preference shares [member]", "terseLabel": "Preference shares [member]" } } }, "localname": "PreferenceSharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProceedsFromBorrowingsClassifiedAsFinancingActivities": { "auth_ref": [ "r290" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from borrowings obtained. [Refer: Borrowings]" } }, "en-us": { "role": { "label": "Proceeds from borrowings, classified as financing activities", "terseLabel": "+ Proceeds from new loans and borrowings net of issue costs" } } }, "localname": "ProceedsFromBorrowingsClassifiedAsFinancingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssueOfOrdinaryShares": { "auth_ref": [ "r356" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]" } }, "en-us": { "role": { "label": "Proceeds from issue of ordinary shares", "terseLabel": "Proceeds from issue of ordinary shares", "verboseLabel": "Gross amount received from issuance of shares" } } }, "localname": "ProceedsFromIssueOfOrdinaryShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromIssuingShares": { "auth_ref": [ "r289" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from issuing shares." } }, "en-us": { "role": { "label": "Proceeds from issuing shares", "terseLabel": "+ Proceeds from issue of share capital (net)" } } }, "localname": "ProceedsFromIssuingShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r288" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 3.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The cash inflow from sales of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Proceeds from sales of property, plant and equipment, classified as investing activities", "terseLabel": "+ Proceeds from disposal of / reimbursement of property, plant and equipment" } } }, "localname": "ProceedsFromSalesOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLoss": { "auth_ref": [ "r2", "r38", "r139", "r151", "r153", "r235", "r238", "r294", "r308", "r309" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genfit.com/role/ConsolidatedStatementsofOperations_1": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss": { "order": 1.0, "parentTag": "ifrs-full_ComprehensiveIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Profit (loss)", "terseLabel": "+ Net profit (loss)", "totalLabel": "Net profit (loss)", "verboseLabel": "Profit (loss)" } } }, "localname": "ProfitLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity", "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/ConsolidatedStatementsofOtherComprehensiveLoss", "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToNoncontrollingInterests": { "auth_ref": [ "r41", "r155" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInOperationsBeforeChangesInWorkingCapital", "weight": 1.0 }, "http://www.genfit.com/role/ConsolidatedStatementsofOperations_1": { "order": 2.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to non-controlling interests. [Refer: Profit (loss); Non-controlling interests]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to non-controlling interests", "terseLabel": "Profit (loss), attributable to non-controlling interests" } } }, "localname": "ProfitLossAttributableToNoncontrollingInterests", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossAttributableToOwnersOfParent": { "auth_ref": [ "r42" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations_1": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from continuing and discontinued operations attributable to owners of the parent. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss), attributable to owners of parent", "terseLabel": "Attributable to owners of the Company" } } }, "localname": "ProfitLossAttributableToOwnersOfParent", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossBeforeTax": { "auth_ref": [ "r208", "r266", "r267", "r306", "r307" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "ifrs-full_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) before tax expense or income. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) before tax", "terseLabel": "Profit (loss) before tax", "totalLabel": "Net profit (loss) before tax" } } }, "localname": "ProfitLossBeforeTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitLossFromOperatingActivities": { "auth_ref": [ "r281", "r337" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossBeforeTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) from operating activities", "totalLabel": "Operating income (loss)" } } }, "localname": "ProfitLossFromOperatingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments": { "auth_ref": [ "r103" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The profit (loss) on disposal of investments and changes in the value of investments. [Refer: Profit (loss)]" } }, "en-us": { "role": { "label": "Profit (loss) on disposal of investments and changes in value of investments", "terseLabel": "Profit (loss) on disposal of investments and changes in value of investments" } } }, "localname": "ProfitsLossesOnDisposalOfInvestmentsAndChangesInValueOfInvestments", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipment": { "auth_ref": [ "r9", "r71" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_NoncurrentAssets", "weight": 1.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 2.0, "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period." } }, "en-us": { "role": { "label": "Property, plant and equipment", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Property, plant and equipment" } } }, "localname": "PropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusAxis": { "auth_ref": [ "r187" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Property, plant and equipment by operating lease status [axis]", "terseLabel": "Property, plant and equipment by operating lease status [axis]" } } }, "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_PropertyPlantAndEquipmentByOperatingLeaseStatusMember": { "auth_ref": [ "r187" ], "lang": { "en": { "role": { "documentation": "This member stands for all property, plant and equipment when disaggregated by the operating lease status by a lessor. It also represents the standard value for the 'Property, plant and equipment by operating lease status' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment by operating lease status [member]", "terseLabel": "Property, plant and equipment by operating lease status [member]" } } }, "localname": "PropertyPlantAndEquipmentByOperatingLeaseStatusMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PropertyPlantAndEquipmentMember": { "auth_ref": [ "r72", "r282", "r297" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment. It also represents the standard value for the 'Classes of property, plant and equipment' axis if no other member is used. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment [member]", "terseLabel": "Property, plant and equipment [member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/LoansandBorrowingsSummaryofBankLoansDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PropertyPlantAndEquipmentNotSubjectToOperatingLeasesMember": { "auth_ref": [ "r187" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment that is not subject to operating leases. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment not subject to operating leases [member]", "terseLabel": "Property, plant and equipment not subject to operating leases [member]" } } }, "localname": "PropertyPlantAndEquipmentNotSubjectToOperatingLeasesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_PropertyPlantAndEquipmentSubjectToOperatingLeasesMember": { "auth_ref": [ "r187" ], "lang": { "en": { "role": { "documentation": "This member stands for property, plant and equipment that is subject to operating leases. Operating lease is a lease that does not transfer substantially all the risks and rewards incidental to ownership of an underlying asset. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Property, plant and equipment subject to operating leases [member]", "terseLabel": "Property, plant and equipment subject to operating leases [member]" } } }, "localname": "PropertyPlantAndEquipmentSubjectToOperatingLeasesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ProportionOfOwnershipInterestInAssociate": { "auth_ref": [ "r106", "r108", "r157" ], "lang": { "en": { "role": { "documentation": "The proportion of ownership interest in an associate attributable to the entity. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Proportion of ownership interest in associate", "terseLabel": "Proportion of ownership interest in associate (as a percent)" } } }, "localname": "ProportionOfOwnershipInterestInAssociate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "percentItemType" }, "ifrs-full_ProvisionUsedOtherProvisions": { "auth_ref": [ "r119" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Provision used, other provisions", "terseLabel": "Provision used, other provisions" } } }, "localname": "ProvisionUsedOtherProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ProvisionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Provisions [abstract]", "terseLabel": "Provisions [abstract]" } } }, "localname": "ProvisionsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_ProvisionsForEmployeeBenefits": { "auth_ref": [ "r31" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of provisions for employee benefits. [Refer: Employee benefits expense; Provisions]" } }, "en-us": { "role": { "label": "Provisions for employee benefits", "terseLabel": "Provisions for employee benefits" } } }, "localname": "ProvisionsForEmployeeBenefits", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails", "http://www.genfit.com/role/EmployeeBenefitsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities": { "auth_ref": [ "r355" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 1.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of financial instruments. [Refer: Financial instruments, class [member]]" } }, "en-us": { "role": { "label": "Purchase of financial instruments, classified as investing activities", "negatedLabel": "- Acquisition of financial instruments" } } }, "localname": "PurchaseOfFinancialInstrumentsClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfInterestsInAssociates": { "auth_ref": [ "r355" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 2.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of interests in associates. [Refer: Associates [member]]" } }, "en-us": { "role": { "label": "Purchase of interests in associates", "terseLabel": "Purchase of interests in associates" } } }, "localname": "PurchaseOfInterestsInAssociates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod": { "auth_ref": [ "r355" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchase of interests in investments accounted for using the equity method. [Refer: Investments accounted for using equity method]" } }, "en-us": { "role": { "label": "Purchase of interests in investments accounted for using equity method", "terseLabel": "Subscription of new ordinary shares" } } }, "localname": "PurchaseOfInterestsInInvestmentsAccountedForUsingEquityMethod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": { "auth_ref": [ "r287" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows": { "order": 4.0, "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Purchase of property, plant and equipment, classified as investing activities", "negatedLabel": "- Acquisition of property, plant and equipment" } } }, "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofCashFlows" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RangeAxis": { "auth_ref": [ "r175", "r195", "r249", "r295", "r296", "r362" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Range [axis]", "terseLabel": "Range [axis]" } } }, "localname": "RangeAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_RangesMember": { "auth_ref": [ "r175", "r195", "r249", "r295", "r296", "r362" ], "lang": { "en": { "role": { "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used." } }, "en-us": { "role": { "label": "Ranges [member]", "terseLabel": "Ranges [member]" } } }, "localname": "RangesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax": { "auth_ref": [ "r50", "r89" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of reclassification adjustments related to exchange differences when the financial statements of foreign operations are translated, net of tax. Reclassification adjustments are amounts reclassified to profit (loss) in the current period that were recognised in other comprehensive income in the current or previous periods. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reclassification adjustments on exchange differences on translation of foreign operations, net of tax", "terseLabel": "Translation adjustments" } } }, "localname": "ReclassificationAdjustmentsOnExchangeDifferencesOnTranslationNetOfTax", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReclassificationIntoLoansAndReceivables": { "auth_ref": [ "r264" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of financial assets reclassified into the loans and receivables category. [Refer: Loans and receivables; Financial assets]" } }, "en-us": { "role": { "label": "Reclassification into loans and receivables", "terseLabel": "Carrying value loans and receivables" } } }, "localname": "ReclassificationIntoLoansAndReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Reconciliation of changes in deferred tax liability (asset) [abstract]", "terseLabel": "Reconciliation of changes in deferred tax liability (asset) [abstract]" } } }, "localname": "ReconciliationOfChangesInDeferredTaxLiabilityAssetAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_ResearchAndDevelopmentExpense": { "auth_ref": [ "r130" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 3.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 }, "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "order": 1.0, "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss." } }, "en-us": { "role": { "label": "Research and development expense", "negatedLabel": "Research and development expenses", "terseLabel": "Research and development expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslation": { "auth_ref": [ "r91" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 1.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing exchange differences on translation of financial statements recognised in other comprehensive income and accumulated in equity. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation", "terseLabel": "Currency translation adjustment" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslation", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReserveOfExchangeDifferencesOnTranslationMember": { "auth_ref": [ "r91", "r268" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing accumulated exchange differences on the translation of financial statements recognised in other comprehensive income. [Refer: Other comprehensive income]" } }, "en-us": { "role": { "label": "Reserve of exchange differences on translation [member]", "terseLabel": "Currency translation adjustment" } } }, "localname": "ReserveOfExchangeDifferencesOnTranslationMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RestructuringProvision": { "auth_ref": [ "r283" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Restructuring provision", "terseLabel": "Provision recognized for closing costs" } } }, "localname": "RestructuringProvision", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RestructuringProvisionMember": { "auth_ref": [ "r283" ], "lang": { "en": { "role": { "documentation": "This member stands for a provision for restructuring, such as the sale or termination of a line of business; closure of business locations in a country or region or relocation of activities from one country or region to another; changes in management structure; and fundamental reorganisations that have a material effect on the nature and focus of the entity's operations. [Refer: Other provisions [member]]" } }, "en-us": { "role": { "label": "Restructuring provision [member]", "terseLabel": "Restructuring provision" } } }, "localname": "RestructuringProvisionMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriod": { "auth_ref": [ "r334" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity\u2019s cumulative undistributed earnings or deficit excluding the profit or loss for the reporting period. [Refer: Retained earnings]" } }, "en-us": { "role": { "label": "Retained earnings, excluding profit (loss) for reporting period", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsExcludingProfitLossForReportingPeriod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsExcludingProfitLossForReportingPeriodMember": { "auth_ref": [ "r329" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit, excluding profit or loss for the reporting period. [Refer: Retained earnings [member]]" } }, "en-us": { "role": { "label": "Retained earnings, excluding profit (loss) for reporting period [member]", "terseLabel": "Retained earnings, excluding profit (loss) for reporting period [member]" } } }, "localname": "RetainedEarningsExcludingProfitLossForReportingPeriodMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarningsMember": { "auth_ref": [ "r6", "r268" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit." } }, "en-us": { "role": { "label": "Retained earnings [member]", "terseLabel": "Retained earnings (accumulated deficit)" } } }, "localname": "RetainedEarningsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriod": { "auth_ref": [ "r334" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 3.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "A component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings; Profit (loss)]" } }, "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period", "terseLabel": "Net profit (loss)" } } }, "localname": "RetainedEarningsProfitLossForReportingPeriod", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RetainedEarningsProfitLossForReportingPeriodMember": { "auth_ref": [ "r329" ], "lang": { "en": { "role": { "documentation": "This member stands for a component of equity representing the entity\u2019s undistributed profit or loss for the reporting period. [Refer: Retained earnings [member]; Profit (loss)]" } }, "en-us": { "role": { "label": "Retained earnings, profit (loss) for reporting period [member]", "terseLabel": "Net profit (loss)" } } }, "localname": "RetainedEarningsProfitLossForReportingPeriodMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_RevaluationIncreaseDecreasePropertyPlantAndEquipment": { "auth_ref": [ "r69", "r74" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The increase (decrease) in property, plant and equipment resulting from revaluations to fair value. [Refer: Property, plant and equipment; Revaluation surplus]" } }, "en-us": { "role": { "label": "Revaluation increase (decrease), property, plant and equipment", "terseLabel": "Reclassification" } } }, "localname": "RevaluationIncreaseDecreasePropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_Revenue": { "auth_ref": [ "r45", "r163", "r208", "r231", "r237", "r241", "r242", "r244", "r266", "r267", "r294" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims." } }, "en-us": { "role": { "label": "Revenue", "terseLabel": "Revenue", "totalLabel": "Revenues and other income", "verboseLabel": "Total operating income" } } }, "localname": "Revenue", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue [abstract]", "terseLabel": "Revenues and other income" } } }, "localname": "RevenueAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations" ], "xbrltype": "stringItemType" }, "ifrs-full_RevenueFromContractsWithCustomers": { "auth_ref": [ "r178", "r179" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue from contracts with customers. A customer is a party that has contracted with an entity to obtain goods or services that are an output of the entity\u2019s ordinary activities in exchange for consideration." } }, "en-us": { "role": { "label": "Revenue from contracts with customers", "terseLabel": "Revenue from contracts with customers" } } }, "localname": "RevenueFromContractsWithCustomers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromInterest": { "auth_ref": [ "r166", "r232", "r240", "r330" ], "calculation": { "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails": { "order": 1.0, "parentTag": "ifrs-full_FinanceIncome", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of income arising from interest." } }, "en-us": { "role": { "label": "Interest income", "terseLabel": "Interest income" } } }, "localname": "RevenueFromInterest", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/FinancialIncomeandExpensesSummaryofFinancialIncomeandExpensesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RevenueFromRenderingOfServices": { "auth_ref": [ "r330" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 1.0, "parentTag": "ifrs-full_Revenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of revenue arising from the rendering of services. [Refer: Revenue]" } }, "en-us": { "role": { "label": "Revenue from rendering of services", "terseLabel": "Revenue", "verboseLabel": "Industrial income recognized" } } }, "localname": "RevenueFromRenderingOfServices", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReversalOfImpairmentLossRecognisedInProfitOrLoss": { "auth_ref": [ "r114", "r115" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of reversal of impairment loss recognised in profit or loss. [Refer: Reversal of impairment loss; Profit (loss)]" } }, "en-us": { "role": { "label": "Reversal of impairment loss recognised in profit or loss", "terseLabel": "Reversal of impairment loss recognised in profit or loss" } } }, "localname": "ReversalOfImpairmentLossRecognisedInProfitOrLoss", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ReversalOfProvisionsForCostOfRestructuring": { "auth_ref": [ "r52" ], "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of reversals of provisions for the cost of restructuring. [Refer: Restructuring provision]" } }, "en-us": { "role": { "label": "Reversal of provisions for cost of restructuring", "terseLabel": "Reversal of provisions for cost of restructuring" } } }, "localname": "ReversalOfProvisionsForCostOfRestructuring", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ProvisionsAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_RightofuseAssets": { "auth_ref": [ "r185" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee." } }, "en-us": { "role": { "label": "Right-of-use assets", "terseLabel": "Right of use asset" } } }, "localname": "RightofuseAssets", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SalesAndMarketingExpense": { "auth_ref": [ "r337" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofOperations": { "order": 2.0, "parentTag": "ifrs-full_ProfitLossFromOperatingActivities", "weight": -1.0 }, "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails": { "order": 3.0, "parentTag": "gnft_ResearchAndDevelopmentExpenseGeneralAndAdministrativeExpenseMarketingAndMarketAccessExpenseAndOtherOperatingIncomeAndExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense relating to the marketing and selling of goods or services." } }, "en-us": { "role": { "label": "Sales and marketing expense", "negatedLabel": "Marketing and market access expenses" } } }, "localname": "SalesAndMarketingExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofOperations", "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremium": { "auth_ref": [ "r272" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 5.0, "parentTag": "ifrs-full_EquityAttributableToOwnersOfParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium", "terseLabel": "Share premium" } } }, "localname": "SharePremium", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SharePremiumMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value." } }, "en-us": { "role": { "label": "Share premium [member]", "terseLabel": "Share premium" } } }, "localname": "SharePremiumMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_SharebasedPaymentArrangementsMember": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used." } }, "en-us": { "role": { "label": "Share-based payment arrangements [member]", "terseLabel": "Share-based payment arrangements [member]" } } }, "localname": "SharebasedPaymentArrangementsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "domainItemType" }, "ifrs-full_ShorttermDepositsClassifiedAsCashEquivalents": { "auth_ref": [ "r359" ], "calculation": { "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails": { "order": 1.0, "parentTag": "ifrs-full_CashAndCashEquivalents", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A classification of cash equivalents representing short-term deposits. [Refer: Cash equivalents]" } }, "en-us": { "role": { "label": "Short-term deposits, classified as cash equivalents", "terseLabel": "Short-term deposits, classified as cash equivalents" } } }, "localname": "ShorttermDepositsClassifiedAsCashEquivalents", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_SignificantInvestmentsInAssociatesAxis": { "auth_ref": [ "r107", "r109", "r170", "r260", "r263" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Associates [axis]", "terseLabel": "Associates [axis]" } } }, "localname": "SignificantInvestmentsInAssociatesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/CashandCashEquivalentsSummaryofCashandCashEquivalentsDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_SocialSecurityContributions": { "auth_ref": [ "r345" ], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "order": 4.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents social security contributions. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Social security contributions", "negatedLabel": "Social security contributions" } } }, "localname": "SocialSecurityContributions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of cash flows [abstract]", "terseLabel": "Statement of cash flows [abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of changes in equity [abstract]", "terseLabel": "Statement of changes in equity [abstract]" } } }, "localname": "StatementOfChangesInEquityAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityLineItems": { "auth_ref": [], "lang": { "en": { "role": { "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table." } }, "en-us": { "role": { "label": "Statement of changes in equity [line items]", "terseLabel": "Statement of changes in equity [line items]" } } }, "localname": "StatementOfChangesInEquityLineItems", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfChangesInEquityTable": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "Schedule disclosing information related to changes in equity." } }, "en-us": { "role": { "label": "Statement of changes in equity [table]", "terseLabel": "Statement of changes in equity [table]" } } }, "localname": "StatementOfChangesInEquityTable", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "stringItemType" }, "ifrs-full_StatementOfComprehensiveIncomeAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of comprehensive income [abstract]", "terseLabel": "Statement of comprehensive income [abstract]" } } }, "localname": "StatementOfComprehensiveIncomeAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of financial position [abstract]", "terseLabel": "Statement of financial position [abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense": { "auth_ref": [ "r277" ], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 2.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": -1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of benefit arising from a previously unrecognised tax loss, tax credit or temporary difference of a prior period that is used to reduce current tax expense. [Refer: Temporary differences [member]; Unused tax losses [member]; Unused tax credits [member]]" } }, "en-us": { "role": { "label": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense", "terseLabel": "Tax benefit arising from previously unrecognised tax loss, tax credit or temporary difference of prior period used to reduce current tax expense" } } }, "localname": "TaxBenefitArisingFromPreviouslyUnrecognisedTaxLossTaxCreditOrTemporaryDifferenceOfPriorPeriodUsedToReduceCurrentTaxExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfForeignTaxRates": { "auth_ref": [ "r59" ], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 11.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to foreign tax rates. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of foreign tax rates", "negatedTerseLabel": "Tax effect of foreign tax rates", "terseLabel": "Tax effect of foreign tax rates" } } }, "localname": "TaxEffectOfForeignTaxRates", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxEffectOfTaxLosses": { "auth_ref": [ "r59" ], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 6.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount that represents the difference between the tax expense (income) and the product of the accounting profit multiplied by the applicable tax rate(s) that relates to tax losses. [Refer: Accounting profit]" } }, "en-us": { "role": { "label": "Tax effect of tax losses", "negatedTerseLabel": "Tax effect of tax losses", "terseLabel": "Tax effect of tax losses" } } }, "localname": "TaxEffectOfTaxLosses", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TaxExpenseIncomeAtApplicableTaxRate": { "auth_ref": [ "r59" ], "calculation": { "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails": { "order": 9.0, "parentTag": "ifrs-full_IncomeTaxExpenseContinuingOperations", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The product of the accounting profit multiplied by the applicable tax rate(s). [Refer: Accounting profit; Applicable tax rate]" } }, "en-us": { "role": { "label": "Tax expense (income) at applicable tax rate", "negatedTerseLabel": "Tax expense (income) at applicable tax rate", "terseLabel": "Tax expense (income) at applicable tax rate" } } }, "localname": "TaxExpenseIncomeAtApplicableTaxRate", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxScheduleofEffectiveTaxRateDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TemporaryDifferenceMember": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "This member stands for differences between the carrying amount of an asset or liability in the statement of financial position and its tax base. Temporary differences may be either: (a) taxable temporary differences; or (b) deductible temporary differences. [Refer: Carrying amount [member]]" } }, "en-us": { "role": { "label": "Temporary differences [member]", "terseLabel": "Temporary differences" } } }, "localname": "TemporaryDifferenceMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [axis]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [axis]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember": { "auth_ref": [ "r64" ], "lang": { "en": { "role": { "documentation": "This member stands for temporary differences, unused tax losses and unused tax credits. It also represents the standard value for the 'Temporary difference, unused tax losses and unused tax credits' axis if no other member is used. [Refer: Temporary differences [member]; Unused tax credits [member]; Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Temporary difference, unused tax losses and unused tax credits [member]", "terseLabel": "Temporary difference, unused tax losses and unused tax credits [member]" } } }, "localname": "TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxBreakdownofDeferredTaxesbyNatureDetails", "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TerminationBenefitsExpense": { "auth_ref": [ "r344" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of expense in relation to termination benefits. Termination benefits are employee benefits provided in exchange for the termination of an employee's employment as a result of either: (a) an entity's decision to terminate an employee's employment before the normal retirement date; or (b) an employee's decision to accept an offer of benefits in exchange for the termination of employment. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Termination benefits expense", "terseLabel": "Employee expenses related to work force reduction" } } }, "localname": "TerminationBenefitsExpense", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TopOfRangeMember": { "auth_ref": [ "r175", "r195", "r249", "r295", "r296", "r362" ], "lang": { "en": { "role": { "documentation": "This member stands for top of a range." } }, "en-us": { "role": { "label": "Top of range [member]", "terseLabel": "Top of Range" } } }, "localname": "TopOfRangeMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TradeAndOtherCurrentPayables": { "auth_ref": [ "r16" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 6.0, "parentTag": "ifrs-full_CurrentLiabilities", "weight": 1.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 1.0, "parentTag": "gnft_TotalAcquiredLiabilities", "weight": 1.0 }, "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]" } }, "en-us": { "role": { "label": "Trade and other current payables", "terseLabel": "Current trade and other payables", "totalLabel": "Total trade and other current payables" } } }, "localname": "TradeAndOtherCurrentPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other current payables [abstract]", "terseLabel": "Trade and other payables - Current" } } }, "localname": "TradeAndOtherCurrentPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherCurrentPayablesToTradeSuppliers": { "auth_ref": [ "r270", "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 4.0, "parentTag": "ifrs-full_TradeAndOtherCurrentPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The current amount of payment due to suppliers for goods and services used in entity's business. [Refer: Current liabilities; Trade payables]" } }, "en-us": { "role": { "label": "Current trade payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherCurrentPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherCurrentReceivables": { "auth_ref": [ "r14", "r30" ], "calculation": { "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition": { "order": 4.0, "parentTag": "ifrs-full_CurrentAssets", "weight": 1.0 }, "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails": { "order": 3.0, "parentTag": "gnft_TotalAcquiredAssets", "weight": 1.0 }, "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]" } }, "en-us": { "role": { "label": "Trade and other current receivables", "terseLabel": "Current trade and others receivables", "totalLabel": "Total trade and other current receivables" } } }, "localname": "TradeAndOtherCurrentReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofFinancialPosition", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayables": { "auth_ref": [ "r16" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of trade payables and other payables. [Refer: Trade payables; Other payables]" } }, "en-us": { "role": { "label": "Trade and other payables", "terseLabel": "Trade and other payables", "totalLabel": "Total trade and other payables" } } }, "localname": "TradeAndOtherPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherPayablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other payables [abstract]", "terseLabel": "Trade and other payables - Total" } } }, "localname": "TradeAndOtherPayablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TradeAndOtherPayablesToTradeSuppliers": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 1.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payment due to suppliers for goods and services used in the entity's business." } }, "en-us": { "role": { "label": "Trade payables", "terseLabel": "Trade payables" } } }, "localname": "TradeAndOtherPayablesToTradeSuppliers", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherReceivables": { "auth_ref": [ "r14", "r30" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of trade receivables and other receivables. [Refer: Trade receivables; Other receivables]" } }, "en-us": { "role": { "label": "Trade and other receivables", "totalLabel": "Total trade and other receivables" } } }, "localname": "TradeAndOtherReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeAndOtherReceivablesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Trade and other receivables [abstract]", "terseLabel": "Trade and other receivables [abstract]" } } }, "localname": "TradeAndOtherReceivablesAbstract", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "xbrltype": "stringItemType" }, "ifrs-full_TradeReceivables": { "auth_ref": [ "r271" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 1.0, "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount due from customers for goods and services sold." } }, "en-us": { "role": { "label": "Trade receivables", "terseLabel": "Trade receivables" } } }, "localname": "TradeReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_TradeReceivablesMember": { "auth_ref": [ "r214", "r218", "r298", "r330" ], "lang": { "en": { "role": { "documentation": "This member stands for trade receivables. [Refer: Trade receivables]" } }, "en-us": { "role": { "label": "Trade receivables [member]", "terseLabel": "Trade receivables [member]" } } }, "localname": "TradeReceivablesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FairValueofFinancialInstrumentsSummaryofFinancialAssetsAndLiabilitiesCarryingValuesByCategoryAndFairValuesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TreasurySharesMember": { "auth_ref": [ "r6" ], "lang": { "en": { "role": { "documentation": "This member stands for the entity\u2019s own equity instruments, held by the entity or other members of the consolidated group." } }, "en-us": { "role": { "label": "Treasury shares [member]", "terseLabel": "Treasury shares" } } }, "localname": "TreasurySharesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ConsolidatedStatementsofChangesinEquity" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfInterestRatesAxis": { "auth_ref": [ "r361" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of interest rates [axis]", "terseLabel": "Types of interest rates [axis]" } } }, "localname": "TypesOfInterestRatesAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksAxis": { "auth_ref": [ "r209", "r212", "r213", "r250", "r251", "r252", "r254" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of risks [axis]", "terseLabel": "Types of risks [axis]" } } }, "localname": "TypesOfRisksAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofCHFagainstEuroDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "stringItemType" }, "ifrs-full_TypesOfRisksMember": { "auth_ref": [ "r209", "r212", "r213", "r250", "r251", "r252", "r254" ], "lang": { "en": { "role": { "documentation": "This member stands for all types of risks. It also represents the standard value for the 'Types of risks' axis if no other member is used." } }, "en-us": { "role": { "label": "Risks [member]", "terseLabel": "Risks [member]" } } }, "localname": "TypesOfRisksMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/FinancialRisksManagementAdditionalInformationDetails", "http://www.genfit.com/role/FinancialRisksManagementSensitivityofGroupsCashandCashEquivalentsandExpensestoVariation10ofUSDollaragainstEuroDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": { "auth_ref": [ "r196" ], "lang": { "en": { "role": { "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table." } }, "en-us": { "role": { "label": "Types of share-based payment arrangements [axis]", "terseLabel": "Types of share-based payment arrangements [axis]" } } }, "localname": "TypesOfSharebasedPaymentArrangementsAxis", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails", "http://www.genfit.com/role/EquityAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonPerformanceConditionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonRedeemableWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonStockOptionsDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofSharebasedCompensationUnderEachPlanAccordingtoChangeinEstimateDetails", "http://www.genfit.com/role/ShareBasedCompensationTables" ], "xbrltype": "stringItemType" }, "ifrs-full_UnusedProvisionReversedOtherProvisions": { "auth_ref": [ "r120" ], "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount reversed for unused other provisions. [Refer: Other provisions]" } }, "en-us": { "role": { "label": "Unused provision reversed, other provisions", "terseLabel": "Unused provision reversed, other provisions" } } }, "localname": "UnusedProvisionReversedOtherProvisions", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OperatingExpenseAdditionalInformationDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised": { "auth_ref": [ "r61" ], "lang": { "en": { "role": { "documentation": "The amount of unused tax losses for which no deferred tax asset is recognised in the statement of financial position. [Refer: Unused tax losses [member]]" } }, "en-us": { "role": { "label": "Unused tax losses for which no deferred tax asset recognised", "negatedTerseLabel": "Tax loss carry forwards" } } }, "localname": "UnusedTaxLossesForWhichNoDeferredTaxAssetRecognised", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IncomeTaxNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r123" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, intangible assets other than goodwill", "terseLabel": "Estimated useful lives of software and license agreements" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimeIntangibleAssetsOtherThanGoodwill", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment": { "auth_ref": [ "r66" ], "lang": { "en": { "role": { "documentation": "The useful life, measured as period of time, used for property, plant and equipment. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Useful life measured as period of time, property, plant and equipment", "terseLabel": "Estimated useful lives for property, plant and equipment" } } }, "localname": "UsefulLifeMeasuredAsPeriodOfTimePropertyPlantAndEquipment", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "durationItemType" }, "ifrs-full_ValueAddedTaxPayables": { "auth_ref": [ "r335" ], "calculation": { "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails": { "order": 3.0, "parentTag": "ifrs-full_TradeAndOtherPayables", "weight": 1.0 } }, "crdr": "credit", "lang": { "en": { "role": { "documentation": "The amount of payables related to a value added tax." } }, "en-us": { "role": { "label": "Value added tax payables", "terseLabel": "Value added tax payables" } } }, "localname": "ValueAddedTaxPayables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherPayablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherPayablesScheduleofTradeandOtherPayablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_ValueAddedTaxReceivables": { "auth_ref": [ "r333" ], "calculation": { "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails": { "order": 4.0, "parentTag": "ifrs-full_TradeAndOtherReceivables", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "The amount of receivables related to a value added tax." } }, "en-us": { "role": { "label": "Value added tax receivables", "terseLabel": "Value added tax receivables" } } }, "localname": "ValueAddedTaxReceivables", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/TradeandOtherReceivablesAdditionalInformationDetails", "http://www.genfit.com/role/TradeandOtherReceivablesSummaryofTradeandOtherReceivablesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_VehiclesMember": { "auth_ref": [ "r339" ], "lang": { "en": { "role": { "documentation": "This member stands for a class of property, plant and equipment representing vehicles used in the entity's operations, specifically to include aircraft, motor vehicles and ships. [Refer: Property, plant and equipment]" } }, "en-us": { "role": { "label": "Vehicles [member]", "terseLabel": "Vehicles [member]" } } }, "localname": "VehiclesMember", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/PropertyPlantandEquipmentAdditionalInformationDetails", "http://www.genfit.com/role/PropertyPlantandEquipmentSummaryofVariationsinTangibleAssetsDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofEstimatedUsefulLivesDetails" ], "xbrltype": "domainItemType" }, "ifrs-full_WagesAndSalaries": { "auth_ref": [ "r345" ], "calculation": { "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails": { "order": 1.0, "parentTag": "ifrs-full_EmployeeBenefitsExpense", "weight": 1.0 } }, "crdr": "debit", "lang": { "en": { "role": { "documentation": "A class of employee benefits expense that represents wages and salaries. [Refer: Employee benefits expense]" } }, "en-us": { "role": { "label": "Wages and salaries", "negatedLabel": "Wages and salaries" } } }, "localname": "WagesAndSalaries", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofEmployeeExpensesandNumberofEmployeesDetails" ], "xbrltype": "monetaryItemType" }, "ifrs-full_WeightedAverageSharePrice2019": { "auth_ref": [ "r194" ], "lang": { "en": { "role": { "documentation": "The weighted average share price. [Refer: Weighted average [member]]" } }, "en-us": { "role": { "label": "Weighted average share price", "terseLabel": "Weighted average share price" } } }, "localname": "WeightedAverageSharePrice2019", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonFreeSharesDetails" ], "xbrltype": "perShareItemType" }, "ifrs-full_WeightedAverageShares": { "auth_ref": [ "r112" ], "lang": { "en": { "role": { "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor." } }, "en-us": { "role": { "label": "Weighted average number of ordinary shares used in calculating basic earnings per share", "terseLabel": "Weighted average number of ordinary shares for the period (shares)" } } }, "localname": "WeightedAverageShares", "nsuri": "https://xbrl.ifrs.org/taxonomy/2022-03-24/ifrs-full", "presentation": [ "http://www.genfit.com/role/EarningsLossPerShareSummaryofEarningsLossPerShareDetails" ], "xbrltype": "sharesItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAdjustmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption, Adjustment [Member]", "terseLabel": "Cumulative effect, period of adoption, adjustment" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAdjustmentMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_CumulativeEffectPeriodOfAdoptionAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Axis]", "terseLabel": "Cumulative Effect, Period of Adoption [Axis]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "stringItemType" }, "srt_CumulativeEffectPeriodOfAdoptionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cumulative Effect, Period of Adoption [Domain]", "terseLabel": "Cumulative Effect, Period of Adoption [Domain]" } } }, "localname": "CumulativeEffectPeriodOfAdoptionDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/BasisofPresentationDetails" ], "xbrltype": "domainItemType" }, "srt_CurrencyAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Currency [Axis]", "terseLabel": "Currency [Axis]" } } }, "localname": "CurrencyAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails" ], "xbrltype": "stringItemType" }, "srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]", "terseLabel": "Distribution of Assets, Liabilities and Stockholders' Equity [Line Items]" } } }, "localname": "DistributionOfAssetsLiabilitiesAndStockholdersEquityLineItems", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodTerminationofRESOLVEITandthedevelopmentprogramofelafibranorinNASHDetails" ], "xbrltype": "stringItemType" }, "srt_DistributionOfAssetsLiabilitiesAndStockholdersEquityTable": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Distribution of Assets, Liabilities and Stockholders' Equity [Table]", "terseLabel": "Distribution of Assets, Liabilities and Stockholders' Equity [Table]" } } }, "localname": "DistributionOfAssetsLiabilitiesAndStockholdersEquityTable", "nsuri": "http://fasb.org/srt/2022", "xbrltype": "stringItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "terseLabel": "Investment, Name [Domain]" } } }, "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_LitigationCaseAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Axis]", "terseLabel": "Litigation Case [Axis]" } } }, "localname": "LitigationCaseAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "stringItemType" }, "srt_LitigationCaseTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Litigation Case [Domain]", "terseLabel": "Litigation Case [Domain]" } } }, "localname": "LitigationCaseTypeDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/OperatingExpenseSummaryofOperatingExpensesandOtherOperatingIncomeDetails" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationSummaryofKeyTermsandConditionsofShareBasedCompensationBasedonShareWarrantsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/LoansandBorrowingsAdditionalInformationDetails", "http://www.genfit.com/role/ShareBasedCompensationAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/DeferredIncomeandRevenueDetails", "http://www.genfit.com/role/IntangibleAssetsScheduleofVariationsinIntangibleAssetsDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodSignatureofaLicensingandPartnershipAgreementwithIpsenDetails", "http://www.genfit.com/role/OperatingIncomeAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsSummaryofOtherFinancialAssetsDetails", "http://www.genfit.com/role/RelatedPartiesAdditionalInformationDetails", "http://www.genfit.com/role/SummaryofSignificantAccountingPoliciesSummaryofApplicableExchangeRatesUsedtoTranslateFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioForecastMember": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Forecast [Member]", "terseLabel": "Forecast" } } }, "localname": "ScenarioForecastMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Domain]", "terseLabel": "Scenario" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "terseLabel": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails", "http://www.genfit.com/role/OtherFinancialAssetsAdditionalInformationDetails" ], "xbrltype": "stringItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Scenario [Axis]", "terseLabel": "Scenario" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAcquisitionoftheClinicalstageBiopharmaceuticalCompanyVersantisDetails", "http://www.genfit.com/role/MajorEventsinthePeriodandEventsAfterthePeriodAdditionalInformationDetails" ], "xbrltype": "stringItemType" } }, "unitCount": 15 } }, "std_ref": { "r0": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "104", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_104&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r1": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r10": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r100": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Section": "Disclosures", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS24_g13-24__IAS24_g13-24_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_ix&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_v&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "26", "Paragraph": "35", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=26&code=ifrs-tx-2022-en-r&anchor=para_35_b_viii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "27", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=27&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r110": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "67", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_67&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Paragraph": "70", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&anchor=para_70_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "33", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS33_g70-73A__IAS33_g70-73A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "126", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_126_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "129", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_129_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "130", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_130_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "84", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "84", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r120": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "84", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "84", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_84&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS37_g84-92__IAS37_g84-92_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Clause": "vii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e_vii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "122", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_122_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r130": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "126", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_126&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS38_g118-128__IAS38_g118-128_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "32A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_32A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "76", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_76&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "50", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_50&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "10", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_10&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r140": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "28", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_28&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "31", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_31&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "46", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_46&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "50", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_50_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "Presentation of a statement of cash flows", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS07_g10-17__IAS07_g10-17_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_29&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "8", "Paragraph": "30", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2022-en-r&anchor=para_30_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r150": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "24", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_24_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "32", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_32_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "10", "Paragraph": "22", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "12", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_12_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "21", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_21_a_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "k", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_k&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r160": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Clause": "ix", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_ix&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Clause": "viii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B12", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B12_b_viii&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_e&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_f&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B13", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B13_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B16&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "l", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_l&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r170": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B4", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B4_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "93", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_93_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS13_g91-99__IFRS13_g91-99_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "14", "Section": "Explanation of recognised amounts", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS14_g32-36__IFRS14_g32-36_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "105", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_105&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "113", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_113_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "114", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_114&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "n", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_n&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r180": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "116", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_116_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "120", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_120_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "15", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53_j&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "94", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_94&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "95", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_95&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "97", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_97&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "44", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_44&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "o", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_o&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r190": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Clause": "vi", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_b_vi&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "47", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_47_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_a&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r20": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "q", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_q&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r200": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_f_i&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B64", "Subparagraph": "j", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B64_j&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Paragraph": "B67", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_d&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "3", "Section": "Disclosures application of paragraphs 59 and 61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67__IFRS03_gB64-B67_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "5", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2022-en-r&anchor=para_33_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "21C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_21C&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "r", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_r&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r210": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "23B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_23B_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "25", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_25&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_33&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35H", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35H&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35K", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35K&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M_b_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r220": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "36", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_36&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "39", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "39", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42E", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42E_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "42I", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_42I&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "8", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_8_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B52", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B52&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "56", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_56&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r230": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Section": "Defined terms", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&doctype=Appendix&subtype=A&dita_xref=IFRS07_APPA__IFRS07_APPA_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "24", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_24_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r240": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_32&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "33", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_33_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IFRS08_g20-24__IFRS08_g20-24_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "9", "Paragraph": "7.2.34", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.34&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "109A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_109A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "120", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_120&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r250": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "124", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_124&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "125", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_125&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "128", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_128_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "132", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_132_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "C32", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_C32&doctype=Appendix&subtype=C", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "9", "Paragraph": "7.2.42", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=9&code=ifrs-tx-2022-en-r&anchor=para_7.2.42&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39M", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "61", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_61&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r260": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39M", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39M&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39J", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J_a&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "4", "Paragraph": "39J", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39J&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "12", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_12&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "8", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_8_c&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "102", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_102&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r267": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "103", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_103&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r268": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r269": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "68", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_68&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r27": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "66", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_66&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r270": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r271": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r272": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r273": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82A&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r274": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "IG6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG6&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r275": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r276": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "22", "Subparagraph": "i", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_22_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r277": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "80", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_80_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r278": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r279": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "Subparagraph": "h", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37_h&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r28": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "69", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_69&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r280": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "147", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_147_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r281": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "32", "Paragraph": "IE33", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2022-en-r&anchor=para_IE33&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r282": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "36", "Paragraph": "127", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=36&code=ifrs-tx-2022-en-r&anchor=para_127&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r283": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "70", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_70&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r284": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r285": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r286": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "14", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r287": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r288": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r289": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r29": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r290": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r291": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r292": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Section": "A Statement of cash flows for an entity other than a financial institution", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&doctype=Illustrative%20Examples&dita_xref=IAS07_IE_A__IAS07_IE_A_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r293": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "1", "Paragraph": "IG63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2022-en-r&anchor=para_IG63&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r294": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "12", "Paragraph": "B10", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2022-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r295": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "B6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_B6&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r296": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "13", "Paragraph": "IE63", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2022-en-r&anchor=para_IE63&doctype=Illustrative%20Examples", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r297": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "16", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r298": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "35N", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_35N&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r299": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "6", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_6&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r3": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r30": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r300": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B11", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B11&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r301": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35_g&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r302": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "B35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_B35&doctype=Appendix&subtype=B", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r303": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG20C", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG20C&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r304": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG31A", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG31A&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r305": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "IG40B", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_IG40B&doctype=Implementation%20Guidance", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r306": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "23", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_23&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r307": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "8", "Paragraph": "28", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2022-en-r&anchor=para_28_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r308": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective 2023-01-01", "Number": "17", "Paragraph": "113", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2022-en-r&anchor=para_113_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r309": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Effective on first application of IFRS 9", "Number": "4", "Paragraph": "39L", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=4&code=ifrs-tx-2022-en-b&anchor=para_39L_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r31": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r310": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_a&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r311": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r312": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG28", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG28_d&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r313": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_a&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r314": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29_b&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r315": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r316": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r317": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r318": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r319": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r32": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r320": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r321": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r322": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r323": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r324": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r325": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r326": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "10", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_10_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r327": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r328": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r329": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "108", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_108&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r33": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r330": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "112", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_112_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r331": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r332": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "55", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_55&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r333": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r334": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r335": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "78", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_78&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r336": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r337": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "85", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_85&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r338": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r339": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "37", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_37&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r34": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r340": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r341": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "135", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_135_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r342": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r343": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "144", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_144&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r344": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "171", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_171&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r345": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "9", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_9&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r346": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r347": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "37", "Paragraph": "88", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2022-en-r&anchor=para_88&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r348": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r349": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r35": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r350": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "118", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_118&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r351": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "38", "Paragraph": "119", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2022-en-r&anchor=para_119&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r352": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "40", "Paragraph": "79", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2022-en-r&anchor=para_79_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r353": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "41", "Paragraph": "54", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2022-en-r&anchor=para_54_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r354": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "14", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_14&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "16", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_16&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "20", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_20&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "7", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r360": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "2", "Paragraph": "45", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2022-en-r&anchor=para_45&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "39", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_39&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "IssueDate": "2022-03-24", "Name": "IFRS", "Number": "7", "Paragraph": "7", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2022-en-r&anchor=para_7&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Effective 2023-01-01", "Number": "1", "Paragraph": "117", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_117&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "IssueDate": "2022-03-24", "Name": "IAS", "Note": "Expiry date 2023-01-01", "Number": "1", "Paragraph": "117", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-b&anchor=para_117_b&doctype=Standard&forcepdf=true", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "37", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_37_b&doctype=Standard&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "IssueDate": "2022-03-24", "Name": "IFRS", "Note": "Expiry date 2023-01-01", "Number": "7", "Paragraph": "IG29", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2017-en-b&anchor=para_IG29&doctype=Implementation%20Guidance&book=b", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Clause": "iii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d_iii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r40": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81A", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81A_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_a_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "81B", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_81B_b_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "82", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_82_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "91", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_91_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r50": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "92", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_92&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "98", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_98_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "99", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_99&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "10", "Paragraph": "21", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2022-en-r&anchor=para_21&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "79", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_79&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "106", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_106&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r60": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_c_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Clause": "i", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_i&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Paragraph": "81", "Subparagraph": "g", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&anchor=para_81_g&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "12", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=12&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS12_g79-88__IAS12_g79-88_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Clause": "ii", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_ii&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Clause": "iv", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_iv&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "136", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_136&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r70": { "Clause": "v", "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e_v&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "73", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_73&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "75", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_75_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Paragraph": "77", "Subparagraph": "f", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&anchor=para_77_f&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "16", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS16_g73-79__IAS16_g73-79_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "138", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_138&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "140", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_140_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "35", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_35&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r80": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "c", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_c&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "141", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_141_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "142", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_142&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "145", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "145", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_145&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Paragraph": "53", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&anchor=para_53&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "19", "Section": "Scope", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS19_g2-7__IAS19_g2-7_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "2", "Paragraph": "36", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2022-en-r&anchor=para_36_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "48", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_48&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "1", "Paragraph": "54", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2022-en-r&anchor=para_54_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r90": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Paragraph": "52", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&anchor=para_52_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "21", "Section": "Disclosure", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=21&code=ifrs-tx-2022-en-r&doctype=Standard&dita_xref=IAS21_g51-57__IAS21_g51-57_TI", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "a", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_a&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "Subparagraph": "e", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17_e&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "17", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_17&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "18", "Subparagraph": "b", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_18_b&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "Subparagraph": "d", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19_d&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "IssueDate": "2022-03-24", "Name": "IAS", "Number": "24", "Paragraph": "19", "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2022-en-r&anchor=para_19&doctype=Standard", "URIDate": "2022-03-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" }